{"meta":{"dataset":"drug-events","title":"Serious drug adverse event reports by active ingredient (openFDA FAERS)","version":"1.0.0","doi":"10.5281/zenodo.23752994","doiUrl":"https://doi.org/10.5281/zenodo.23752994","conceptDoi":"10.5281/zenodo.23752993","license":"CC BY 4.0","licenseUrl":"https://creativecommons.org/licenses/by/4.0/","attribution":"Source: Probative, Serious drug adverse event reports by active ingredient (openFDA FAERS), version 1.0.0, https://doi.org/10.5281/zenodo.23752994, licensed CC BY 4.0.","citation":"Probative. (2026). Serious drug adverse event reports by active ingredient (openFDA FAERS) (Version 1.0.0) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.23752994","disclaimer":"Not legal advice. This is not medical advice either. A report in the FDA Adverse Event Reporting System is not proof that a drug caused an event; reports come from patients, clinicians and manufacturers, can be duplicated and are not verified. Questions about a medicine are for a health professional, and questions about an injury are for a licensed attorney.","notice":"Probative is a marketing firm, not a law firm; not legal advice.","lastChecked":"2026-10-29","url":"https://probativegrowth.com/data/v1/drug-events/drug-events.json","humanUrl":"https://probativegrowth.com/data/drug-events/","statusCodes":{"P":"primary source","S":"secondary source","D":"ABA model default","U":"open question"}},"key":"ingredient","records":[{"id":"drug-events:US","dataset":"drug-events","jurisdiction":"US","ingredient":"All drugs","level":"us","rank":0,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"All drug adverse event reports openFDA holds for reports received 2024Q3 to 2026Q2: 2,649,395 reports, 1,430,033 serious (54.0%) and 197,378 with a death outcome. A report names a drug and an event; it does not show that the drug caused the event.","value":2649395,"unit":"FAERS reports received in the window","reports":2649395,"serious":1430033,"deaths":197378,"serious_pct":54,"death_pct":7.4,"reports_q1":332487,"reports_q2":335367,"reports_q3":325255,"reports_q4":323832,"reports_q5":339468,"reports_q6":319214,"reports_q7":320823,"reports_q8":352949,"serious_q1":174773,"serious_q2":180705,"serious_q3":177462,"serious_q4":176520,"serious_q5":182037,"serious_q6":175649,"serious_q7":177782,"serious_q8":185105,"topReactions":null,"mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dupilumab","dataset":"drug-events","jurisdiction":"US","ingredient":"DUPILUMAB","level":"ingredient","rank":1,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DUPILUMAB: 230,520 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 23,391 were serious (10.1%) and 1,075 reported a death outcome (0.5%). Most reported reactions: PRURITUS (31,755); DERMATITIS ATOPIC (26,189); INJECTION SITE PAIN (20,196); PRODUCT USE IN UNAPPROVED INDICATION (18,405); RASH (17,149). Named in open multidistrict litigation MDL-3180. A report does not show that the drug caused the event.","value":230520,"unit":"FAERS reports received in the window","reports":230520,"serious":23391,"deaths":1075,"serious_pct":10.1,"death_pct":0.5,"reports_q1":21069,"reports_q2":28387,"reports_q3":26974,"reports_q4":28787,"reports_q5":30187,"reports_q6":28932,"reports_q7":26464,"reports_q8":39720,"serious_q1":2361,"serious_q2":2704,"serious_q3":2567,"serious_q4":2706,"serious_q5":2945,"serious_q6":3046,"serious_q7":3298,"serious_q8":3764,"topReactions":"PRURITUS (31,755); DERMATITIS ATOPIC (26,189); INJECTION SITE PAIN (20,196); PRODUCT USE IN UNAPPROVED INDICATION (18,405); RASH (17,149)","mdl":"MDL-3180","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:tirzepatide","dataset":"drug-events","jurisdiction":"US","ingredient":"TIRZEPATIDE","level":"ingredient","rank":2,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TIRZEPATIDE: 120,102 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 24,360 were serious (20.3%) and 734 reported a death outcome (0.6%). Most reported reactions: INCORRECT DOSE ADMINISTERED (19,670); NAUSEA (12,596); INJECTION SITE PAIN (8,498); DIARRHOEA (7,901); EXTRA DOSE ADMINISTERED (7,055). Named in open multidistrict litigation MDL-3094, MDL-3163. A report does not show that the drug caused the event.","value":120102,"unit":"FAERS reports received in the window","reports":120102,"serious":24360,"deaths":734,"serious_pct":20.3,"death_pct":0.6,"reports_q1":8963,"reports_q2":9489,"reports_q3":11639,"reports_q4":15612,"reports_q5":17781,"reports_q6":17270,"reports_q7":19467,"reports_q8":19881,"serious_q1":1511,"serious_q2":1878,"serious_q3":2063,"serious_q4":3062,"serious_q5":3987,"serious_q6":3773,"serious_q7":3723,"serious_q8":4363,"topReactions":"INCORRECT DOSE ADMINISTERED (19,670); NAUSEA (12,596); INJECTION SITE PAIN (8,498); DIARRHOEA (7,901); EXTRA DOSE ADMINISTERED (7,055)","mdl":"MDL-3094; MDL-3163","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:acetaminophen","dataset":"drug-events","jurisdiction":"US","ingredient":"ACETAMINOPHEN","level":"ingredient","rank":3,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ACETAMINOPHEN: 98,552 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 66,782 were serious (67.8%) and 13,298 reported a death outcome (13.5%). Most reported reactions: OFF LABEL USE (9,309); FATIGUE (7,677); NAUSEA (7,011); HEADACHE (6,697); DRUG INEFFECTIVE (6,674). Named in open multidistrict litigation MDL-3043. A report does not show that the drug caused the event.","value":98552,"unit":"FAERS reports received in the window","reports":98552,"serious":66782,"deaths":13298,"serious_pct":67.8,"death_pct":13.5,"reports_q1":11004,"reports_q2":14610,"reports_q3":13705,"reports_q4":10900,"reports_q5":13651,"reports_q6":12811,"reports_q7":11849,"reports_q8":10022,"serious_q1":7751,"serious_q2":9250,"serious_q3":9521,"serious_q4":7627,"serious_q5":9003,"serious_q6":8082,"serious_q7":8624,"serious_q8":6924,"topReactions":"OFF LABEL USE (9,309); FATIGUE (7,677); NAUSEA (7,011); HEADACHE (6,697); DRUG INEFFECTIVE (6,674)","mdl":"MDL-3043","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ibuprofen","dataset":"drug-events","jurisdiction":"US","ingredient":"IBUPROFEN","level":"ingredient","rank":4,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"IBUPROFEN: 80,477 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 63,369 were serious (78.7%) and 12,236 reported a death outcome (15.2%). Most reported reactions: OFF LABEL USE (8,084); FATIGUE (5,820); NAUSEA (5,710); DRUG INEFFECTIVE (5,416); TOXICITY TO VARIOUS AGENTS (5,163). A report does not show that the drug caused the event.","value":80477,"unit":"FAERS reports received in the window","reports":80477,"serious":63369,"deaths":12236,"serious_pct":78.7,"death_pct":15.2,"reports_q1":9381,"reports_q2":11460,"reports_q3":11382,"reports_q4":9225,"reports_q5":10005,"reports_q6":9926,"reports_q7":10271,"reports_q8":8827,"serious_q1":7314,"serious_q2":8899,"serious_q3":9021,"serious_q4":7364,"serious_q5":7848,"serious_q6":7676,"serious_q7":8322,"serious_q8":6925,"topReactions":"OFF LABEL USE (8,084); FATIGUE (5,820); NAUSEA (5,710); DRUG INEFFECTIVE (5,416); TOXICITY TO VARIOUS AGENTS (5,163)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:prednisone","dataset":"drug-events","jurisdiction":"US","ingredient":"PREDNISONE","level":"ingredient","rank":5,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PREDNISONE: 76,235 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 60,530 were serious (79.4%) and 10,008 reported a death outcome (13.1%). Most reported reactions: OFF LABEL USE (12,324); DRUG INEFFECTIVE (8,919); FATIGUE (5,918); DYSPNOEA (5,022); CONDITION AGGRAVATED (4,914). A report does not show that the drug caused the event.","value":76235,"unit":"FAERS reports received in the window","reports":76235,"serious":60530,"deaths":10008,"serious_pct":79.4,"death_pct":13.1,"reports_q1":9878,"reports_q2":12116,"reports_q3":9484,"reports_q4":9314,"reports_q5":10619,"reports_q6":8736,"reports_q7":8074,"reports_q8":8014,"serious_q1":7993,"serious_q2":9307,"serious_q3":7770,"serious_q4":7175,"serious_q5":8579,"serious_q6":7145,"serious_q7":6429,"serious_q8":6132,"topReactions":"OFF LABEL USE (12,324); DRUG INEFFECTIVE (8,919); FATIGUE (5,918); DYSPNOEA (5,022); CONDITION AGGRAVATED (4,914)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:diphenhydramine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"DIPHENHYDRAMINE HYDROCHLORIDE","level":"ingredient","rank":6,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DIPHENHYDRAMINE HYDROCHLORIDE: 71,901 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 58,022 were serious (80.7%) and 13,008 reported a death outcome (18.1%). Most reported reactions: OFF LABEL USE (8,246); FATIGUE (5,789); TOXICITY TO VARIOUS AGENTS (5,627); NAUSEA (5,562); HEADACHE (4,946). A report does not show that the drug caused the event.","value":71901,"unit":"FAERS reports received in the window","reports":71901,"serious":58022,"deaths":13008,"serious_pct":80.7,"death_pct":18.1,"reports_q1":8217,"reports_q2":10442,"reports_q3":10217,"reports_q4":8318,"reports_q5":8864,"reports_q6":8667,"reports_q7":9253,"reports_q8":7923,"serious_q1":6665,"serious_q2":8267,"serious_q3":8487,"serious_q4":6717,"serious_q5":7085,"serious_q6":6852,"serious_q7":7722,"serious_q8":6227,"topReactions":"OFF LABEL USE (8,246); FATIGUE (5,789); TOXICITY TO VARIOUS AGENTS (5,627); NAUSEA (5,562); HEADACHE (4,946)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dextromethorphan-hydrobromide","dataset":"drug-events","jurisdiction":"US","ingredient":"DEXTROMETHORPHAN HYDROBROMIDE","level":"ingredient","rank":7,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DEXTROMETHORPHAN HYDROBROMIDE: 65,295 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 51,465 were serious (78.8%) and 11,419 reported a death outcome (17.5%). Most reported reactions: OFF LABEL USE (7,010); TOXICITY TO VARIOUS AGENTS (4,868); FATIGUE (4,779); NAUSEA (4,771); DRUG INEFFECTIVE (4,696). A report does not show that the drug caused the event.","value":65295,"unit":"FAERS reports received in the window","reports":65295,"serious":51465,"deaths":11419,"serious_pct":78.8,"death_pct":17.5,"reports_q1":7557,"reports_q2":9460,"reports_q3":8983,"reports_q4":7837,"reports_q5":7982,"reports_q6":7987,"reports_q7":8342,"reports_q8":7147,"serious_q1":5987,"serious_q2":7489,"serious_q3":7520,"serious_q4":5829,"serious_q5":6259,"serious_q6":6079,"serious_q7":6892,"serious_q8":5410,"topReactions":"OFF LABEL USE (7,010); TOXICITY TO VARIOUS AGENTS (4,868); FATIGUE (4,779); NAUSEA (4,771); DRUG INEFFECTIVE (4,696)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:aspirin","dataset":"drug-events","jurisdiction":"US","ingredient":"ASPIRIN","level":"ingredient","rank":8,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ASPIRIN: 64,516 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 42,251 were serious (65.5%) and 4,539 reported a death outcome (7.0%). Most reported reactions: FATIGUE (4,949); OFF LABEL USE (4,259); DIARRHOEA (3,961); DYSPNOEA (3,496); NAUSEA (3,320). A report does not show that the drug caused the event.","value":64516,"unit":"FAERS reports received in the window","reports":64516,"serious":42251,"deaths":4539,"serious_pct":65.5,"death_pct":7,"reports_q1":8295,"reports_q2":8980,"reports_q3":8631,"reports_q4":7914,"reports_q5":8643,"reports_q6":7201,"reports_q7":7441,"reports_q8":7411,"serious_q1":5557,"serious_q2":5340,"serious_q3":5537,"serious_q4":5295,"serious_q5":5464,"serious_q6":5087,"serious_q7":5197,"serious_q8":4774,"topReactions":"FATIGUE (4,949); OFF LABEL USE (4,259); DIARRHOEA (3,961); DYSPNOEA (3,496); NAUSEA (3,320)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:albuterol-sulfate","dataset":"drug-events","jurisdiction":"US","ingredient":"ALBUTEROL SULFATE","level":"ingredient","rank":9,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ALBUTEROL SULFATE: 58,865 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 28,932 were serious (49.1%) and 3,185 reported a death outcome (5.4%). Most reported reactions: DYSPNOEA (8,109); DRUG DOSE OMISSION BY DEVICE (5,209); DEVICE DELIVERY SYSTEM ISSUE (4,891); WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (4,772); COUGH (4,566). A report does not show that the drug caused the event.","value":58865,"unit":"FAERS reports received in the window","reports":58865,"serious":28932,"deaths":3185,"serious_pct":49.1,"death_pct":5.4,"reports_q1":7243,"reports_q2":7502,"reports_q3":7196,"reports_q4":8190,"reports_q5":7482,"reports_q6":7081,"reports_q7":7042,"reports_q8":7129,"serious_q1":3997,"serious_q2":3741,"serious_q3":3872,"serious_q4":3430,"serious_q5":3627,"serious_q6":3355,"serious_q7":3627,"serious_q8":3283,"topReactions":"DYSPNOEA (8,109); DRUG DOSE OMISSION BY DEVICE (5,209); DEVICE DELIVERY SYSTEM ISSUE (4,891); WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (4,772); COUGH (4,566)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:doxylamine-succinate","dataset":"drug-events","jurisdiction":"US","ingredient":"DOXYLAMINE SUCCINATE","level":"ingredient","rank":10,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DOXYLAMINE SUCCINATE: 57,103 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 48,783 were serious (85.4%) and 10,999 reported a death outcome (19.3%). Most reported reactions: OFF LABEL USE (6,597); TOXICITY TO VARIOUS AGENTS (4,798); FATIGUE (4,326); NAUSEA (4,282); HEADACHE (3,874). A report does not show that the drug caused the event.","value":57103,"unit":"FAERS reports received in the window","reports":57103,"serious":48783,"deaths":10999,"serious_pct":85.4,"death_pct":19.3,"reports_q1":6524,"reports_q2":8365,"reports_q3":8215,"reports_q4":6239,"reports_q5":6982,"reports_q6":7266,"reports_q7":7469,"reports_q8":6043,"serious_q1":5633,"serious_q2":7078,"serious_q3":7196,"serious_q4":5437,"serious_q5":5944,"serious_q6":5810,"serious_q7":6559,"serious_q8":5126,"topReactions":"OFF LABEL USE (6,597); TOXICITY TO VARIOUS AGENTS (4,798); FATIGUE (4,326); NAUSEA (4,282); HEADACHE (3,874)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:metformin-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"METFORMIN HYDROCHLORIDE","level":"ingredient","rank":11,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METFORMIN HYDROCHLORIDE: 50,725 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 36,917 were serious (72.8%) and 4,756 reported a death outcome (9.4%). Most reported reactions: DIARRHOEA (4,216); NAUSEA (4,015); LACTIC ACIDOSIS (3,427); OFF LABEL USE (3,424); VOMITING (3,159). A report does not show that the drug caused the event.","value":50725,"unit":"FAERS reports received in the window","reports":50725,"serious":36917,"deaths":4756,"serious_pct":72.8,"death_pct":9.4,"reports_q1":6540,"reports_q2":6195,"reports_q3":6278,"reports_q4":5914,"reports_q5":7486,"reports_q6":5871,"reports_q7":5970,"reports_q8":6471,"serious_q1":4652,"serious_q2":4554,"serious_q3":4600,"serious_q4":4264,"serious_q5":5361,"serious_q6":4404,"serious_q7":4457,"serious_q8":4625,"topReactions":"DIARRHOEA (4,216); NAUSEA (4,015); LACTIC ACIDOSIS (3,427); OFF LABEL USE (3,424); VOMITING (3,159)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lenalidomide","dataset":"drug-events","jurisdiction":"US","ingredient":"LENALIDOMIDE","level":"ingredient","rank":12,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LENALIDOMIDE: 48,889 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 27,059 were serious (55.3%) and 3,769 reported a death outcome (7.7%). Most reported reactions: OFF LABEL USE (5,559); DIARRHOEA (4,011); FATIGUE (3,374); PRODUCT DOSE OMISSION ISSUE (3,058); RASH (2,460). A report does not show that the drug caused the event.","value":48889,"unit":"FAERS reports received in the window","reports":48889,"serious":27059,"deaths":3769,"serious_pct":55.3,"death_pct":7.7,"reports_q1":7444,"reports_q2":6689,"reports_q3":6643,"reports_q4":6207,"reports_q5":5727,"reports_q6":5323,"reports_q7":5332,"reports_q8":5524,"serious_q1":4016,"serious_q2":3648,"serious_q3":3412,"serious_q4":3463,"serious_q5":3279,"serious_q6":3098,"serious_q7":2917,"serious_q8":3226,"topReactions":"OFF LABEL USE (5,559); DIARRHOEA (4,011); FATIGUE (3,374); PRODUCT DOSE OMISSION ISSUE (3,058); RASH (2,460)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pantoprazole-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"PANTOPRAZOLE SODIUM","level":"ingredient","rank":13,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PANTOPRAZOLE SODIUM: 47,606 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 36,536 were serious (76.7%) and 6,086 reported a death outcome (12.8%). Most reported reactions: OFF LABEL USE (4,871); FATIGUE (4,276); DIARRHOEA (4,021); NAUSEA (3,970); HEADACHE (3,346). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":47606,"unit":"FAERS reports received in the window","reports":47606,"serious":36536,"deaths":6086,"serious_pct":76.7,"death_pct":12.8,"reports_q1":6022,"reports_q2":6184,"reports_q3":6079,"reports_q4":5727,"reports_q5":6399,"reports_q6":5560,"reports_q7":5678,"reports_q8":5957,"serious_q1":4675,"serious_q2":4851,"serious_q3":4735,"serious_q4":4439,"serious_q5":4862,"serious_q6":4342,"serious_q7":4355,"serious_q8":4277,"topReactions":"OFF LABEL USE (4,871); FATIGUE (4,276); DIARRHOEA (4,021); NAUSEA (3,970); HEADACHE (3,346)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:methotrexate-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"METHOTREXATE SODIUM","level":"ingredient","rank":14,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METHOTREXATE SODIUM: 46,382 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 40,868 were serious (88.1%) and 7,348 reported a death outcome (15.8%). Most reported reactions: OFF LABEL USE (8,009); DRUG INEFFECTIVE (6,137); PAIN (3,713); RHEUMATOID ARTHRITIS (3,672); ARTHRALGIA (3,596). A report does not show that the drug caused the event.","value":46382,"unit":"FAERS reports received in the window","reports":46382,"serious":40868,"deaths":7348,"serious_pct":88.1,"death_pct":15.8,"reports_q1":6613,"reports_q2":6968,"reports_q3":6173,"reports_q4":5851,"reports_q5":6345,"reports_q6":5410,"reports_q7":4422,"reports_q8":4600,"serious_q1":5809,"serious_q2":5933,"serious_q3":5510,"serious_q4":5027,"serious_q5":5679,"serious_q6":4859,"serious_q7":3955,"serious_q8":4096,"topReactions":"OFF LABEL USE (8,009); DRUG INEFFECTIVE (6,137); PAIN (3,713); RHEUMATOID ARTHRITIS (3,672); ARTHRALGIA (3,596)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ascorbic-acid","dataset":"drug-events","jurisdiction":"US","ingredient":"ASCORBIC ACID","level":"ingredient","rank":15,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ASCORBIC ACID: 43,852 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 31,190 were serious (71.1%) and 6,452 reported a death outcome (14.7%). Most reported reactions: OFF LABEL USE (5,310); FATIGUE (5,061); PAIN (4,046); DIARRHOEA (3,723); HEADACHE (3,585). A report does not show that the drug caused the event.","value":43852,"unit":"FAERS reports received in the window","reports":43852,"serious":31190,"deaths":6452,"serious_pct":71.1,"death_pct":14.7,"reports_q1":5590,"reports_q2":5728,"reports_q3":5623,"reports_q4":5568,"reports_q5":6101,"reports_q6":5027,"reports_q7":5056,"reports_q8":5159,"serious_q1":3977,"serious_q2":4280,"serious_q3":4122,"serious_q4":3973,"serious_q5":4192,"serious_q6":3751,"serious_q7":3564,"serious_q8":3331,"topReactions":"OFF LABEL USE (5,310); FATIGUE (5,061); PAIN (4,046); DIARRHOEA (3,723); HEADACHE (3,585)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:rituximab","dataset":"drug-events","jurisdiction":"US","ingredient":"RITUXIMAB","level":"ingredient","rank":16,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RITUXIMAB: 43,612 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 35,546 were serious (81.5%) and 8,794 reported a death outcome (20.2%). Most reported reactions: OFF LABEL USE (13,236); DRUG INEFFECTIVE (4,512); PNEUMONIA (3,667); NO ADVERSE EVENT (3,433); PAIN (3,332). A report does not show that the drug caused the event.","value":43612,"unit":"FAERS reports received in the window","reports":43612,"serious":35546,"deaths":8794,"serious_pct":81.5,"death_pct":20.2,"reports_q1":4592,"reports_q2":11233,"reports_q3":4550,"reports_q4":4481,"reports_q5":5428,"reports_q6":4849,"reports_q7":4058,"reports_q8":4421,"serious_q1":4244,"serious_q2":5226,"serious_q3":4217,"serious_q4":4200,"serious_q5":5170,"serious_q6":4457,"serious_q7":3855,"serious_q8":4177,"topReactions":"OFF LABEL USE (13,236); DRUG INEFFECTIVE (4,512); PNEUMONIA (3,667); NO ADVERSE EVENT (3,433); PAIN (3,332)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:niacinamide","dataset":"drug-events","jurisdiction":"US","ingredient":"NIACINAMIDE","level":"ingredient","rank":17,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"NIACINAMIDE: 43,318 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 30,630 were serious (70.7%) and 6,342 reported a death outcome (14.6%). Most reported reactions: OFF LABEL USE (5,175); FATIGUE (5,083); PAIN (3,996); DIARRHOEA (3,675); HEADACHE (3,550). A report does not show that the drug caused the event.","value":43318,"unit":"FAERS reports received in the window","reports":43318,"serious":30630,"deaths":6342,"serious_pct":70.7,"death_pct":14.6,"reports_q1":5459,"reports_q2":5686,"reports_q3":5598,"reports_q4":5479,"reports_q5":6013,"reports_q6":4987,"reports_q7":5043,"reports_q8":5053,"serious_q1":3893,"serious_q2":4212,"serious_q3":4114,"serious_q4":3872,"serious_q5":4135,"serious_q6":3674,"serious_q7":3507,"serious_q8":3223,"topReactions":"OFF LABEL USE (5,175); FATIGUE (5,083); PAIN (3,996); DIARRHOEA (3,675); HEADACHE (3,550)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sodium-bicarbonate","dataset":"drug-events","jurisdiction":"US","ingredient":"SODIUM BICARBONATE","level":"ingredient","rank":18,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SODIUM BICARBONATE: 42,497 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 27,849 were serious (65.5%) and 3,172 reported a death outcome (7.5%). Most reported reactions: FATIGUE (2,971); OFF LABEL USE (2,921); DIARRHOEA (2,907); NAUSEA (2,837); DRUG INEFFECTIVE (2,376). A report does not show that the drug caused the event.","value":42497,"unit":"FAERS reports received in the window","reports":42497,"serious":27849,"deaths":3172,"serious_pct":65.5,"death_pct":7.5,"reports_q1":5329,"reports_q2":5056,"reports_q3":5317,"reports_q4":5181,"reports_q5":6051,"reports_q6":5076,"reports_q7":5136,"reports_q8":5351,"serious_q1":3533,"serious_q2":3365,"serious_q3":3512,"serious_q4":3456,"serious_q5":3887,"serious_q6":3435,"serious_q7":3348,"serious_q8":3313,"topReactions":"FATIGUE (2,971); OFF LABEL USE (2,921); DIARRHOEA (2,907); NAUSEA (2,837); DRUG INEFFECTIVE (2,376)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:gabapentin","dataset":"drug-events","jurisdiction":"US","ingredient":"GABAPENTIN","level":"ingredient","rank":19,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"GABAPENTIN: 41,933 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 26,422 were serious (63.0%) and 3,693 reported a death outcome (8.8%). Most reported reactions: OFF LABEL USE (3,958); FATIGUE (3,095); NAUSEA (3,037); DRUG INEFFECTIVE (2,970); DIARRHOEA (2,566). A report does not show that the drug caused the event.","value":41933,"unit":"FAERS reports received in the window","reports":41933,"serious":26422,"deaths":3693,"serious_pct":63,"death_pct":8.8,"reports_q1":5237,"reports_q2":5131,"reports_q3":5707,"reports_q4":5178,"reports_q5":5839,"reports_q6":4722,"reports_q7":5279,"reports_q8":4840,"serious_q1":3254,"serious_q2":3246,"serious_q3":3590,"serious_q4":3384,"serious_q5":3548,"serious_q6":3024,"serious_q7":3441,"serious_q8":2935,"topReactions":"OFF LABEL USE (3,958); FATIGUE (3,095); NAUSEA (3,037); DRUG INEFFECTIVE (2,970); DIARRHOEA (2,566)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:omeprazole-magnesium","dataset":"drug-events","jurisdiction":"US","ingredient":"OMEPRAZOLE MAGNESIUM","level":"ingredient","rank":20,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OMEPRAZOLE MAGNESIUM: 41,104 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 26,100 were serious (63.5%) and 2,685 reported a death outcome (6.5%). Most reported reactions: FATIGUE (2,997); DIARRHOEA (2,899); NAUSEA (2,801); OFF LABEL USE (2,688); HEADACHE (2,264). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":41104,"unit":"FAERS reports received in the window","reports":41104,"serious":26100,"deaths":2685,"serious_pct":63.5,"death_pct":6.5,"reports_q1":5136,"reports_q2":4893,"reports_q3":5172,"reports_q4":5009,"reports_q5":5800,"reports_q6":4960,"reports_q7":4905,"reports_q8":5229,"serious_q1":3317,"serious_q2":3118,"serious_q3":3317,"serious_q4":3246,"serious_q5":3636,"serious_q6":3274,"serious_q7":3097,"serious_q8":3095,"topReactions":"FATIGUE (2,997); DIARRHOEA (2,899); NAUSEA (2,801); OFF LABEL USE (2,688); HEADACHE (2,264)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:furosemide","dataset":"drug-events","jurisdiction":"US","ingredient":"FUROSEMIDE","level":"ingredient","rank":21,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FUROSEMIDE: 40,752 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 29,902 were serious (73.4%) and 4,697 reported a death outcome (11.5%). Most reported reactions: DYSPNOEA (3,185); OFF LABEL USE (2,751); FATIGUE (2,709); DIARRHOEA (2,637); HEADACHE (2,303). A report does not show that the drug caused the event.","value":40752,"unit":"FAERS reports received in the window","reports":40752,"serious":29902,"deaths":4697,"serious_pct":73.4,"death_pct":11.5,"reports_q1":5460,"reports_q2":5530,"reports_q3":5274,"reports_q4":5165,"reports_q5":5154,"reports_q6":4676,"reports_q7":4735,"reports_q8":4758,"serious_q1":4080,"serious_q2":4201,"serious_q3":3911,"serious_q4":3761,"serious_q5":3677,"serious_q6":3455,"serious_q7":3471,"serious_q8":3346,"topReactions":"DYSPNOEA (3,185); OFF LABEL USE (2,751); FATIGUE (2,709); DIARRHOEA (2,637); HEADACHE (2,303)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:phenylephrine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"PHENYLEPHRINE HYDROCHLORIDE","level":"ingredient","rank":22,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PHENYLEPHRINE HYDROCHLORIDE: 40,700 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,602 were serious (55.5%) and 3,834 reported a death outcome (9.4%). Most reported reactions: OFF LABEL USE (4,202); FATIGUE (3,835); DRUG INEFFECTIVE (3,736); HEADACHE (3,485); NAUSEA (3,367). A report does not show that the drug caused the event.","value":40700,"unit":"FAERS reports received in the window","reports":40700,"serious":22602,"deaths":3834,"serious_pct":55.5,"death_pct":9.4,"reports_q1":4597,"reports_q2":4939,"reports_q3":4749,"reports_q4":4751,"reports_q5":6730,"reports_q6":5939,"reports_q7":4687,"reports_q8":4308,"serious_q1":2776,"serious_q2":2821,"serious_q3":2767,"serious_q4":2689,"serious_q5":3630,"serious_q6":2856,"serious_q7":2687,"serious_q8":2376,"topReactions":"OFF LABEL USE (4,202); FATIGUE (3,835); DRUG INEFFECTIVE (3,736); HEADACHE (3,485); NAUSEA (3,367)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:semaglutide","dataset":"drug-events","jurisdiction":"US","ingredient":"SEMAGLUTIDE","level":"ingredient","rank":23,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SEMAGLUTIDE: 40,353 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 20,629 were serious (51.1%) and 674 reported a death outcome (1.7%). Most reported reactions: NAUSEA (5,594); OFF LABEL USE (4,590); VOMITING (3,962); DIARRHOEA (3,595); IMPAIRED GASTRIC EMPTYING (3,281). Named in open multidistrict litigation MDL-3094, MDL-3163. A report does not show that the drug caused the event.","value":40353,"unit":"FAERS reports received in the window","reports":40353,"serious":20629,"deaths":674,"serious_pct":51.1,"death_pct":1.7,"reports_q1":5857,"reports_q2":2480,"reports_q3":2849,"reports_q4":2695,"reports_q5":11817,"reports_q6":2652,"reports_q7":2625,"reports_q8":9378,"serious_q1":2248,"serious_q2":1988,"serious_q3":2310,"serious_q4":2167,"serious_q5":4332,"serious_q6":2177,"serious_q7":2190,"serious_q8":3217,"topReactions":"NAUSEA (5,594); OFF LABEL USE (4,590); VOMITING (3,962); DIARRHOEA (3,595); IMPAIRED GASTRIC EMPTYING (3,281)","mdl":"MDL-3094; MDL-3163","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dexamethasone","dataset":"drug-events","jurisdiction":"US","ingredient":"DEXAMETHASONE","level":"ingredient","rank":24,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DEXAMETHASONE: 39,534 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 34,129 were serious (86.3%) and 5,535 reported a death outcome (14.0%). Most reported reactions: OFF LABEL USE (4,807); DRUG INEFFECTIVE (3,016); FATIGUE (2,561); DIARRHOEA (2,218); NAUSEA (2,087). A report does not show that the drug caused the event.","value":39534,"unit":"FAERS reports received in the window","reports":39534,"serious":34129,"deaths":5535,"serious_pct":86.3,"death_pct":14,"reports_q1":5636,"reports_q2":5721,"reports_q3":4747,"reports_q4":4734,"reports_q5":4959,"reports_q6":4643,"reports_q7":4427,"reports_q8":4667,"serious_q1":4865,"serious_q2":4818,"serious_q3":4041,"serious_q4":4070,"serious_q5":4256,"serious_q6":4025,"serious_q7":3876,"serious_q8":4178,"topReactions":"OFF LABEL USE (4,807); DRUG INEFFECTIVE (3,016); FATIGUE (2,561); DIARRHOEA (2,218); NAUSEA (2,087)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:methotrexate","dataset":"drug-events","jurisdiction":"US","ingredient":"METHOTREXATE","level":"ingredient","rank":25,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METHOTREXATE: 39,176 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 34,824 were serious (88.9%) and 6,736 reported a death outcome (17.2%). Most reported reactions: OFF LABEL USE (6,673); DRUG INEFFECTIVE (5,486); PAIN (3,372); RHEUMATOID ARTHRITIS (3,304); ARTHRALGIA (3,237). A report does not show that the drug caused the event.","value":39176,"unit":"FAERS reports received in the window","reports":39176,"serious":34824,"deaths":6736,"serious_pct":88.9,"death_pct":17.2,"reports_q1":5376,"reports_q2":5925,"reports_q3":5152,"reports_q4":4899,"reports_q5":5359,"reports_q6":4670,"reports_q7":3807,"reports_q8":3988,"serious_q1":4856,"serious_q2":5056,"serious_q3":4681,"serious_q4":4225,"serious_q5":4864,"serious_q6":4199,"serious_q7":3404,"serious_q8":3539,"topReactions":"OFF LABEL USE (6,673); DRUG INEFFECTIVE (5,486); PAIN (3,372); RHEUMATOID ARTHRITIS (3,304); ARTHRALGIA (3,237)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:metoprolol-tartrate","dataset":"drug-events","jurisdiction":"US","ingredient":"METOPROLOL TARTRATE","level":"ingredient","rank":26,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METOPROLOL TARTRATE: 39,113 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 23,558 were serious (60.2%) and 3,381 reported a death outcome (8.6%). Most reported reactions: FATIGUE (3,177); DIARRHOEA (2,644); OFF LABEL USE (2,605); NAUSEA (2,379); DYSPNOEA (2,198). A report does not show that the drug caused the event.","value":39113,"unit":"FAERS reports received in the window","reports":39113,"serious":23558,"deaths":3381,"serious_pct":60.2,"death_pct":8.6,"reports_q1":4790,"reports_q2":4690,"reports_q3":5037,"reports_q4":5007,"reports_q5":5327,"reports_q6":4338,"reports_q7":4715,"reports_q8":5209,"serious_q1":2902,"serious_q2":3046,"serious_q3":3164,"serious_q4":3075,"serious_q5":2992,"serious_q6":2770,"serious_q7":2979,"serious_q8":2630,"topReactions":"FATIGUE (3,177); DIARRHOEA (2,644); OFF LABEL USE (2,605); NAUSEA (2,379); DYSPNOEA (2,198)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:omeprazole","dataset":"drug-events","jurisdiction":"US","ingredient":"OMEPRAZOLE","level":"ingredient","rank":27,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OMEPRAZOLE: 38,581 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 24,807 were serious (64.3%) and 2,556 reported a death outcome (6.6%). Most reported reactions: FATIGUE (2,770); DIARRHOEA (2,694); NAUSEA (2,580); OFF LABEL USE (2,486); HEADACHE (2,121). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":38581,"unit":"FAERS reports received in the window","reports":38581,"serious":24807,"deaths":2556,"serious_pct":64.3,"death_pct":6.6,"reports_q1":4829,"reports_q2":4553,"reports_q3":4833,"reports_q4":4702,"reports_q5":5489,"reports_q6":4653,"reports_q7":4630,"reports_q8":4892,"serious_q1":3134,"serious_q2":2944,"serious_q3":3142,"serious_q4":3084,"serious_q5":3464,"serious_q6":3095,"serious_q7":2978,"serious_q8":2966,"topReactions":"FATIGUE (2,770); DIARRHOEA (2,694); NAUSEA (2,580); OFF LABEL USE (2,486); HEADACHE (2,121)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:amlodipine","dataset":"drug-events","jurisdiction":"US","ingredient":"AMLODIPINE","level":"ingredient","rank":28,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AMLODIPINE: 36,887 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 28,456 were serious (77.1%) and 3,769 reported a death outcome (10.2%). Most reported reactions: FATIGUE (2,458); OFF LABEL USE (2,424); DIARRHOEA (2,130); NAUSEA (1,882); DRUG INEFFECTIVE (1,781). A report does not show that the drug caused the event.","value":36887,"unit":"FAERS reports received in the window","reports":36887,"serious":28456,"deaths":3769,"serious_pct":77.1,"death_pct":10.2,"reports_q1":4399,"reports_q2":4569,"reports_q3":4951,"reports_q4":4348,"reports_q5":4816,"reports_q6":4205,"reports_q7":5101,"reports_q8":4498,"serious_q1":3403,"serious_q2":3496,"serious_q3":3852,"serious_q4":3275,"serious_q5":3675,"serious_q6":3333,"serious_q7":4028,"serious_q8":3394,"topReactions":"FATIGUE (2,458); OFF LABEL USE (2,424); DIARRHOEA (2,130); NAUSEA (1,882); DRUG INEFFECTIVE (1,781)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:amlodipine-benzoate","dataset":"drug-events","jurisdiction":"US","ingredient":"AMLODIPINE BENZOATE","level":"ingredient","rank":29,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AMLODIPINE BENZOATE: 36,857 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 28,427 were serious (77.1%) and 3,763 reported a death outcome (10.2%). Most reported reactions: FATIGUE (2,458); OFF LABEL USE (2,426); DIARRHOEA (2,129); NAUSEA (1,882); DRUG INEFFECTIVE (1,779). A report does not show that the drug caused the event.","value":36857,"unit":"FAERS reports received in the window","reports":36857,"serious":28427,"deaths":3763,"serious_pct":77.1,"death_pct":10.2,"reports_q1":4403,"reports_q2":4566,"reports_q3":4941,"reports_q4":4334,"reports_q5":4815,"reports_q6":4201,"reports_q7":5100,"reports_q8":4497,"serious_q1":3401,"serious_q2":3493,"serious_q3":3843,"serious_q4":3263,"serious_q5":3672,"serious_q6":3331,"serious_q7":4030,"serious_q8":3394,"topReactions":"FATIGUE (2,458); OFF LABEL USE (2,426); DIARRHOEA (2,129); NAUSEA (1,882); DRUG INEFFECTIVE (1,779)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:risankizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"RISANKIZUMAB","level":"ingredient","rank":30,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RISANKIZUMAB: 36,490 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 29,604 were serious (81.1%) and 1,447 reported a death outcome (4.0%). Most reported reactions: PSORIASIS (1,807); DEVICE ISSUE (1,806); ARTHRALGIA (1,452); CROHN^S DISEASE (1,388); PAIN (1,377). A report does not show that the drug caused the event.","value":36490,"unit":"FAERS reports received in the window","reports":36490,"serious":29604,"deaths":1447,"serious_pct":81.1,"death_pct":4,"reports_q1":3692,"reports_q2":3975,"reports_q3":4117,"reports_q4":4893,"reports_q5":5314,"reports_q6":5246,"reports_q7":4772,"reports_q8":4481,"serious_q1":3141,"serious_q2":3318,"serious_q3":3409,"serious_q4":3940,"serious_q5":4379,"serious_q6":4276,"serious_q7":3792,"serious_q8":3349,"topReactions":"PSORIASIS (1,807); DEVICE ISSUE (1,806); ARTHRALGIA (1,452); CROHN^S DISEASE (1,388); PAIN (1,377)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:insulin-glargine","dataset":"drug-events","jurisdiction":"US","ingredient":"INSULIN GLARGINE","level":"ingredient","rank":31,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"INSULIN GLARGINE: 35,584 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,489 were serious (32.3%) and 1,013 reported a death outcome (2.8%). Most reported reactions: OFF LABEL USE (9,124); BLOOD GLUCOSE INCREASED (3,278); PRODUCT STORAGE ERROR (2,501); INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1,364); NAUSEA (1,264). A report does not show that the drug caused the event.","value":35584,"unit":"FAERS reports received in the window","reports":35584,"serious":11489,"deaths":1013,"serious_pct":32.3,"death_pct":2.8,"reports_q1":3675,"reports_q2":4335,"reports_q3":4789,"reports_q4":5173,"reports_q5":4686,"reports_q6":3915,"reports_q7":4025,"reports_q8":4986,"serious_q1":1379,"serious_q2":1366,"serious_q3":1489,"serious_q4":1449,"serious_q5":1668,"serious_q6":1301,"serious_q7":1412,"serious_q8":1425,"topReactions":"OFF LABEL USE (9,124); BLOOD GLUCOSE INCREASED (3,278); PRODUCT STORAGE ERROR (2,501); INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1,364); NAUSEA (1,264)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:calcium-carbonate","dataset":"drug-events","jurisdiction":"US","ingredient":"CALCIUM CARBONATE","level":"ingredient","rank":32,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CALCIUM CARBONATE: 34,898 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 27,579 were serious (79.0%) and 6,072 reported a death outcome (17.4%). Most reported reactions: OFF LABEL USE (4,686); FATIGUE (3,960); PAIN (3,359); DRUG INEFFECTIVE (3,147); NAUSEA (3,096). A report does not show that the drug caused the event.","value":34898,"unit":"FAERS reports received in the window","reports":34898,"serious":27579,"deaths":6072,"serious_pct":79,"death_pct":17.4,"reports_q1":4494,"reports_q2":4707,"reports_q3":4459,"reports_q4":4384,"reports_q5":4746,"reports_q6":4200,"reports_q7":3952,"reports_q8":3956,"serious_q1":3662,"serious_q2":3802,"serious_q3":3580,"serious_q4":3453,"serious_q5":3730,"serious_q6":3413,"serious_q7":3018,"serious_q8":2921,"topReactions":"OFF LABEL USE (4,686); FATIGUE (3,960); PAIN (3,359); DRUG INEFFECTIVE (3,147); NAUSEA (3,096)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pembrolizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"PEMBROLIZUMAB","level":"ingredient","rank":33,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PEMBROLIZUMAB: 33,470 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 30,333 were serious (90.6%) and 5,018 reported a death outcome (15.0%). Most reported reactions: MALIGNANT NEOPLASM PROGRESSION (3,285); DIARRHOEA (1,794); DEATH (1,457); OFF LABEL USE (1,448); FATIGUE (1,369). A report does not show that the drug caused the event.","value":33470,"unit":"FAERS reports received in the window","reports":33470,"serious":30333,"deaths":5018,"serious_pct":90.6,"death_pct":15,"reports_q1":3889,"reports_q2":4328,"reports_q3":4092,"reports_q4":4449,"reports_q5":4507,"reports_q6":4318,"reports_q7":3890,"reports_q8":3997,"serious_q1":3332,"serious_q2":3911,"serious_q3":3696,"serious_q4":4046,"serious_q5":4105,"serious_q6":3991,"serious_q7":3535,"serious_q8":3717,"topReactions":"MALIGNANT NEOPLASM PROGRESSION (3,285); DIARRHOEA (1,794); DEATH (1,457); OFF LABEL USE (1,448); FATIGUE (1,369)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:magnesium-oxide","dataset":"drug-events","jurisdiction":"US","ingredient":"MAGNESIUM OXIDE","level":"ingredient","rank":34,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MAGNESIUM OXIDE: 33,342 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 26,476 were serious (79.4%) and 5,780 reported a death outcome (17.3%). Most reported reactions: OFF LABEL USE (4,311); FATIGUE (3,641); PAIN (3,117); DIARRHOEA (2,871); DRUG INEFFECTIVE (2,834). A report does not show that the drug caused the event.","value":33342,"unit":"FAERS reports received in the window","reports":33342,"serious":26476,"deaths":5780,"serious_pct":79.4,"death_pct":17.3,"reports_q1":4341,"reports_q2":4556,"reports_q3":4331,"reports_q4":4221,"reports_q5":4460,"reports_q6":3971,"reports_q7":3823,"reports_q8":3639,"serious_q1":3547,"serious_q2":3709,"serious_q3":3467,"serious_q4":3374,"serious_q5":3520,"serious_q6":3239,"serious_q7":2917,"serious_q8":2703,"topReactions":"OFF LABEL USE (4,311); FATIGUE (3,641); PAIN (3,117); DIARRHOEA (2,871); DRUG INEFFECTIVE (2,834)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:upadacitinib","dataset":"drug-events","jurisdiction":"US","ingredient":"UPADACITINIB","level":"ingredient","rank":35,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"UPADACITINIB: 33,208 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 26,234 were serious (79.0%) and 1,363 reported a death outcome (4.1%). Most reported reactions: DRUG INEFFECTIVE (1,724); ARTHRALGIA (1,707); PAIN (1,655); SURGERY (1,220); FATIGUE (1,026). A report does not show that the drug caused the event.","value":33208,"unit":"FAERS reports received in the window","reports":33208,"serious":26234,"deaths":1363,"serious_pct":79,"death_pct":4.1,"reports_q1":3842,"reports_q2":4133,"reports_q3":4175,"reports_q4":4464,"reports_q5":4206,"reports_q6":4389,"reports_q7":4178,"reports_q8":3821,"serious_q1":2906,"serious_q2":3072,"serious_q3":3108,"serious_q4":3454,"serious_q5":3381,"serious_q6":3756,"serious_q7":3478,"serious_q8":3079,"topReactions":"DRUG INEFFECTIVE (1,724); ARTHRALGIA (1,707); PAIN (1,655); SURGERY (1,220); FATIGUE (1,026)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:rosuvastatin-calcium","dataset":"drug-events","jurisdiction":"US","ingredient":"ROSUVASTATIN CALCIUM","level":"ingredient","rank":36,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ROSUVASTATIN CALCIUM: 33,092 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,888 were serious (69.2%) and 1,790 reported a death outcome (5.4%). Most reported reactions: FATIGUE (2,584); NAUSEA (2,090); DIARRHOEA (2,030); DYSPNOEA (2,019); OFF LABEL USE (1,987). A report does not show that the drug caused the event.","value":33092,"unit":"FAERS reports received in the window","reports":33092,"serious":22888,"deaths":1790,"serious_pct":69.2,"death_pct":5.4,"reports_q1":3738,"reports_q2":3692,"reports_q3":3980,"reports_q4":3987,"reports_q5":4844,"reports_q6":4144,"reports_q7":4258,"reports_q8":4449,"serious_q1":2680,"serious_q2":2690,"serious_q3":2830,"serious_q4":2756,"serious_q5":3221,"serious_q6":3026,"serious_q7":2962,"serious_q8":2723,"topReactions":"FATIGUE (2,584); NAUSEA (2,090); DIARRHOEA (2,030); DYSPNOEA (2,019); OFF LABEL USE (1,987)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:guaifenesin","dataset":"drug-events","jurisdiction":"US","ingredient":"GUAIFENESIN","level":"ingredient","rank":37,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"GUAIFENESIN: 32,979 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 15,090 were serious (45.8%) and 2,001 reported a death outcome (6.1%). Most reported reactions: DRUG INEFFECTIVE (3,078); EXPOSURE DURING PREGNANCY (3,020); FATIGUE (3,010); HEADACHE (2,748); OFF LABEL USE (2,702). A report does not show that the drug caused the event.","value":32979,"unit":"FAERS reports received in the window","reports":32979,"serious":15090,"deaths":2001,"serious_pct":45.8,"death_pct":6.1,"reports_q1":3685,"reports_q2":3719,"reports_q3":3502,"reports_q4":4173,"reports_q5":5937,"reports_q6":4948,"reports_q7":3548,"reports_q8":3467,"serious_q1":1745,"serious_q2":1831,"serious_q3":1844,"serious_q4":1765,"serious_q5":2664,"serious_q6":1938,"serious_q7":1757,"serious_q8":1546,"topReactions":"DRUG INEFFECTIVE (3,078); EXPOSURE DURING PREGNANCY (3,020); FATIGUE (3,010); HEADACHE (2,748); OFF LABEL USE (2,702)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cyanocobalamin","dataset":"drug-events","jurisdiction":"US","ingredient":"CYANOCOBALAMIN","level":"ingredient","rank":38,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CYANOCOBALAMIN: 32,225 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 25,673 were serious (79.7%) and 5,529 reported a death outcome (17.2%). Most reported reactions: OFF LABEL USE (4,289); FATIGUE (3,702); PAIN (3,272); DRUG INEFFECTIVE (2,856); ARTHRALGIA (2,819). A report does not show that the drug caused the event.","value":32225,"unit":"FAERS reports received in the window","reports":32225,"serious":25673,"deaths":5529,"serious_pct":79.7,"death_pct":17.2,"reports_q1":4192,"reports_q2":4470,"reports_q3":4049,"reports_q4":4117,"reports_q5":4312,"reports_q6":3889,"reports_q7":3640,"reports_q8":3556,"serious_q1":3407,"serious_q2":3626,"serious_q3":3305,"serious_q4":3270,"serious_q5":3447,"serious_q6":3177,"serious_q7":2819,"serious_q8":2622,"topReactions":"OFF LABEL USE (4,289); FATIGUE (3,702); PAIN (3,272); DRUG INEFFECTIVE (2,856); ARTHRALGIA (2,819)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pyridoxine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"PYRIDOXINE HYDROCHLORIDE","level":"ingredient","rank":39,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PYRIDOXINE HYDROCHLORIDE: 32,080 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 24,859 were serious (77.5%) and 5,481 reported a death outcome (17.1%). Most reported reactions: OFF LABEL USE (4,158); FATIGUE (3,696); PAIN (3,182); ARTHRALGIA (2,848); DRUG INEFFECTIVE (2,817). A report does not show that the drug caused the event.","value":32080,"unit":"FAERS reports received in the window","reports":32080,"serious":24859,"deaths":5481,"serious_pct":77.5,"death_pct":17.1,"reports_q1":4104,"reports_q2":4404,"reports_q3":4082,"reports_q4":4066,"reports_q5":4353,"reports_q6":3784,"reports_q7":3697,"reports_q8":3590,"serious_q1":3263,"serious_q2":3501,"serious_q3":3260,"serious_q4":3160,"serious_q5":3345,"serious_q6":3002,"serious_q7":2765,"serious_q8":2563,"topReactions":"OFF LABEL USE (4,158); FATIGUE (3,696); PAIN (3,182); ARTHRALGIA (2,848); DRUG INEFFECTIVE (2,817)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cyclophosphamide","dataset":"drug-events","jurisdiction":"US","ingredient":"CYCLOPHOSPHAMIDE","level":"ingredient","rank":40,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CYCLOPHOSPHAMIDE: 31,930 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 30,289 were serious (94.9%) and 5,366 reported a death outcome (16.8%). Most reported reactions: OFF LABEL USE (3,946); DRUG INEFFECTIVE (2,661); FEBRILE NEUTROPENIA (2,642); NEUTROPENIA (1,860); MYELOSUPPRESSION (1,695). A report does not show that the drug caused the event.","value":31930,"unit":"FAERS reports received in the window","reports":31930,"serious":30289,"deaths":5366,"serious_pct":94.9,"death_pct":16.8,"reports_q1":4525,"reports_q2":4997,"reports_q3":3638,"reports_q4":3763,"reports_q5":4448,"reports_q6":3654,"reports_q7":3316,"reports_q8":3589,"serious_q1":4354,"serious_q2":4192,"serious_q3":3517,"serious_q4":3684,"serious_q5":4343,"serious_q6":3516,"serious_q7":3179,"serious_q8":3504,"topReactions":"OFF LABEL USE (3,946); DRUG INEFFECTIVE (2,661); FEBRILE NEUTROPENIA (2,642); NEUTROPENIA (1,860); MYELOSUPPRESSION (1,695)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cyclophosphamide-anhydrous","dataset":"drug-events","jurisdiction":"US","ingredient":"CYCLOPHOSPHAMIDE ANHYDROUS","level":"ingredient","rank":41,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CYCLOPHOSPHAMIDE ANHYDROUS: 31,929 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 30,289 were serious (94.9%) and 5,366 reported a death outcome (16.8%). Most reported reactions: OFF LABEL USE (3,946); DRUG INEFFECTIVE (2,661); FEBRILE NEUTROPENIA (2,642); NEUTROPENIA (1,860); MYELOSUPPRESSION (1,695). A report does not show that the drug caused the event.","value":31929,"unit":"FAERS reports received in the window","reports":31929,"serious":30289,"deaths":5366,"serious_pct":94.9,"death_pct":16.8,"reports_q1":4525,"reports_q2":4997,"reports_q3":3638,"reports_q4":3762,"reports_q5":4448,"reports_q6":3654,"reports_q7":3316,"reports_q8":3589,"serious_q1":4354,"serious_q2":4192,"serious_q3":3517,"serious_q4":3684,"serious_q5":4343,"serious_q6":3516,"serious_q7":3179,"serious_q8":3504,"topReactions":"OFF LABEL USE (3,946); DRUG INEFFECTIVE (2,661); FEBRILE NEUTROPENIA (2,642); NEUTROPENIA (1,860); MYELOSUPPRESSION (1,695)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cetirizine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"CETIRIZINE HYDROCHLORIDE","level":"ingredient","rank":42,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CETIRIZINE HYDROCHLORIDE: 31,679 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 17,268 were serious (54.5%) and 4,380 reported a death outcome (13.8%). Most reported reactions: OFF LABEL USE (3,912); FATIGUE (3,780); DRUG INEFFECTIVE (3,539); RASH (3,172); PRURITUS (3,134). A report does not show that the drug caused the event.","value":31679,"unit":"FAERS reports received in the window","reports":31679,"serious":17268,"deaths":4380,"serious_pct":54.5,"death_pct":13.8,"reports_q1":3687,"reports_q2":4248,"reports_q3":4427,"reports_q4":3890,"reports_q5":4137,"reports_q6":3561,"reports_q7":3809,"reports_q8":3920,"serious_q1":2146,"serious_q2":2496,"serious_q3":2582,"serious_q4":2035,"serious_q5":2288,"serious_q6":2056,"serious_q7":1904,"serious_q8":1761,"topReactions":"OFF LABEL USE (3,912); FATIGUE (3,780); DRUG INEFFECTIVE (3,539); RASH (3,172); PRURITUS (3,134)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:levothyroxine-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"LEVOTHYROXINE SODIUM","level":"ingredient","rank":43,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LEVOTHYROXINE SODIUM: 30,743 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 17,725 were serious (57.7%) and 2,377 reported a death outcome (7.7%). Most reported reactions: FATIGUE (2,847); HEADACHE (2,364); OFF LABEL USE (2,315); NAUSEA (2,231); DIARRHOEA (2,092). A report does not show that the drug caused the event.","value":30743,"unit":"FAERS reports received in the window","reports":30743,"serious":17725,"deaths":2377,"serious_pct":57.7,"death_pct":7.7,"reports_q1":3761,"reports_q2":3641,"reports_q3":4077,"reports_q4":3498,"reports_q5":4209,"reports_q6":3807,"reports_q7":3871,"reports_q8":3879,"serious_q1":2175,"serious_q2":2115,"serious_q3":2301,"serious_q4":2143,"serious_q5":2305,"serious_q6":2220,"serious_q7":2381,"serious_q8":2085,"topReactions":"FATIGUE (2,847); HEADACHE (2,364); OFF LABEL USE (2,315); NAUSEA (2,231); DIARRHOEA (2,092)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:tacrolimus","dataset":"drug-events","jurisdiction":"US","ingredient":"TACROLIMUS","level":"ingredient","rank":44,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TACROLIMUS: 29,164 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 24,700 were serious (84.7%) and 3,923 reported a death outcome (13.5%). Most reported reactions: OFF LABEL USE (3,865); DRUG INEFFECTIVE (2,525); ACUTE KIDNEY INJURY (1,366); DRUG INTERACTION (1,109); PRODUCT USE IN UNAPPROVED INDICATION (915). A report does not show that the drug caused the event.","value":29164,"unit":"FAERS reports received in the window","reports":29164,"serious":24700,"deaths":3923,"serious_pct":84.7,"death_pct":13.5,"reports_q1":3327,"reports_q2":4673,"reports_q3":3785,"reports_q4":3051,"reports_q5":3871,"reports_q6":3826,"reports_q7":3201,"reports_q8":3430,"serious_q1":2909,"serious_q2":3932,"serious_q3":3206,"serious_q4":2568,"serious_q5":3352,"serious_q6":3178,"serious_q7":2721,"serious_q8":2834,"topReactions":"OFF LABEL USE (3,865); DRUG INEFFECTIVE (2,525); ACUTE KIDNEY INJURY (1,366); DRUG INTERACTION (1,109); PRODUCT USE IN UNAPPROVED INDICATION (915)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:mycophenolate-mofetil","dataset":"drug-events","jurisdiction":"US","ingredient":"MYCOPHENOLATE MOFETIL","level":"ingredient","rank":45,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MYCOPHENOLATE MOFETIL: 28,983 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 25,241 were serious (87.1%) and 5,667 reported a death outcome (19.6%). Most reported reactions: OFF LABEL USE (5,853); DRUG INEFFECTIVE (3,104); DIARRHOEA (1,630); CONDITION AGGRAVATED (1,409); FATIGUE (1,379). A report does not show that the drug caused the event.","value":28983,"unit":"FAERS reports received in the window","reports":28983,"serious":25241,"deaths":5667,"serious_pct":87.1,"death_pct":19.6,"reports_q1":3283,"reports_q2":4781,"reports_q3":3186,"reports_q4":3037,"reports_q5":3845,"reports_q6":4172,"reports_q7":3352,"reports_q8":3327,"serious_q1":2943,"serious_q2":3900,"serious_q3":2810,"serious_q4":2712,"serious_q5":3446,"serious_q6":3537,"serious_q7":2931,"serious_q8":2962,"topReactions":"OFF LABEL USE (5,853); DRUG INEFFECTIVE (3,104); DIARRHOEA (1,630); CONDITION AGGRAVATED (1,409); FATIGUE (1,379)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:fluticasone-propionate","dataset":"drug-events","jurisdiction":"US","ingredient":"FLUTICASONE PROPIONATE","level":"ingredient","rank":46,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FLUTICASONE PROPIONATE: 28,612 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,978 were serious (45.4%) and 1,426 reported a death outcome (5.0%). Most reported reactions: PRODUCT DOSE OMISSION ISSUE (2,842); DYSPNOEA (2,841); OFF LABEL USE (2,397); DRUG INEFFECTIVE (2,265); HEADACHE (2,134). A report does not show that the drug caused the event.","value":28612,"unit":"FAERS reports received in the window","reports":28612,"serious":12978,"deaths":1426,"serious_pct":45.4,"death_pct":5,"reports_q1":3262,"reports_q2":4271,"reports_q3":3518,"reports_q4":3407,"reports_q5":3488,"reports_q6":3431,"reports_q7":3904,"reports_q8":3331,"serious_q1":1700,"serious_q2":1781,"serious_q3":1802,"serious_q4":1544,"serious_q5":1667,"serious_q6":1574,"serious_q7":1559,"serious_q8":1351,"topReactions":"PRODUCT DOSE OMISSION ISSUE (2,842); DYSPNOEA (2,841); OFF LABEL USE (2,397); DRUG INEFFECTIVE (2,265); HEADACHE (2,134)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:selenium","dataset":"drug-events","jurisdiction":"US","ingredient":"SELENIUM","level":"ingredient","rank":47,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SELENIUM: 28,583 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 23,120 were serious (80.9%) and 5,161 reported a death outcome (18.1%). Most reported reactions: OFF LABEL USE (3,935); FATIGUE (3,308); PAIN (2,994); ARTHRALGIA (2,653); DRUG INEFFECTIVE (2,622). A report does not show that the drug caused the event.","value":28583,"unit":"FAERS reports received in the window","reports":28583,"serious":23120,"deaths":5161,"serious_pct":80.9,"death_pct":18.1,"reports_q1":3678,"reports_q2":4065,"reports_q3":3689,"reports_q4":3645,"reports_q5":3835,"reports_q6":3423,"reports_q7":3225,"reports_q8":3023,"serious_q1":3057,"serious_q2":3318,"serious_q3":3037,"serious_q4":2949,"serious_q5":3121,"serious_q6":2821,"serious_q7":2529,"serious_q8":2288,"topReactions":"OFF LABEL USE (3,935); FATIGUE (3,308); PAIN (2,994); ARTHRALGIA (2,653); DRUG INEFFECTIVE (2,622)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:zinc-oxide","dataset":"drug-events","jurisdiction":"US","ingredient":"ZINC OXIDE","level":"ingredient","rank":48,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ZINC OXIDE: 28,149 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 23,079 were serious (82.0%) and 5,228 reported a death outcome (18.6%). Most reported reactions: OFF LABEL USE (3,992); FATIGUE (3,163); PAIN (2,982); DRUG INEFFECTIVE (2,675); ARTHRALGIA (2,604). A report does not show that the drug caused the event.","value":28149,"unit":"FAERS reports received in the window","reports":28149,"serious":23079,"deaths":5228,"serious_pct":82,"death_pct":18.6,"reports_q1":3682,"reports_q2":3997,"reports_q3":3615,"reports_q4":3574,"reports_q5":3746,"reports_q6":3323,"reports_q7":3134,"reports_q8":3078,"serious_q1":3084,"serious_q2":3306,"serious_q3":3027,"serious_q4":2933,"serious_q5":3115,"serious_q6":2770,"serious_q7":2493,"serious_q8":2351,"topReactions":"OFF LABEL USE (3,992); FATIGUE (3,163); PAIN (2,982); DRUG INEFFECTIVE (2,675); ARTHRALGIA (2,604)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:infliximab","dataset":"drug-events","jurisdiction":"US","ingredient":"INFLIXIMAB","level":"ingredient","rank":49,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"INFLIXIMAB: 28,138 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 25,629 were serious (91.1%) and 4,353 reported a death outcome (15.5%). Most reported reactions: OFF LABEL USE (8,309); CONDITION AGGRAVATED (4,414); DRUG INEFFECTIVE (3,821); INTENTIONAL PRODUCT USE ISSUE (3,304); ARTHRALGIA (3,123). A report does not show that the drug caused the event.","value":28138,"unit":"FAERS reports received in the window","reports":28138,"serious":25629,"deaths":4353,"serious_pct":91.1,"death_pct":15.5,"reports_q1":3890,"reports_q2":4154,"reports_q3":3795,"reports_q4":3182,"reports_q5":3623,"reports_q6":3846,"reports_q7":2674,"reports_q8":2974,"serious_q1":3466,"serious_q2":3630,"serious_q3":3514,"serious_q4":2940,"serious_q5":3462,"serious_q6":3441,"serious_q7":2457,"serious_q8":2719,"topReactions":"OFF LABEL USE (8,309); CONDITION AGGRAVATED (4,414); DRUG INEFFECTIVE (3,821); INTENTIONAL PRODUCT USE ISSUE (3,304); ARTHRALGIA (3,123)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:carboplatin","dataset":"drug-events","jurisdiction":"US","ingredient":"CARBOPLATIN","level":"ingredient","rank":50,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CARBOPLATIN: 28,062 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 27,105 were serious (96.6%) and 3,329 reported a death outcome (11.9%). Most reported reactions: OFF LABEL USE (2,488); MYELOSUPPRESSION (2,048); NEUTROPENIA (1,412); MALIGNANT NEOPLASM PROGRESSION (1,281); ANAEMIA (1,280). A report does not show that the drug caused the event.","value":28062,"unit":"FAERS reports received in the window","reports":28062,"serious":27105,"deaths":3329,"serious_pct":96.6,"death_pct":11.9,"reports_q1":3393,"reports_q2":3747,"reports_q3":3402,"reports_q4":3437,"reports_q5":3724,"reports_q6":3554,"reports_q7":3280,"reports_q8":3525,"serious_q1":3198,"serious_q2":3550,"serious_q3":3291,"serious_q4":3332,"serious_q5":3628,"serious_q6":3463,"serious_q7":3187,"serious_q8":3456,"topReactions":"OFF LABEL USE (2,488); MYELOSUPPRESSION (2,048); NEUTROPENIA (1,412); MALIGNANT NEOPLASM PROGRESSION (1,281); ANAEMIA (1,280)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:folic-acid","dataset":"drug-events","jurisdiction":"US","ingredient":"FOLIC ACID","level":"ingredient","rank":51,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FOLIC ACID: 27,513 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,440 were serious (81.6%) and 5,135 reported a death outcome (18.7%). Most reported reactions: OFF LABEL USE (3,838); FATIGUE (3,158); PAIN (2,917); ARTHRALGIA (2,584); DRUG INEFFECTIVE (2,545). A report does not show that the drug caused the event.","value":27513,"unit":"FAERS reports received in the window","reports":27513,"serious":22440,"deaths":5135,"serious_pct":81.6,"death_pct":18.7,"reports_q1":3608,"reports_q2":3908,"reports_q3":3522,"reports_q4":3505,"reports_q5":3655,"reports_q6":3244,"reports_q7":3066,"reports_q8":3005,"serious_q1":3004,"serious_q2":3222,"serious_q3":2936,"serious_q4":2851,"serious_q5":3017,"serious_q6":2702,"serious_q7":2431,"serious_q8":2277,"topReactions":"OFF LABEL USE (3,838); FATIGUE (3,158); PAIN (2,917); ARTHRALGIA (2,584); DRUG INEFFECTIVE (2,545)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sertraline-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"SERTRALINE HYDROCHLORIDE","level":"ingredient","rank":52,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SERTRALINE HYDROCHLORIDE: 27,510 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 20,397 were serious (74.1%) and 2,074 reported a death outcome (7.5%). Most reported reactions: NAUSEA (1,799); OFF LABEL USE (1,712); FATIGUE (1,477); DRUG INEFFECTIVE (1,475); DIARRHOEA (1,358). A report does not show that the drug caused the event.","value":27510,"unit":"FAERS reports received in the window","reports":27510,"serious":20397,"deaths":2074,"serious_pct":74.1,"death_pct":7.5,"reports_q1":3346,"reports_q2":3250,"reports_q3":3797,"reports_q4":3498,"reports_q5":3680,"reports_q6":3107,"reports_q7":3609,"reports_q8":3223,"serious_q1":2449,"serious_q2":2427,"serious_q3":2883,"serious_q4":2678,"serious_q5":2760,"serious_q6":2315,"serious_q7":2597,"serious_q8":2288,"topReactions":"NAUSEA (1,799); OFF LABEL USE (1,712); FATIGUE (1,477); DRUG INEFFECTIVE (1,475); DIARRHOEA (1,358)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:riboflavin","dataset":"drug-events","jurisdiction":"US","ingredient":"RIBOFLAVIN","level":"ingredient","rank":53,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RIBOFLAVIN: 27,426 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,392 were serious (81.6%) and 5,128 reported a death outcome (18.7%). Most reported reactions: OFF LABEL USE (3,837); FATIGUE (3,155); PAIN (2,916); ARTHRALGIA (2,583); DRUG INEFFECTIVE (2,545). A report does not show that the drug caused the event.","value":27426,"unit":"FAERS reports received in the window","reports":27426,"serious":22392,"deaths":5128,"serious_pct":81.6,"death_pct":18.7,"reports_q1":3593,"reports_q2":3901,"reports_q3":3519,"reports_q4":3492,"reports_q5":3643,"reports_q6":3236,"reports_q7":3054,"reports_q8":2988,"serious_q1":2998,"serious_q2":3217,"serious_q3":2935,"serious_q4":2841,"serious_q5":3016,"serious_q6":2696,"serious_q7":2422,"serious_q8":2267,"topReactions":"OFF LABEL USE (3,837); FATIGUE (3,155); PAIN (2,916); ARTHRALGIA (2,583); DRUG INEFFECTIVE (2,545)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:thiamine-mononitrate","dataset":"drug-events","jurisdiction":"US","ingredient":"THIAMINE MONONITRATE","level":"ingredient","rank":54,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"THIAMINE MONONITRATE: 27,424 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,391 were serious (81.6%) and 5,128 reported a death outcome (18.7%). Most reported reactions: OFF LABEL USE (3,837); FATIGUE (3,154); PAIN (2,916); ARTHRALGIA (2,583); DRUG INEFFECTIVE (2,545). A report does not show that the drug caused the event.","value":27424,"unit":"FAERS reports received in the window","reports":27424,"serious":22391,"deaths":5128,"serious_pct":81.6,"death_pct":18.7,"reports_q1":3593,"reports_q2":3901,"reports_q3":3518,"reports_q4":3492,"reports_q5":3643,"reports_q6":3235,"reports_q7":3054,"reports_q8":2988,"serious_q1":2998,"serious_q2":3217,"serious_q3":2934,"serious_q4":2841,"serious_q5":3016,"serious_q6":2696,"serious_q7":2422,"serious_q8":2267,"topReactions":"OFF LABEL USE (3,837); FATIGUE (3,154); PAIN (2,916); ARTHRALGIA (2,583); DRUG INEFFECTIVE (2,545)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cholecalciferol","dataset":"drug-events","jurisdiction":"US","ingredient":"CHOLECALCIFEROL","level":"ingredient","rank":55,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CHOLECALCIFEROL: 27,356 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,357 were serious (81.7%) and 5,122 reported a death outcome (18.7%). Most reported reactions: OFF LABEL USE (3,836); FATIGUE (3,150); PAIN (2,916); ARTHRALGIA (2,585); DRUG INEFFECTIVE (2,543). A report does not show that the drug caused the event.","value":27356,"unit":"FAERS reports received in the window","reports":27356,"serious":22357,"deaths":5122,"serious_pct":81.7,"death_pct":18.7,"reports_q1":3583,"reports_q2":3888,"reports_q3":3513,"reports_q4":3481,"reports_q5":3632,"reports_q6":3229,"reports_q7":3044,"reports_q8":2986,"serious_q1":2997,"serious_q2":3209,"serious_q3":2931,"serious_q4":2835,"serious_q5":3008,"serious_q6":2691,"serious_q7":2417,"serious_q8":2269,"topReactions":"OFF LABEL USE (3,836); FATIGUE (3,150); PAIN (2,916); ARTHRALGIA (2,585); DRUG INEFFECTIVE (2,543)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:alpha-tocopherol-acetate-dl","dataset":"drug-events","jurisdiction":"US","ingredient":".ALPHA.-TOCOPHEROL ACETATE, DL-","level":"ingredient","rank":56,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":".ALPHA.-TOCOPHEROL ACETATE, DL-: 27,334 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,338 were serious (81.7%) and 5,120 reported a death outcome (18.7%). Most reported reactions: OFF LABEL USE (3,834); FATIGUE (3,148); PAIN (2,915); ARTHRALGIA (2,583); DRUG INEFFECTIVE (2,542). A report does not show that the drug caused the event.","value":27334,"unit":"FAERS reports received in the window","reports":27334,"serious":22338,"deaths":5120,"serious_pct":81.7,"death_pct":18.7,"reports_q1":3581,"reports_q2":3888,"reports_q3":3509,"reports_q4":3478,"reports_q5":3630,"reports_q6":3227,"reports_q7":3044,"reports_q8":2977,"serious_q1":2995,"serious_q2":3209,"serious_q3":2927,"serious_q4":2833,"serious_q5":3007,"serious_q6":2690,"serious_q7":2417,"serious_q8":2260,"topReactions":"OFF LABEL USE (3,834); FATIGUE (3,148); PAIN (2,915); ARTHRALGIA (2,583); DRUG INEFFECTIVE (2,542)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:molybdenum","dataset":"drug-events","jurisdiction":"US","ingredient":"MOLYBDENUM","level":"ingredient","rank":57,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MOLYBDENUM: 27,181 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,249 were serious (81.9%) and 5,111 reported a death outcome (18.8%). Most reported reactions: OFF LABEL USE (3,822); FATIGUE (3,130); PAIN (2,906); ARTHRALGIA (2,568); DRUG INEFFECTIVE (2,533). A report does not show that the drug caused the event.","value":27181,"unit":"FAERS reports received in the window","reports":27181,"serious":22249,"deaths":5111,"serious_pct":81.9,"death_pct":18.8,"reports_q1":3568,"reports_q2":3863,"reports_q3":3488,"reports_q4":3453,"reports_q5":3610,"reports_q6":3210,"reports_q7":3028,"reports_q8":2961,"serious_q1":2987,"serious_q2":3190,"serious_q3":2914,"serious_q4":2821,"serious_q5":2991,"serious_q6":2685,"serious_q7":2408,"serious_q8":2253,"topReactions":"OFF LABEL USE (3,822); FATIGUE (3,130); PAIN (2,906); ARTHRALGIA (2,568); DRUG INEFFECTIVE (2,533)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:vitamin-a-acetate","dataset":"drug-events","jurisdiction":"US","ingredient":"VITAMIN A ACETATE","level":"ingredient","rank":58,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VITAMIN A ACETATE: 27,134 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,233 were serious (81.9%) and 5,106 reported a death outcome (18.8%). Most reported reactions: OFF LABEL USE (3,822); FATIGUE (3,129); PAIN (2,906); ARTHRALGIA (2,568); DRUG INEFFECTIVE (2,533). A report does not show that the drug caused the event.","value":27134,"unit":"FAERS reports received in the window","reports":27134,"serious":22233,"deaths":5106,"serious_pct":81.9,"death_pct":18.8,"reports_q1":3561,"reports_q2":3863,"reports_q3":3487,"reports_q4":3447,"reports_q5":3599,"reports_q6":3203,"reports_q7":3022,"reports_q8":2952,"serious_q1":2986,"serious_q2":3191,"serious_q3":2915,"serious_q4":2818,"serious_q5":2990,"serious_q6":2681,"serious_q7":2403,"serious_q8":2249,"topReactions":"OFF LABEL USE (3,822); FATIGUE (3,129); PAIN (2,906); ARTHRALGIA (2,568); DRUG INEFFECTIVE (2,533)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:manganese-sulfate","dataset":"drug-events","jurisdiction":"US","ingredient":"MANGANESE SULFATE","level":"ingredient","rank":59,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MANGANESE SULFATE: 27,133 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,231 were serious (81.9%) and 5,107 reported a death outcome (18.8%). Most reported reactions: OFF LABEL USE (3,821); FATIGUE (3,128); PAIN (2,904); ARTHRALGIA (2,568); DRUG INEFFECTIVE (2,533). A report does not show that the drug caused the event.","value":27133,"unit":"FAERS reports received in the window","reports":27133,"serious":22231,"deaths":5107,"serious_pct":81.9,"death_pct":18.8,"reports_q1":3560,"reports_q2":3863,"reports_q3":3486,"reports_q4":3448,"reports_q5":3599,"reports_q6":3202,"reports_q7":3024,"reports_q8":2951,"serious_q1":2984,"serious_q2":3191,"serious_q3":2914,"serious_q4":2819,"serious_q5":2990,"serious_q6":2680,"serious_q7":2404,"serious_q8":2249,"topReactions":"OFF LABEL USE (3,821); FATIGUE (3,128); PAIN (2,904); ARTHRALGIA (2,568); DRUG INEFFECTIVE (2,533)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:chromium-nicotinate","dataset":"drug-events","jurisdiction":"US","ingredient":"CHROMIUM NICOTINATE","level":"ingredient","rank":60,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CHROMIUM NICOTINATE: 27,127 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,227 were serious (81.9%) and 5,106 reported a death outcome (18.8%). Most reported reactions: OFF LABEL USE (3,821); FATIGUE (3,128); PAIN (2,904); ARTHRALGIA (2,568); DRUG INEFFECTIVE (2,533). A report does not show that the drug caused the event.","value":27127,"unit":"FAERS reports received in the window","reports":27127,"serious":22227,"deaths":5106,"serious_pct":81.9,"death_pct":18.8,"reports_q1":3559,"reports_q2":3862,"reports_q3":3486,"reports_q4":3447,"reports_q5":3599,"reports_q6":3202,"reports_q7":3022,"reports_q8":2950,"serious_q1":2984,"serious_q2":3190,"serious_q3":2914,"serious_q4":2818,"serious_q5":2990,"serious_q6":2680,"serious_q7":2403,"serious_q8":2248,"topReactions":"OFF LABEL USE (3,821); FATIGUE (3,128); PAIN (2,904); ARTHRALGIA (2,568); DRUG INEFFECTIVE (2,533)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lisinopril","dataset":"drug-events","jurisdiction":"US","ingredient":"LISINOPRIL","level":"ingredient","rank":61,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LISINOPRIL: 27,112 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 15,008 were serious (55.4%) and 2,802 reported a death outcome (10.3%). Most reported reactions: FATIGUE (2,707); DIARRHOEA (2,365); OFF LABEL USE (2,278); NAUSEA (2,191); DRUG INEFFECTIVE (1,840). A report does not show that the drug caused the event.","value":27112,"unit":"FAERS reports received in the window","reports":27112,"serious":15008,"deaths":2802,"serious_pct":55.4,"death_pct":10.3,"reports_q1":3357,"reports_q2":3419,"reports_q3":3568,"reports_q4":3380,"reports_q5":4049,"reports_q6":3027,"reports_q7":3171,"reports_q8":3141,"serious_q1":1808,"serious_q2":1979,"serious_q3":2044,"serious_q4":1791,"serious_q5":2187,"serious_q6":1788,"serious_q7":1801,"serious_q8":1610,"topReactions":"FATIGUE (2,707); DIARRHOEA (2,365); OFF LABEL USE (2,278); NAUSEA (2,191); DRUG INEFFECTIVE (1,840)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:methylprednisolone-sodium-succinate","dataset":"drug-events","jurisdiction":"US","ingredient":"METHYLPREDNISOLONE SODIUM SUCCINATE","level":"ingredient","rank":62,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METHYLPREDNISOLONE SODIUM SUCCINATE: 26,624 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 23,513 were serious (88.3%) and 5,482 reported a death outcome (20.6%). Most reported reactions: OFF LABEL USE (6,614); DRUG INEFFECTIVE (4,010); CONDITION AGGRAVATED (2,035); PAIN (1,884); NAUSEA (1,795). A report does not show that the drug caused the event.","value":26624,"unit":"FAERS reports received in the window","reports":26624,"serious":23513,"deaths":5482,"serious_pct":88.3,"death_pct":20.6,"reports_q1":3252,"reports_q2":4479,"reports_q3":3379,"reports_q4":3011,"reports_q5":3800,"reports_q6":3258,"reports_q7":2788,"reports_q8":2657,"serious_q1":2925,"serious_q2":3400,"serious_q3":3054,"serious_q4":2724,"serious_q5":3499,"serious_q6":2963,"serious_q7":2559,"serious_q8":2389,"topReactions":"OFF LABEL USE (6,614); DRUG INEFFECTIVE (4,010); CONDITION AGGRAVATED (2,035); PAIN (1,884); NAUSEA (1,795)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dapagliflozin-propanediol","dataset":"drug-events","jurisdiction":"US","ingredient":"DAPAGLIFLOZIN PROPANEDIOL","level":"ingredient","rank":63,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DAPAGLIFLOZIN PROPANEDIOL: 26,135 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 22,471 were serious (86.0%) and 5,655 reported a death outcome (21.6%). Most reported reactions: DEATH (4,841); DIARRHOEA (1,032); NAUSEA (1,005); FATIGUE (929); ACUTE KIDNEY INJURY (922). A report does not show that the drug caused the event.","value":26135,"unit":"FAERS reports received in the window","reports":26135,"serious":22471,"deaths":5655,"serious_pct":86,"death_pct":21.6,"reports_q1":3103,"reports_q2":3541,"reports_q3":3250,"reports_q4":3510,"reports_q5":3251,"reports_q6":3205,"reports_q7":3106,"reports_q8":3169,"serious_q1":2675,"serious_q2":3114,"serious_q3":2826,"serious_q4":2976,"serious_q5":2710,"serious_q6":2844,"serious_q7":2539,"serious_q8":2787,"topReactions":"DEATH (4,841); DIARRHOEA (1,032); NAUSEA (1,005); FATIGUE (929); ACUTE KIDNEY INJURY (922)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:montelukast-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"MONTELUKAST SODIUM","level":"ingredient","rank":64,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MONTELUKAST SODIUM: 26,053 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,388 were serious (55.2%) and 1,044 reported a death outcome (4.0%). Most reported reactions: DYSPNOEA (2,871); ASTHMA (2,791); DRUG INEFFECTIVE (2,023); COUGH (1,946); PNEUMONIA (1,879). A report does not show that the drug caused the event.","value":26053,"unit":"FAERS reports received in the window","reports":26053,"serious":14388,"deaths":1044,"serious_pct":55.2,"death_pct":4,"reports_q1":3310,"reports_q2":3726,"reports_q3":3352,"reports_q4":2907,"reports_q5":3316,"reports_q6":2934,"reports_q7":3206,"reports_q8":3302,"serious_q1":2030,"serious_q2":1964,"serious_q3":1979,"serious_q4":1554,"serious_q5":1796,"serious_q6":1657,"serious_q7":1831,"serious_q8":1577,"topReactions":"DYSPNOEA (2,871); ASTHMA (2,791); DRUG INEFFECTIVE (2,023); COUGH (1,946); PNEUMONIA (1,879)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pregabalin","dataset":"drug-events","jurisdiction":"US","ingredient":"PREGABALIN","level":"ingredient","rank":65,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PREGABALIN: 25,986 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 21,599 were serious (83.1%) and 4,049 reported a death outcome (15.6%). Most reported reactions: OFF LABEL USE (2,500); FATIGUE (2,324); DRUG INEFFECTIVE (2,079); HEADACHE (1,966); NAUSEA (1,965). A report does not show that the drug caused the event.","value":25986,"unit":"FAERS reports received in the window","reports":25986,"serious":21599,"deaths":4049,"serious_pct":83.1,"death_pct":15.6,"reports_q1":3655,"reports_q2":3297,"reports_q3":3026,"reports_q4":3096,"reports_q5":3785,"reports_q6":3088,"reports_q7":2983,"reports_q8":3056,"serious_q1":2961,"serious_q2":2812,"serious_q3":2505,"serious_q4":2639,"serious_q5":3093,"serious_q6":2637,"serious_q7":2437,"serious_q8":2515,"topReactions":"OFF LABEL USE (2,500); FATIGUE (2,324); DRUG INEFFECTIVE (2,079); HEADACHE (1,966); NAUSEA (1,965)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sodium-chloride","dataset":"drug-events","jurisdiction":"US","ingredient":"SODIUM CHLORIDE","level":"ingredient","rank":66,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SODIUM CHLORIDE: 25,974 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 19,388 were serious (74.6%) and 1,742 reported a death outcome (6.7%). Most reported reactions: MYELOSUPPRESSION (2,779); NAUSEA (1,826); OFF LABEL USE (1,714); DYSPNOEA (1,550); FATIGUE (1,312). A report does not show that the drug caused the event.","value":25974,"unit":"FAERS reports received in the window","reports":25974,"serious":19388,"deaths":1742,"serious_pct":74.6,"death_pct":6.7,"reports_q1":3100,"reports_q2":3512,"reports_q3":3195,"reports_q4":3264,"reports_q5":3532,"reports_q6":3043,"reports_q7":3125,"reports_q8":3203,"serious_q1":2286,"serious_q2":2550,"serious_q3":2353,"serious_q4":2528,"serious_q5":2652,"serious_q6":2319,"serious_q7":2364,"serious_q8":2336,"topReactions":"MYELOSUPPRESSION (2,779); NAUSEA (1,826); OFF LABEL USE (1,714); DYSPNOEA (1,550); FATIGUE (1,312)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:prednisolone","dataset":"drug-events","jurisdiction":"US","ingredient":"PREDNISOLONE","level":"ingredient","rank":67,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PREDNISOLONE: 25,924 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 24,121 were serious (93.0%) and 4,040 reported a death outcome (15.6%). Most reported reactions: OFF LABEL USE (4,513); DRUG INEFFECTIVE (2,674); CONDITION AGGRAVATED (1,445); DIARRHOEA (1,074); PYREXIA (1,057). A report does not show that the drug caused the event.","value":25924,"unit":"FAERS reports received in the window","reports":25924,"serious":24121,"deaths":4040,"serious_pct":93,"death_pct":15.6,"reports_q1":3441,"reports_q2":3970,"reports_q3":3293,"reports_q4":2914,"reports_q5":3253,"reports_q6":3252,"reports_q7":2915,"reports_q8":2886,"serious_q1":3253,"serious_q2":3493,"serious_q3":3138,"serious_q4":2778,"serious_q5":2963,"serious_q6":3001,"serious_q7":2777,"serious_q8":2718,"topReactions":"OFF LABEL USE (4,513); DRUG INEFFECTIVE (2,674); CONDITION AGGRAVATED (1,445); DIARRHOEA (1,074); PYREXIA (1,057)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ondansetron-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"ONDANSETRON HYDROCHLORIDE","level":"ingredient","rank":68,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ONDANSETRON HYDROCHLORIDE: 24,404 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 17,242 were serious (70.7%) and 2,220 reported a death outcome (9.1%). Most reported reactions: NAUSEA (3,152); FATIGUE (2,576); OFF LABEL USE (2,429); DIARRHOEA (2,063); VOMITING (1,686). A report does not show that the drug caused the event.","value":24404,"unit":"FAERS reports received in the window","reports":24404,"serious":17242,"deaths":2220,"serious_pct":70.7,"death_pct":9.1,"reports_q1":3036,"reports_q2":2906,"reports_q3":3134,"reports_q4":2962,"reports_q5":3166,"reports_q6":2979,"reports_q7":3204,"reports_q8":3017,"serious_q1":2186,"serious_q2":2137,"serious_q3":2172,"serious_q4":2098,"serious_q5":2226,"serious_q6":2139,"serious_q7":2232,"serious_q8":2052,"topReactions":"NAUSEA (3,152); FATIGUE (2,576); OFF LABEL USE (2,429); DIARRHOEA (2,063); VOMITING (1,686)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:rosuvastatin","dataset":"drug-events","jurisdiction":"US","ingredient":"ROSUVASTATIN","level":"ingredient","rank":69,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ROSUVASTATIN: 24,370 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 17,831 were serious (73.2%) and 1,382 reported a death outcome (5.7%). Most reported reactions: FATIGUE (1,784); OFF LABEL USE (1,586); NAUSEA (1,540); DIARRHOEA (1,492); VOMITING (1,260). A report does not show that the drug caused the event.","value":24370,"unit":"FAERS reports received in the window","reports":24370,"serious":17831,"deaths":1382,"serious_pct":73.2,"death_pct":5.7,"reports_q1":2709,"reports_q2":2800,"reports_q3":2967,"reports_q4":2995,"reports_q5":3492,"reports_q6":3071,"reports_q7":3117,"reports_q8":3219,"serious_q1":2099,"serious_q2":2106,"serious_q3":2190,"serious_q4":2159,"serious_q5":2568,"serious_q6":2357,"serious_q7":2233,"serious_q8":2119,"topReactions":"FATIGUE (1,784); OFF LABEL USE (1,586); NAUSEA (1,540); DIARRHOEA (1,492); VOMITING (1,260)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:oxycodone-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"OXYCODONE HYDROCHLORIDE","level":"ingredient","rank":70,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OXYCODONE HYDROCHLORIDE: 24,086 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 18,459 were serious (76.6%) and 6,714 reported a death outcome (27.9%). Most reported reactions: OFF LABEL USE (3,179); FATIGUE (2,741); NAUSEA (2,639); PAIN (2,547); DRUG INEFFECTIVE (2,466). A report does not show that the drug caused the event.","value":24086,"unit":"FAERS reports received in the window","reports":24086,"serious":18459,"deaths":6714,"serious_pct":76.6,"death_pct":27.9,"reports_q1":3002,"reports_q2":3004,"reports_q3":3363,"reports_q4":2887,"reports_q5":3399,"reports_q6":2774,"reports_q7":2846,"reports_q8":2811,"serious_q1":2341,"serious_q2":2420,"serious_q3":2682,"serious_q4":2265,"serious_q5":2493,"serious_q6":2120,"serious_q7":2108,"serious_q8":2030,"topReactions":"OFF LABEL USE (3,179); FATIGUE (2,741); NAUSEA (2,639); PAIN (2,547); DRUG INEFFECTIVE (2,466)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:famotidine","dataset":"drug-events","jurisdiction":"US","ingredient":"FAMOTIDINE","level":"ingredient","rank":71,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FAMOTIDINE: 23,936 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,587 were serious (52.6%) and 1,257 reported a death outcome (5.3%). Most reported reactions: OFF LABEL USE (1,852); FATIGUE (1,819); NAUSEA (1,804); DIARRHOEA (1,744); DRUG INEFFECTIVE (1,385). A report does not show that the drug caused the event.","value":23936,"unit":"FAERS reports received in the window","reports":23936,"serious":12587,"deaths":1257,"serious_pct":52.6,"death_pct":5.3,"reports_q1":2646,"reports_q2":3125,"reports_q3":2869,"reports_q4":2989,"reports_q5":3177,"reports_q6":2766,"reports_q7":3180,"reports_q8":3184,"serious_q1":1473,"serious_q2":1603,"serious_q3":1543,"serious_q4":1596,"serious_q5":1647,"serious_q6":1498,"serious_q7":1747,"serious_q8":1480,"topReactions":"OFF LABEL USE (1,852); FATIGUE (1,819); NAUSEA (1,804); DIARRHOEA (1,744); DRUG INEFFECTIVE (1,385)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cyclosporine","dataset":"drug-events","jurisdiction":"US","ingredient":"CYCLOSPORINE","level":"ingredient","rank":72,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CYCLOSPORINE: 23,507 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 13,056 were serious (55.5%) and 2,073 reported a death outcome (8.8%). Most reported reactions: DRUG INEFFECTIVE (3,917); EYE IRRITATION (3,361); OFF LABEL USE (2,967); EYE PAIN (1,581); CONDITION AGGRAVATED (848). A report does not show that the drug caused the event.","value":23507,"unit":"FAERS reports received in the window","reports":23507,"serious":13056,"deaths":2073,"serious_pct":55.5,"death_pct":8.8,"reports_q1":2638,"reports_q2":4148,"reports_q3":2127,"reports_q4":2049,"reports_q5":3035,"reports_q6":3340,"reports_q7":2982,"reports_q8":3188,"serious_q1":1688,"serious_q2":2100,"serious_q3":1582,"serious_q4":1520,"serious_q5":1690,"serious_q6":1447,"serious_q7":1581,"serious_q8":1448,"topReactions":"DRUG INEFFECTIVE (3,917); EYE IRRITATION (3,361); OFF LABEL USE (2,967); EYE PAIN (1,581); CONDITION AGGRAVATED (848)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:bupropion-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"BUPROPION HYDROCHLORIDE","level":"ingredient","rank":73,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BUPROPION HYDROCHLORIDE: 23,348 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,339 were serious (48.6%) and 1,681 reported a death outcome (7.2%). Most reported reactions: NAUSEA (2,126); DRUG INEFFECTIVE (1,669); HEADACHE (1,654); FATIGUE (1,561); OFF LABEL USE (1,444). A report does not show that the drug caused the event.","value":23348,"unit":"FAERS reports received in the window","reports":23348,"serious":11339,"deaths":1681,"serious_pct":48.6,"death_pct":7.2,"reports_q1":2867,"reports_q2":3431,"reports_q3":4003,"reports_q4":2409,"reports_q5":2448,"reports_q6":2932,"reports_q7":2496,"reports_q8":2762,"serious_q1":1259,"serious_q2":1469,"serious_q3":1528,"serious_q4":1325,"serious_q5":1429,"serious_q6":1263,"serious_q7":1563,"serious_q8":1503,"topReactions":"NAUSEA (2,126); DRUG INEFFECTIVE (1,669); HEADACHE (1,654); FATIGUE (1,561); OFF LABEL USE (1,444)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:quetiapine-fumarate","dataset":"drug-events","jurisdiction":"US","ingredient":"QUETIAPINE FUMARATE","level":"ingredient","rank":74,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"QUETIAPINE FUMARATE: 23,327 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 20,347 were serious (87.2%) and 4,784 reported a death outcome (20.5%). Most reported reactions: OFF LABEL USE (2,533); DRUG INEFFECTIVE (2,216); TOXICITY TO VARIOUS AGENTS (1,686); VOMITING (1,672); FATIGUE (1,604). A report does not show that the drug caused the event.","value":23327,"unit":"FAERS reports received in the window","reports":23327,"serious":20347,"deaths":4784,"serious_pct":87.2,"death_pct":20.5,"reports_q1":2989,"reports_q2":3067,"reports_q3":3246,"reports_q4":2743,"reports_q5":2929,"reports_q6":2690,"reports_q7":2994,"reports_q8":2669,"serious_q1":2590,"serious_q2":2721,"serious_q3":2833,"serious_q4":2355,"serious_q5":2596,"serious_q6":2370,"serious_q7":2589,"serious_q8":2293,"topReactions":"OFF LABEL USE (2,533); DRUG INEFFECTIVE (2,216); TOXICITY TO VARIOUS AGENTS (1,686); VOMITING (1,672); FATIGUE (1,604)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:omalizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"OMALIZUMAB","level":"ingredient","rank":75,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OMALIZUMAB: 23,074 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,957 were serious (34.5%) and 235 reported a death outcome (1.0%). Most reported reactions: OFF LABEL USE (5,485); NO ADVERSE EVENT (5,469); URTICARIA (4,221); ASTHMA (2,329); DRUG INEFFECTIVE (2,271). A report does not show that the drug caused the event.","value":23074,"unit":"FAERS reports received in the window","reports":23074,"serious":7957,"deaths":235,"serious_pct":34.5,"death_pct":1,"reports_q1":2265,"reports_q2":6136,"reports_q3":2903,"reports_q4":1850,"reports_q5":2534,"reports_q6":2556,"reports_q7":2434,"reports_q8":2396,"serious_q1":871,"serious_q2":838,"serious_q3":1470,"serious_q4":665,"serious_q5":974,"serious_q6":990,"serious_q7":1027,"serious_q8":1122,"topReactions":"OFF LABEL USE (5,485); NO ADVERSE EVENT (5,469); URTICARIA (4,221); ASTHMA (2,329); DRUG INEFFECTIVE (2,271)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:budesonide","dataset":"drug-events","jurisdiction":"US","ingredient":"BUDESONIDE","level":"ingredient","rank":76,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BUDESONIDE: 22,761 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,453 were serious (54.7%) and 945 reported a death outcome (4.2%). Most reported reactions: DYSPNOEA (2,337); DRUG INEFFECTIVE (2,020); ASTHMA (1,985); OFF LABEL USE (1,955); PRODUCT DOSE OMISSION ISSUE (1,710). A report does not show that the drug caused the event.","value":22761,"unit":"FAERS reports received in the window","reports":22761,"serious":12453,"deaths":945,"serious_pct":54.7,"death_pct":4.2,"reports_q1":2836,"reports_q2":2765,"reports_q3":2806,"reports_q4":3028,"reports_q5":2892,"reports_q6":2415,"reports_q7":3508,"reports_q8":2511,"serious_q1":1939,"serious_q2":1593,"serious_q3":1643,"serious_q4":1476,"serious_q5":1492,"serious_q6":1423,"serious_q7":1633,"serious_q8":1254,"topReactions":"DYSPNOEA (2,337); DRUG INEFFECTIVE (2,020); ASTHMA (1,985); OFF LABEL USE (1,955); PRODUCT DOSE OMISSION ISSUE (1,710)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:vedolizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"VEDOLIZUMAB","level":"ingredient","rank":77,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VEDOLIZUMAB: 22,234 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 20,240 were serious (91.0%) and 1,652 reported a death outcome (7.4%). Most reported reactions: COLITIS ULCERATIVE (4,578); OFF LABEL USE (4,046); CROHN^S DISEASE (2,900); DIARRHOEA (2,475); DRUG INEFFECTIVE (2,185). A report does not show that the drug caused the event.","value":22234,"unit":"FAERS reports received in the window","reports":22234,"serious":20240,"deaths":1652,"serious_pct":91,"death_pct":7.4,"reports_q1":2825,"reports_q2":2995,"reports_q3":2737,"reports_q4":2860,"reports_q5":2810,"reports_q6":2817,"reports_q7":3333,"reports_q8":1857,"serious_q1":2554,"serious_q2":2717,"serious_q3":2516,"serious_q4":2647,"serious_q5":2507,"serious_q6":2608,"serious_q7":3093,"serious_q8":1598,"topReactions":"COLITIS ULCERATIVE (4,578); OFF LABEL USE (4,046); CROHN^S DISEASE (2,900); DIARRHOEA (2,475); DRUG INEFFECTIVE (2,185)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:spironolactone","dataset":"drug-events","jurisdiction":"US","ingredient":"SPIRONOLACTONE","level":"ingredient","rank":78,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SPIRONOLACTONE: 21,797 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,674 were serious (67.3%) and 1,689 reported a death outcome (7.7%). Most reported reactions: DYSPNOEA (1,561); DIARRHOEA (1,478); FATIGUE (1,458); OFF LABEL USE (1,389); NAUSEA (1,352). A report does not show that the drug caused the event.","value":21797,"unit":"FAERS reports received in the window","reports":21797,"serious":14674,"deaths":1689,"serious_pct":67.3,"death_pct":7.7,"reports_q1":2767,"reports_q2":2859,"reports_q3":2858,"reports_q4":2764,"reports_q5":2600,"reports_q6":2574,"reports_q7":2675,"reports_q8":2700,"serious_q1":1914,"serious_q2":2048,"serious_q3":1891,"serious_q4":1852,"serious_q5":1712,"serious_q6":1761,"serious_q7":1768,"serious_q8":1728,"topReactions":"DYSPNOEA (1,561); DIARRHOEA (1,478); FATIGUE (1,458); OFF LABEL USE (1,389); NAUSEA (1,352)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:atorvastatin-calcium-trihydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"ATORVASTATIN CALCIUM TRIHYDRATE","level":"ingredient","rank":79,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ATORVASTATIN CALCIUM TRIHYDRATE: 21,426 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,405 were serious (53.2%) and 1,239 reported a death outcome (5.8%). Most reported reactions: FATIGUE (1,905); DIARRHOEA (1,643); HEADACHE (1,597); DYSPNOEA (1,532); NAUSEA (1,388). A report does not show that the drug caused the event.","value":21426,"unit":"FAERS reports received in the window","reports":21426,"serious":11405,"deaths":1239,"serious_pct":53.2,"death_pct":5.8,"reports_q1":2709,"reports_q2":2371,"reports_q3":2740,"reports_q4":2697,"reports_q5":3143,"reports_q6":2435,"reports_q7":2660,"reports_q8":2671,"serious_q1":1441,"serious_q2":1408,"serious_q3":1541,"serious_q4":1434,"serious_q5":1470,"serious_q6":1369,"serious_q7":1464,"serious_q8":1278,"topReactions":"FATIGUE (1,905); DIARRHOEA (1,643); HEADACHE (1,597); DYSPNOEA (1,532); NAUSEA (1,388)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:diclofenac-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"DICLOFENAC SODIUM","level":"ingredient","rank":80,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DICLOFENAC SODIUM: 21,376 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 13,554 were serious (63.4%) and 5,122 reported a death outcome (24.0%). Most reported reactions: PRODUCT USE IN UNAPPROVED INDICATION (3,863); OFF LABEL USE (3,658); DRUG INEFFECTIVE (3,323); PAIN (2,822); FATIGUE (2,798). A report does not show that the drug caused the event.","value":21376,"unit":"FAERS reports received in the window","reports":21376,"serious":13554,"deaths":5122,"serious_pct":63.4,"death_pct":24,"reports_q1":2658,"reports_q2":4023,"reports_q3":3210,"reports_q4":2189,"reports_q5":2674,"reports_q6":2606,"reports_q7":1917,"reports_q8":2099,"serious_q1":1777,"serious_q2":2068,"serious_q3":2031,"serious_q4":1406,"serious_q5":1955,"serious_q6":1639,"serious_q7":1290,"serious_q8":1388,"topReactions":"PRODUCT USE IN UNAPPROVED INDICATION (3,863); OFF LABEL USE (3,658); DRUG INEFFECTIVE (3,323); PAIN (2,822); FATIGUE (2,798)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:bisoprolol-fumarate","dataset":"drug-events","jurisdiction":"US","ingredient":"BISOPROLOL FUMARATE","level":"ingredient","rank":81,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BISOPROLOL FUMARATE: 21,173 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 20,365 were serious (96.2%) and 2,314 reported a death outcome (10.9%). Most reported reactions: ACUTE KIDNEY INJURY (1,367); FATIGUE (1,162); OFF LABEL USE (1,131); DIARRHOEA (1,033); DYSPNOEA (1,010). A report does not show that the drug caused the event.","value":21173,"unit":"FAERS reports received in the window","reports":21173,"serious":20365,"deaths":2314,"serious_pct":96.2,"death_pct":10.9,"reports_q1":2864,"reports_q2":2715,"reports_q3":2592,"reports_q4":2666,"reports_q5":2574,"reports_q6":2651,"reports_q7":2524,"reports_q8":2587,"serious_q1":2729,"serious_q2":2612,"serious_q3":2490,"serious_q4":2603,"serious_q5":2451,"serious_q6":2562,"serious_q7":2414,"serious_q8":2504,"topReactions":"ACUTE KIDNEY INJURY (1,367); FATIGUE (1,162); OFF LABEL USE (1,131); DIARRHOEA (1,033); DYSPNOEA (1,010)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:methylprednisolone","dataset":"drug-events","jurisdiction":"US","ingredient":"METHYLPREDNISOLONE","level":"ingredient","rank":82,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METHYLPREDNISOLONE: 21,166 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 18,632 were serious (88.0%) and 3,407 reported a death outcome (16.1%). Most reported reactions: OFF LABEL USE (4,884); DRUG INEFFECTIVE (3,117); CONDITION AGGRAVATED (1,272); NAUSEA (1,116); PNEUMONIA (1,105). A report does not show that the drug caused the event.","value":21166,"unit":"FAERS reports received in the window","reports":21166,"serious":18632,"deaths":3407,"serious_pct":88,"death_pct":16.1,"reports_q1":2645,"reports_q2":3424,"reports_q3":2648,"reports_q4":2383,"reports_q5":3019,"reports_q6":2598,"reports_q7":2352,"reports_q8":2097,"serious_q1":2358,"serious_q2":2651,"serious_q3":2354,"serious_q4":2137,"serious_q5":2777,"serious_q6":2341,"serious_q7":2140,"serious_q8":1874,"topReactions":"OFF LABEL USE (4,884); DRUG INEFFECTIVE (3,117); CONDITION AGGRAVATED (1,272); NAUSEA (1,116); PNEUMONIA (1,105)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:paclitaxel","dataset":"drug-events","jurisdiction":"US","ingredient":"PACLITAXEL","level":"ingredient","rank":83,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PACLITAXEL: 21,157 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 20,355 were serious (96.2%) and 2,158 reported a death outcome (10.2%). Most reported reactions: MYELOSUPPRESSION (2,080); OFF LABEL USE (1,686); NEUTROPENIA (1,066); MALIGNANT NEOPLASM PROGRESSION (1,036); NAUSEA (893). A report does not show that the drug caused the event.","value":21157,"unit":"FAERS reports received in the window","reports":21157,"serious":20355,"deaths":2158,"serious_pct":96.2,"death_pct":10.2,"reports_q1":2572,"reports_q2":2916,"reports_q3":2507,"reports_q4":2532,"reports_q5":2882,"reports_q6":2763,"reports_q7":2489,"reports_q8":2496,"serious_q1":2331,"serious_q2":2796,"serious_q3":2419,"serious_q4":2457,"serious_q5":2819,"serious_q6":2695,"serious_q7":2411,"serious_q8":2427,"topReactions":"MYELOSUPPRESSION (2,080); OFF LABEL USE (1,686); NEUTROPENIA (1,066); MALIGNANT NEOPLASM PROGRESSION (1,036); NAUSEA (893)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:adalimumab","dataset":"drug-events","jurisdiction":"US","ingredient":"ADALIMUMAB","level":"ingredient","rank":84,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ADALIMUMAB: 20,935 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 18,104 were serious (86.5%) and 4,648 reported a death outcome (22.2%). Most reported reactions: OFF LABEL USE (3,777); DRUG INEFFECTIVE (3,126); FATIGUE (2,341); PAIN (2,290); ARTHRALGIA (2,285). A report does not show that the drug caused the event.","value":20935,"unit":"FAERS reports received in the window","reports":20935,"serious":18104,"deaths":4648,"serious_pct":86.5,"death_pct":22.2,"reports_q1":2511,"reports_q2":2834,"reports_q3":2654,"reports_q4":2506,"reports_q5":2965,"reports_q6":2698,"reports_q7":2018,"reports_q8":2749,"serious_q1":2104,"serious_q2":2532,"serious_q3":2351,"serious_q4":2073,"serious_q5":2596,"serious_q6":2302,"serious_q7":1714,"serious_q8":2432,"topReactions":"OFF LABEL USE (3,777); DRUG INEFFECTIVE (3,126); FATIGUE (2,341); PAIN (2,290); ARTHRALGIA (2,285)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:fluticasone-furoate","dataset":"drug-events","jurisdiction":"US","ingredient":"FLUTICASONE FUROATE","level":"ingredient","rank":85,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FLUTICASONE FUROATE: 20,494 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,053 were serious (44.2%) and 1,118 reported a death outcome (5.5%). Most reported reactions: DYSPNOEA (2,712); DRUG INEFFECTIVE (1,914); COUGH (1,696); PRODUCT DOSE OMISSION ISSUE (1,681); WRONG TECHNIQUE IN DEVICE USAGE PROCESS (1,600). A report does not show that the drug caused the event.","value":20494,"unit":"FAERS reports received in the window","reports":20494,"serious":9053,"deaths":1118,"serious_pct":44.2,"death_pct":5.5,"reports_q1":2584,"reports_q2":2750,"reports_q3":2816,"reports_q4":2663,"reports_q5":2336,"reports_q6":2423,"reports_q7":2292,"reports_q8":2630,"serious_q1":1297,"serious_q2":1256,"serious_q3":1274,"serious_q4":1163,"serious_q5":1002,"serious_q6":954,"serious_q7":1025,"serious_q8":1082,"topReactions":"DYSPNOEA (2,712); DRUG INEFFECTIVE (1,914); COUGH (1,696); PRODUCT DOSE OMISSION ISSUE (1,681); WRONG TECHNIQUE IN DEVICE USAGE PROCESS (1,600)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dextrose-monohydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"DEXTROSE MONOHYDRATE","level":"ingredient","rank":86,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DEXTROSE MONOHYDRATE: 20,365 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,385 were serious (70.6%) and 2,053 reported a death outcome (10.1%). Most reported reactions: NAUSEA (1,410); DYSPNOEA (1,393); DIARRHOEA (1,383); FATIGUE (1,266); OFF LABEL USE (1,203). A report does not show that the drug caused the event.","value":20365,"unit":"FAERS reports received in the window","reports":20365,"serious":14385,"deaths":2053,"serious_pct":70.6,"death_pct":10.1,"reports_q1":2591,"reports_q2":2619,"reports_q3":2566,"reports_q4":2653,"reports_q5":2648,"reports_q6":2476,"reports_q7":2456,"reports_q8":2356,"serious_q1":1818,"serious_q2":1885,"serious_q3":1814,"serious_q4":1873,"serious_q5":1862,"serious_q6":1761,"serious_q7":1782,"serious_q8":1590,"topReactions":"NAUSEA (1,410); DYSPNOEA (1,393); DIARRHOEA (1,383); FATIGUE (1,266); OFF LABEL USE (1,203)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:empagliflozin","dataset":"drug-events","jurisdiction":"US","ingredient":"EMPAGLIFLOZIN","level":"ingredient","rank":87,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"EMPAGLIFLOZIN: 20,255 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 13,324 were serious (65.8%) and 1,195 reported a death outcome (5.9%). Most reported reactions: NAUSEA (1,446); DIARRHOEA (1,425); OFF LABEL USE (1,250); FATIGUE (1,149); VOMITING (1,134). A report does not show that the drug caused the event.","value":20255,"unit":"FAERS reports received in the window","reports":20255,"serious":13324,"deaths":1195,"serious_pct":65.8,"death_pct":5.9,"reports_q1":2639,"reports_q2":2371,"reports_q3":2441,"reports_q4":2502,"reports_q5":2836,"reports_q6":2239,"reports_q7":2693,"reports_q8":2534,"serious_q1":1664,"serious_q2":1703,"serious_q3":1614,"serious_q4":1657,"serious_q5":1900,"serious_q6":1544,"serious_q7":1672,"serious_q8":1570,"topReactions":"NAUSEA (1,446); DIARRHOEA (1,425); OFF LABEL USE (1,250); FATIGUE (1,149); VOMITING (1,134)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:bimekizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"BIMEKIZUMAB","level":"ingredient","rank":88,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BIMEKIZUMAB: 20,216 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,553 were serious (32.4%) and 128 reported a death outcome (0.6%). Most reported reactions: PRODUCT DOSE OMISSION ISSUE (3,706); PSORIASIS (2,487); DRUG INEFFECTIVE (1,928); HIDRADENITIS (1,574); OFF LABEL USE (1,565). A report does not show that the drug caused the event.","value":20216,"unit":"FAERS reports received in the window","reports":20216,"serious":6553,"deaths":128,"serious_pct":32.4,"death_pct":0.6,"reports_q1":338,"reports_q2":1572,"reports_q3":1580,"reports_q4":2480,"reports_q5":1112,"reports_q6":5755,"reports_q7":2433,"reports_q8":4946,"serious_q1":323,"serious_q2":533,"serious_q3":715,"serious_q4":935,"serious_q5":1069,"serious_q6":1042,"serious_q7":967,"serious_q8":969,"topReactions":"PRODUCT DOSE OMISSION ISSUE (3,706); PSORIASIS (2,487); DRUG INEFFECTIVE (1,928); HIDRADENITIS (1,574); OFF LABEL USE (1,565)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pimavanserin-tartrate","dataset":"drug-events","jurisdiction":"US","ingredient":"PIMAVANSERIN TARTRATE","level":"ingredient","rank":89,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PIMAVANSERIN TARTRATE: 20,205 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,665 were serious (57.7%) and 4,009 reported a death outcome (19.8%). Most reported reactions: HALLUCINATION (4,225); DEATH (3,405); DRUG INEFFECTIVE (1,963); PRODUCT USE ISSUE (1,563); PRODUCT DOSE OMISSION ISSUE (1,390). A report does not show that the drug caused the event.","value":20205,"unit":"FAERS reports received in the window","reports":20205,"serious":11665,"deaths":4009,"serious_pct":57.7,"death_pct":19.8,"reports_q1":2215,"reports_q2":2496,"reports_q3":2674,"reports_q4":3089,"reports_q5":2411,"reports_q6":2326,"reports_q7":2590,"reports_q8":2404,"serious_q1":946,"serious_q2":1394,"serious_q3":1544,"serious_q4":1651,"serious_q5":1519,"serious_q6":1481,"serious_q7":1688,"serious_q8":1442,"topReactions":"HALLUCINATION (4,225); DEATH (3,405); DRUG INEFFECTIVE (1,963); PRODUCT USE ISSUE (1,563); PRODUCT DOSE OMISSION ISSUE (1,390)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:treprostinil","dataset":"drug-events","jurisdiction":"US","ingredient":"TREPROSTINIL","level":"ingredient","rank":90,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TREPROSTINIL: 20,110 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,518 were serious (47.3%) and 1,173 reported a death outcome (5.8%). Most reported reactions: DYSPNOEA (3,096); HEADACHE (2,993); COUGH (2,715); DIARRHOEA (2,325); NAUSEA (1,897). A report does not show that the drug caused the event.","value":20110,"unit":"FAERS reports received in the window","reports":20110,"serious":9518,"deaths":1173,"serious_pct":47.3,"death_pct":5.8,"reports_q1":2388,"reports_q2":2555,"reports_q3":2736,"reports_q4":2869,"reports_q5":2607,"reports_q6":2475,"reports_q7":2294,"reports_q8":2186,"serious_q1":1135,"serious_q2":1221,"serious_q3":1312,"serious_q4":1335,"serious_q5":1221,"serious_q6":1151,"serious_q7":1145,"serious_q8":998,"topReactions":"DYSPNOEA (3,096); HEADACHE (2,993); COUGH (2,715); DIARRHOEA (2,325); NAUSEA (1,897)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:certolizumab-pegol","dataset":"drug-events","jurisdiction":"US","ingredient":"CERTOLIZUMAB PEGOL","level":"ingredient","rank":91,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CERTOLIZUMAB PEGOL: 19,990 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,028 were serious (70.2%) and 3,264 reported a death outcome (16.3%). Most reported reactions: RHEUMATOID ARTHRITIS (4,536); OFF LABEL USE (3,141); DRUG INEFFECTIVE (3,019); PSORIATIC ARTHROPATHY (2,694); MATERNAL EXPOSURE DURING PREGNANCY (2,460). A report does not show that the drug caused the event.","value":19990,"unit":"FAERS reports received in the window","reports":19990,"serious":14028,"deaths":3264,"serious_pct":70.2,"death_pct":16.3,"reports_q1":1967,"reports_q2":2470,"reports_q3":2073,"reports_q4":6332,"reports_q5":2112,"reports_q6":1574,"reports_q7":1601,"reports_q8":1861,"serious_q1":1905,"serious_q2":2412,"serious_q3":2007,"serious_q4":1995,"serious_q5":2039,"serious_q6":1523,"serious_q7":1121,"serious_q8":1026,"topReactions":"RHEUMATOID ARTHRITIS (4,536); OFF LABEL USE (3,141); DRUG INEFFECTIVE (3,019); PSORIATIC ARTHROPATHY (2,694); MATERNAL EXPOSURE DURING PREGNANCY (2,460)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sodium-cation","dataset":"drug-events","jurisdiction":"US","ingredient":"SODIUM CATION","level":"ingredient","rank":92,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SODIUM CATION: 19,975 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 15,285 were serious (76.5%) and 1,006 reported a death outcome (5.0%). Most reported reactions: MYELOSUPPRESSION (2,773); NAUSEA (1,518); OFF LABEL USE (1,455); DYSPNOEA (1,304); HEADACHE (1,094). A report does not show that the drug caused the event.","value":19975,"unit":"FAERS reports received in the window","reports":19975,"serious":15285,"deaths":1006,"serious_pct":76.5,"death_pct":5,"reports_q1":2455,"reports_q2":2712,"reports_q3":2456,"reports_q4":2469,"reports_q5":2656,"reports_q6":2299,"reports_q7":2430,"reports_q8":2498,"serious_q1":1860,"serious_q2":2018,"serious_q3":1836,"serious_q4":1980,"serious_q5":2092,"serious_q6":1796,"serious_q7":1873,"serious_q8":1830,"topReactions":"MYELOSUPPRESSION (2,773); NAUSEA (1,518); OFF LABEL USE (1,455); DYSPNOEA (1,304); HEADACHE (1,094)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:vilanterol-trifenatate","dataset":"drug-events","jurisdiction":"US","ingredient":"VILANTEROL TRIFENATATE","level":"ingredient","rank":93,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VILANTEROL TRIFENATATE: 19,775 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,254 were serious (41.7%) and 1,075 reported a death outcome (5.4%). Most reported reactions: DYSPNOEA (2,647); PRODUCT DOSE OMISSION ISSUE (1,737); WRONG TECHNIQUE IN DEVICE USAGE PROCESS (1,736); DRUG INEFFECTIVE (1,648); COUGH (1,588). A report does not show that the drug caused the event.","value":19775,"unit":"FAERS reports received in the window","reports":19775,"serious":8254,"deaths":1075,"serious_pct":41.7,"death_pct":5.4,"reports_q1":2504,"reports_q2":2635,"reports_q3":2683,"reports_q4":2646,"reports_q5":2250,"reports_q6":2342,"reports_q7":2206,"reports_q8":2509,"serious_q1":1192,"serious_q2":1171,"serious_q3":1130,"serious_q4":1122,"serious_q5":901,"serious_q6":860,"serious_q7":943,"serious_q8":935,"topReactions":"DYSPNOEA (2,647); PRODUCT DOSE OMISSION ISSUE (1,737); WRONG TECHNIQUE IN DEVICE USAGE PROCESS (1,736); DRUG INEFFECTIVE (1,648); COUGH (1,588)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:abatacept","dataset":"drug-events","jurisdiction":"US","ingredient":"ABATACEPT","level":"ingredient","rank":94,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ABATACEPT: 19,463 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,739 were serious (44.9%) and 3,398 reported a death outcome (17.5%). Most reported reactions: ARTHRALGIA (4,697); JOINT SWELLING (4,512); RHEUMATOID ARTHRITIS (3,377); PAIN (3,286); OFF LABEL USE (2,272). A report does not show that the drug caused the event.","value":19463,"unit":"FAERS reports received in the window","reports":19463,"serious":8739,"deaths":3398,"serious_pct":44.9,"death_pct":17.5,"reports_q1":2667,"reports_q2":2819,"reports_q3":2402,"reports_q4":2419,"reports_q5":2548,"reports_q6":2285,"reports_q7":2103,"reports_q8":2220,"serious_q1":1360,"serious_q2":1512,"serious_q3":1124,"serious_q4":975,"serious_q5":1188,"serious_q6":1033,"serious_q7":763,"serious_q8":784,"topReactions":"ARTHRALGIA (4,697); JOINT SWELLING (4,512); RHEUMATOID ARTHRITIS (3,377); PAIN (3,286); OFF LABEL USE (2,272)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:epinephrine-bitartrate","dataset":"drug-events","jurisdiction":"US","ingredient":"EPINEPHRINE BITARTRATE","level":"ingredient","rank":95,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"EPINEPHRINE BITARTRATE: 19,349 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,149 were serious (62.8%) and 1,365 reported a death outcome (7.1%). Most reported reactions: DRUG INEFFECTIVE (2,213); OFF LABEL USE (1,505); NAUSEA (1,123); FATIGUE (1,094); HEADACHE (1,083). A report does not show that the drug caused the event.","value":19349,"unit":"FAERS reports received in the window","reports":19349,"serious":12149,"deaths":1365,"serious_pct":62.8,"death_pct":7.1,"reports_q1":2367,"reports_q2":2589,"reports_q3":2545,"reports_q4":2560,"reports_q5":2410,"reports_q6":2256,"reports_q7":2378,"reports_q8":2244,"serious_q1":1520,"serious_q2":1577,"serious_q3":1547,"serious_q4":1617,"serious_q5":1570,"serious_q6":1395,"serious_q7":1573,"serious_q8":1350,"topReactions":"DRUG INEFFECTIVE (2,213); OFF LABEL USE (1,505); NAUSEA (1,123); FATIGUE (1,094); HEADACHE (1,083)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:bevacizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"BEVACIZUMAB","level":"ingredient","rank":96,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BEVACIZUMAB: 19,100 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 16,816 were serious (88.0%) and 3,352 reported a death outcome (17.5%). Most reported reactions: OFF LABEL USE (4,079); DEATH (1,378); DISEASE PROGRESSION (1,026); FATIGUE (954); DIARRHOEA (914). A report does not show that the drug caused the event.","value":19100,"unit":"FAERS reports received in the window","reports":19100,"serious":16816,"deaths":3352,"serious_pct":88,"death_pct":17.5,"reports_q1":2580,"reports_q2":2224,"reports_q3":2249,"reports_q4":2134,"reports_q5":2565,"reports_q6":2648,"reports_q7":2333,"reports_q8":2367,"serious_q1":1915,"serious_q2":1978,"serious_q3":1947,"serious_q4":1921,"serious_q5":2326,"serious_q6":2388,"serious_q7":2107,"serious_q8":2234,"topReactions":"OFF LABEL USE (4,079); DEATH (1,378); DISEASE PROGRESSION (1,026); FATIGUE (954); DIARRHOEA (914)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:hydroxychloroquine-sulfate","dataset":"drug-events","jurisdiction":"US","ingredient":"HYDROXYCHLOROQUINE SULFATE","level":"ingredient","rank":97,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"HYDROXYCHLOROQUINE SULFATE: 19,023 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,908 were serious (78.4%) and 4,044 reported a death outcome (21.3%). Most reported reactions: OFF LABEL USE (3,500); DRUG INEFFECTIVE (2,819); RHEUMATOID ARTHRITIS (2,546); FATIGUE (2,459); PAIN (2,393). A report does not show that the drug caused the event.","value":19023,"unit":"FAERS reports received in the window","reports":19023,"serious":14908,"deaths":4044,"serious_pct":78.4,"death_pct":21.3,"reports_q1":2490,"reports_q2":2922,"reports_q3":2645,"reports_q4":2130,"reports_q5":2684,"reports_q6":2323,"reports_q7":1943,"reports_q8":1886,"serious_q1":2044,"serious_q2":2273,"serious_q3":2159,"serious_q4":1662,"serious_q5":2081,"serious_q6":1834,"serious_q7":1495,"serious_q8":1360,"topReactions":"OFF LABEL USE (3,500); DRUG INEFFECTIVE (2,819); RHEUMATOID ARTHRITIS (2,546); FATIGUE (2,459); PAIN (2,393)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ondansetron","dataset":"drug-events","jurisdiction":"US","ingredient":"ONDANSETRON","level":"ingredient","rank":98,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ONDANSETRON: 18,937 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,152 were serious (74.7%) and 1,846 reported a death outcome (9.7%). Most reported reactions: NAUSEA (2,297); FATIGUE (2,018); OFF LABEL USE (1,934); DIARRHOEA (1,568); VOMITING (1,291). A report does not show that the drug caused the event.","value":18937,"unit":"FAERS reports received in the window","reports":18937,"serious":14152,"deaths":1846,"serious_pct":74.7,"death_pct":9.7,"reports_q1":2389,"reports_q2":2267,"reports_q3":2463,"reports_q4":2295,"reports_q5":2379,"reports_q6":2257,"reports_q7":2469,"reports_q8":2418,"serious_q1":1829,"serious_q2":1745,"serious_q3":1805,"serious_q4":1718,"serious_q5":1764,"serious_q6":1735,"serious_q7":1809,"serious_q8":1747,"topReactions":"NAUSEA (2,297); FATIGUE (2,018); OFF LABEL USE (1,934); DIARRHOEA (1,568); VOMITING (1,291)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:escitalopram-oxalate","dataset":"drug-events","jurisdiction":"US","ingredient":"ESCITALOPRAM OXALATE","level":"ingredient","rank":99,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ESCITALOPRAM OXALATE: 18,546 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,243 were serious (66.0%) and 1,399 reported a death outcome (7.5%). Most reported reactions: OFF LABEL USE (1,420); DRUG INEFFECTIVE (1,416); FATIGUE (1,377); NAUSEA (1,242); DIARRHOEA (1,121). A report does not show that the drug caused the event.","value":18546,"unit":"FAERS reports received in the window","reports":18546,"serious":12243,"deaths":1399,"serious_pct":66,"death_pct":7.5,"reports_q1":2380,"reports_q2":2286,"reports_q3":2428,"reports_q4":2244,"reports_q5":2409,"reports_q6":2150,"reports_q7":2284,"reports_q8":2365,"serious_q1":1588,"serious_q2":1524,"serious_q3":1725,"serious_q4":1501,"serious_q5":1569,"serious_q6":1436,"serious_q7":1461,"serious_q8":1439,"topReactions":"OFF LABEL USE (1,420); DRUG INEFFECTIVE (1,416); FATIGUE (1,377); NAUSEA (1,242); DIARRHOEA (1,121)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:levetiracetam","dataset":"drug-events","jurisdiction":"US","ingredient":"LEVETIRACETAM","level":"ingredient","rank":100,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LEVETIRACETAM: 18,502 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 15,121 were serious (81.7%) and 1,368 reported a death outcome (7.4%). Most reported reactions: SEIZURE (2,258); DRUG INEFFECTIVE (2,183); OFF LABEL USE (2,083); MATERNAL EXPOSURE DURING PREGNANCY (698); FATIGUE (645). A report does not show that the drug caused the event.","value":18502,"unit":"FAERS reports received in the window","reports":18502,"serious":15121,"deaths":1368,"serious_pct":81.7,"death_pct":7.4,"reports_q1":2368,"reports_q2":2339,"reports_q3":2795,"reports_q4":2144,"reports_q5":1988,"reports_q6":1982,"reports_q7":2704,"reports_q8":2182,"serious_q1":2087,"serious_q2":2068,"serious_q3":1974,"serious_q4":1914,"serious_q5":1754,"serious_q6":1711,"serious_q7":1737,"serious_q8":1876,"topReactions":"SEIZURE (2,258); DRUG INEFFECTIVE (2,183); OFF LABEL USE (2,083); MATERNAL EXPOSURE DURING PREGNANCY (698); FATIGUE (645)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dapagliflozin","dataset":"drug-events","jurisdiction":"US","ingredient":"DAPAGLIFLOZIN","level":"ingredient","rank":101,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DAPAGLIFLOZIN: 18,453 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 18,083 were serious (98.0%) and 4,709 reported a death outcome (25.5%). Most reported reactions: DEATH (3,989); ACUTE KIDNEY INJURY (831); OFF LABEL USE (575); DIARRHOEA (534); NAUSEA (519). A report does not show that the drug caused the event.","value":18453,"unit":"FAERS reports received in the window","reports":18453,"serious":18083,"deaths":4709,"serious_pct":98,"death_pct":25.5,"reports_q1":1368,"reports_q2":2506,"reports_q3":2468,"reports_q4":2623,"reports_q5":2264,"reports_q6":2527,"reports_q7":2200,"reports_q8":2497,"serious_q1":1334,"serious_q2":2461,"serious_q3":2418,"serious_q4":2583,"serious_q5":2217,"serious_q6":2484,"serious_q7":2139,"serious_q8":2447,"topReactions":"DEATH (3,989); ACUTE KIDNEY INJURY (831); OFF LABEL USE (575); DIARRHOEA (534); NAUSEA (519)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dapagliflozin-2-3-butanediol-monohydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"DAPAGLIFLOZIN 2,3-BUTANEDIOL MONOHYDRATE","level":"ingredient","rank":102,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DAPAGLIFLOZIN 2,3-BUTANEDIOL MONOHYDRATE: 18,451 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 18,081 were serious (98.0%) and 4,709 reported a death outcome (25.5%). Most reported reactions: DEATH (3,989); ACUTE KIDNEY INJURY (830); OFF LABEL USE (575); DIARRHOEA (534); NAUSEA (519). A report does not show that the drug caused the event.","value":18451,"unit":"FAERS reports received in the window","reports":18451,"serious":18081,"deaths":4709,"serious_pct":98,"death_pct":25.5,"reports_q1":1368,"reports_q2":2506,"reports_q3":2468,"reports_q4":2622,"reports_q5":2264,"reports_q6":2527,"reports_q7":2200,"reports_q8":2496,"serious_q1":1334,"serious_q2":2461,"serious_q3":2418,"serious_q4":2582,"serious_q5":2217,"serious_q6":2484,"serious_q7":2139,"serious_q8":2446,"topReactions":"DEATH (3,989); ACUTE KIDNEY INJURY (830); OFF LABEL USE (575); DIARRHOEA (534); NAUSEA (519)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:potassium-chloride","dataset":"drug-events","jurisdiction":"US","ingredient":"POTASSIUM CHLORIDE","level":"ingredient","rank":103,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"POTASSIUM CHLORIDE: 18,402 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,360 were serious (61.7%) and 1,724 reported a death outcome (9.4%). Most reported reactions: DIARRHOEA (1,490); FATIGUE (1,451); NAUSEA (1,442); DYSPNOEA (1,356); HEADACHE (1,305). A report does not show that the drug caused the event.","value":18402,"unit":"FAERS reports received in the window","reports":18402,"serious":11360,"deaths":1724,"serious_pct":61.7,"death_pct":9.4,"reports_q1":2245,"reports_q2":2304,"reports_q3":2703,"reports_q4":2403,"reports_q5":2345,"reports_q6":2297,"reports_q7":2167,"reports_q8":1938,"serious_q1":1406,"serious_q2":1523,"serious_q3":1604,"serious_q4":1521,"serious_q5":1448,"serious_q6":1378,"serious_q7":1386,"serious_q8":1094,"topReactions":"DIARRHOEA (1,490); FATIGUE (1,451); NAUSEA (1,442); DYSPNOEA (1,356); HEADACHE (1,305)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:amlodipine-besylate","dataset":"drug-events","jurisdiction":"US","ingredient":"AMLODIPINE BESYLATE","level":"ingredient","rank":104,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AMLODIPINE BESYLATE: 18,150 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,831 were serious (59.7%) and 1,221 reported a death outcome (6.7%). Most reported reactions: FATIGUE (1,551); DYSPNOEA (1,266); OFF LABEL USE (1,185); DIARRHOEA (1,183); HEADACHE (1,101). A report does not show that the drug caused the event.","value":18150,"unit":"FAERS reports received in the window","reports":18150,"serious":10831,"deaths":1221,"serious_pct":59.7,"death_pct":6.7,"reports_q1":2246,"reports_q2":2130,"reports_q3":2302,"reports_q4":2347,"reports_q5":2569,"reports_q6":2059,"reports_q7":2224,"reports_q8":2273,"serious_q1":1329,"serious_q2":1400,"serious_q3":1442,"serious_q4":1393,"serious_q5":1420,"serious_q6":1271,"serious_q7":1330,"serious_q8":1246,"topReactions":"FATIGUE (1,551); DYSPNOEA (1,266); OFF LABEL USE (1,185); DIARRHOEA (1,183); HEADACHE (1,101)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:hydrochlorothiazide","dataset":"drug-events","jurisdiction":"US","ingredient":"HYDROCHLOROTHIAZIDE","level":"ingredient","rank":105,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"HYDROCHLOROTHIAZIDE: 17,948 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,000 were serious (61.3%) and 1,200 reported a death outcome (6.7%). Most reported reactions: FATIGUE (1,552); OFF LABEL USE (1,295); NAUSEA (1,292); DIARRHOEA (1,261); DRUG INEFFECTIVE (1,165). A report does not show that the drug caused the event.","value":17948,"unit":"FAERS reports received in the window","reports":17948,"serious":11000,"deaths":1200,"serious_pct":61.3,"death_pct":6.7,"reports_q1":2302,"reports_q2":2187,"reports_q3":2383,"reports_q4":2212,"reports_q5":2516,"reports_q6":2061,"reports_q7":2084,"reports_q8":2203,"serious_q1":1437,"serious_q2":1415,"serious_q3":1509,"serious_q4":1349,"serious_q5":1466,"serious_q6":1316,"serious_q7":1296,"serious_q8":1212,"topReactions":"FATIGUE (1,552); OFF LABEL USE (1,295); NAUSEA (1,292); DIARRHOEA (1,261); DRUG INEFFECTIVE (1,165)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:allopurinol-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"ALLOPURINOL SODIUM","level":"ingredient","rank":106,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ALLOPURINOL SODIUM: 17,845 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 13,756 were serious (77.1%) and 2,115 reported a death outcome (11.9%). Most reported reactions: OFF LABEL USE (1,317); FATIGUE (1,139); DIARRHOEA (1,061); NAUSEA (895); DYSPNOEA (887). A report does not show that the drug caused the event.","value":17845,"unit":"FAERS reports received in the window","reports":17845,"serious":13756,"deaths":2115,"serious_pct":77.1,"death_pct":11.9,"reports_q1":2272,"reports_q2":2226,"reports_q3":2159,"reports_q4":2467,"reports_q5":2323,"reports_q6":2142,"reports_q7":2196,"reports_q8":2060,"serious_q1":1811,"serious_q2":1741,"serious_q3":1688,"serious_q4":1922,"serious_q5":1705,"serious_q6":1691,"serious_q7":1660,"serious_q8":1538,"topReactions":"OFF LABEL USE (1,317); FATIGUE (1,139); DIARRHOEA (1,061); NAUSEA (895); DYSPNOEA (887)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:naproxen-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"NAPROXEN SODIUM","level":"ingredient","rank":107,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"NAPROXEN SODIUM: 17,809 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,456 were serious (69.9%) and 3,854 reported a death outcome (21.6%). Most reported reactions: DRUG INEFFECTIVE (2,515); OFF LABEL USE (2,508); FATIGUE (2,314); NAUSEA (2,181); PAIN (2,156). A report does not show that the drug caused the event.","value":17809,"unit":"FAERS reports received in the window","reports":17809,"serious":12456,"deaths":3854,"serious_pct":69.9,"death_pct":21.6,"reports_q1":2479,"reports_q2":2487,"reports_q3":2312,"reports_q4":2219,"reports_q5":2699,"reports_q6":1997,"reports_q7":1693,"reports_q8":1923,"serious_q1":1570,"serious_q2":1926,"serious_q3":1689,"serious_q4":1486,"serious_q5":1813,"serious_q6":1535,"serious_q7":1184,"serious_q8":1253,"topReactions":"DRUG INEFFECTIVE (2,515); OFF LABEL USE (2,508); FATIGUE (2,314); NAUSEA (2,181); PAIN (2,156)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:allopurinol","dataset":"drug-events","jurisdiction":"US","ingredient":"ALLOPURINOL","level":"ingredient","rank":108,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ALLOPURINOL: 17,759 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 13,683 were serious (77.0%) and 2,090 reported a death outcome (11.8%). Most reported reactions: OFF LABEL USE (1,301); FATIGUE (1,125); DIARRHOEA (1,055); NAUSEA (884); DYSPNOEA (879). A report does not show that the drug caused the event.","value":17759,"unit":"FAERS reports received in the window","reports":17759,"serious":13683,"deaths":2090,"serious_pct":77,"death_pct":11.8,"reports_q1":2265,"reports_q2":2218,"reports_q3":2149,"reports_q4":2462,"reports_q5":2310,"reports_q6":2129,"reports_q7":2177,"reports_q8":2049,"serious_q1":1805,"serious_q2":1735,"serious_q3":1679,"serious_q4":1919,"serious_q5":1693,"serious_q6":1678,"serious_q7":1645,"serious_q8":1529,"topReactions":"OFF LABEL USE (1,301); FATIGUE (1,125); DIARRHOEA (1,055); NAUSEA (884); DYSPNOEA (879)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:clopidogrel-bisulfate","dataset":"drug-events","jurisdiction":"US","ingredient":"CLOPIDOGREL BISULFATE","level":"ingredient","rank":109,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CLOPIDOGREL BISULFATE: 17,726 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 13,690 were serious (77.2%) and 1,485 reported a death outcome (8.4%). Most reported reactions: FATIGUE (1,096); DIARRHOEA (955); DYSPNOEA (918); OFF LABEL USE (864); DRUG INEFFECTIVE (795). A report does not show that the drug caused the event.","value":17726,"unit":"FAERS reports received in the window","reports":17726,"serious":13690,"deaths":1485,"serious_pct":77.2,"death_pct":8.4,"reports_q1":2360,"reports_q2":2097,"reports_q3":2202,"reports_q4":2263,"reports_q5":2584,"reports_q6":2017,"reports_q7":2099,"reports_q8":2104,"serious_q1":1819,"serious_q2":1681,"serious_q3":1714,"serious_q4":1747,"serious_q5":1961,"serious_q6":1593,"serious_q7":1656,"serious_q8":1519,"topReactions":"FATIGUE (1,096); DIARRHOEA (955); DYSPNOEA (918); OFF LABEL USE (864); DRUG INEFFECTIVE (795)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lorazepam","dataset":"drug-events","jurisdiction":"US","ingredient":"LORAZEPAM","level":"ingredient","rank":110,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LORAZEPAM: 17,658 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,222 were serious (80.5%) and 3,034 reported a death outcome (17.2%). Most reported reactions: OFF LABEL USE (2,155); DRUG INEFFECTIVE (1,771); FATIGUE (1,692); NAUSEA (1,528); DIARRHOEA (1,394). A report does not show that the drug caused the event.","value":17658,"unit":"FAERS reports received in the window","reports":17658,"serious":14222,"deaths":3034,"serious_pct":80.5,"death_pct":17.2,"reports_q1":2369,"reports_q2":2348,"reports_q3":2433,"reports_q4":2118,"reports_q5":2286,"reports_q6":2121,"reports_q7":2018,"reports_q8":1965,"serious_q1":1889,"serious_q2":1956,"serious_q3":1969,"serious_q4":1732,"serious_q5":1848,"serious_q6":1734,"serious_q7":1568,"serious_q8":1526,"topReactions":"OFF LABEL USE (2,155); DRUG INEFFECTIVE (1,771); FATIGUE (1,692); NAUSEA (1,528); DIARRHOEA (1,394)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:doxorubicin-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"DOXORUBICIN HYDROCHLORIDE","level":"ingredient","rank":111,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DOXORUBICIN HYDROCHLORIDE: 17,641 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 16,679 were serious (94.5%) and 2,993 reported a death outcome (17.0%). Most reported reactions: FEBRILE NEUTROPENIA (1,867); OFF LABEL USE (1,788); DRUG INEFFECTIVE (1,436); DISEASE PROGRESSION (1,332); NEUTROPENIA (1,223). A report does not show that the drug caused the event.","value":17641,"unit":"FAERS reports received in the window","reports":17641,"serious":16679,"deaths":2993,"serious_pct":94.5,"death_pct":17,"reports_q1":2672,"reports_q2":2961,"reports_q3":1871,"reports_q4":2006,"reports_q5":2267,"reports_q6":1965,"reports_q7":1837,"reports_q8":2062,"serious_q1":2583,"serious_q2":2442,"serious_q3":1818,"serious_q4":1940,"serious_q5":2205,"serious_q6":1915,"serious_q7":1783,"serious_q8":1993,"topReactions":"FEBRILE NEUTROPENIA (1,867); OFF LABEL USE (1,788); DRUG INEFFECTIVE (1,436); DISEASE PROGRESSION (1,332); NEUTROPENIA (1,223)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:secukinumab","dataset":"drug-events","jurisdiction":"US","ingredient":"SECUKINUMAB","level":"ingredient","rank":112,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SECUKINUMAB: 17,612 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,491 were serious (65.2%) and 4,091 reported a death outcome (23.2%). Most reported reactions: PAIN (2,621); DRUG INEFFECTIVE (2,444); OFF LABEL USE (2,354); PSORIATIC ARTHROPATHY (2,335); FATIGUE (2,208). A report does not show that the drug caused the event.","value":17612,"unit":"FAERS reports received in the window","reports":17612,"serious":11491,"deaths":4091,"serious_pct":65.2,"death_pct":23.2,"reports_q1":2661,"reports_q2":2745,"reports_q3":2533,"reports_q4":2306,"reports_q5":2199,"reports_q6":2160,"reports_q7":1487,"reports_q8":1521,"serious_q1":1471,"serious_q2":1748,"serious_q3":1546,"serious_q4":1412,"serious_q5":1562,"serious_q6":1601,"serious_q7":1030,"serious_q8":1121,"topReactions":"PAIN (2,621); DRUG INEFFECTIVE (2,444); OFF LABEL USE (2,354); PSORIATIC ARTHROPATHY (2,335); FATIGUE (2,208)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:denosumab","dataset":"drug-events","jurisdiction":"US","ingredient":"DENOSUMAB","level":"ingredient","rank":113,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DENOSUMAB: 17,302 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,973 were serious (75.0%) and 2,164 reported a death outcome (12.5%). Most reported reactions: DEATH (1,597); OFF LABEL USE (971); FATIGUE (953); DIARRHOEA (771); OSTEONECROSIS OF JAW (737). A report does not show that the drug caused the event.","value":17302,"unit":"FAERS reports received in the window","reports":17302,"serious":12973,"deaths":2164,"serious_pct":75,"death_pct":12.5,"reports_q1":2529,"reports_q2":1925,"reports_q3":2131,"reports_q4":2064,"reports_q5":1944,"reports_q6":1869,"reports_q7":1728,"reports_q8":3112,"serious_q1":1520,"serious_q2":1453,"serious_q3":1594,"serious_q4":1534,"serious_q5":1467,"serious_q6":1441,"serious_q7":1350,"serious_q8":2614,"topReactions":"DEATH (1,597); OFF LABEL USE (971); FATIGUE (953); DIARRHOEA (771); OSTEONECROSIS OF JAW (737)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:finasteride","dataset":"drug-events","jurisdiction":"US","ingredient":"FINASTERIDE","level":"ingredient","rank":114,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FINASTERIDE: 17,187 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,580 were serious (44.1%) and 768 reported a death outcome (4.5%). Most reported reactions: ADVERSE DRUG REACTION (3,617); ERECTILE DYSFUNCTION (788); DRUG INEFFECTIVE (767); FATIGUE (763); DEPRESSION (743). A report does not show that the drug caused the event.","value":17187,"unit":"FAERS reports received in the window","reports":17187,"serious":7580,"deaths":768,"serious_pct":44.1,"death_pct":4.5,"reports_q1":2692,"reports_q2":1093,"reports_q3":4320,"reports_q4":1968,"reports_q5":2021,"reports_q6":1109,"reports_q7":2584,"reports_q8":1400,"serious_q1":1308,"serious_q2":779,"serious_q3":1042,"serious_q4":875,"serious_q5":835,"serious_q6":778,"serious_q7":1177,"serious_q8":786,"topReactions":"ADVERSE DRUG REACTION (3,617); ERECTILE DYSFUNCTION (788); DRUG INEFFECTIVE (767); FATIGUE (763); DEPRESSION (743)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:clozapine","dataset":"drug-events","jurisdiction":"US","ingredient":"CLOZAPINE","level":"ingredient","rank":115,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CLOZAPINE: 17,089 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 16,118 were serious (94.3%) and 2,978 reported a death outcome (17.4%). Most reported reactions: NEUTROPENIA (2,415); DEATH (2,116); HOSPITALISATION (1,846); OFF LABEL USE (1,173); TREATMENT NONCOMPLIANCE (862). A report does not show that the drug caused the event.","value":17089,"unit":"FAERS reports received in the window","reports":17089,"serious":16118,"deaths":2978,"serious_pct":94.3,"death_pct":17.4,"reports_q1":2781,"reports_q2":2631,"reports_q3":2765,"reports_q4":2038,"reports_q5":1688,"reports_q6":1793,"reports_q7":1875,"reports_q8":1518,"serious_q1":2707,"serious_q2":2515,"serious_q3":2283,"serious_q4":1989,"serious_q5":1658,"serious_q6":1739,"serious_q7":1758,"serious_q8":1469,"topReactions":"NEUTROPENIA (2,415); DEATH (2,116); HOSPITALISATION (1,846); OFF LABEL USE (1,173); TREATMENT NONCOMPLIANCE (862)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:etanercept","dataset":"drug-events","jurisdiction":"US","ingredient":"ETANERCEPT","level":"ingredient","rank":116,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ETANERCEPT: 17,047 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,513 were serious (67.5%) and 3,784 reported a death outcome (22.2%). Most reported reactions: RHEUMATOID ARTHRITIS (2,571); OFF LABEL USE (2,535); PAIN (2,466); DRUG INEFFECTIVE (2,334); FATIGUE (2,162). A report does not show that the drug caused the event.","value":17047,"unit":"FAERS reports received in the window","reports":17047,"serious":11513,"deaths":3784,"serious_pct":67.5,"death_pct":22.2,"reports_q1":3160,"reports_q2":2623,"reports_q3":2205,"reports_q4":2070,"reports_q5":1932,"reports_q6":1645,"reports_q7":1291,"reports_q8":2121,"serious_q1":1625,"serious_q2":1755,"serious_q3":1498,"serious_q4":1350,"serious_q5":1488,"serious_q6":1302,"serious_q7":951,"serious_q8":1544,"topReactions":"RHEUMATOID ARTHRITIS (2,571); OFF LABEL USE (2,535); PAIN (2,466); DRUG INEFFECTIVE (2,334); FATIGUE (2,162)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:umeclidinium-bromide","dataset":"drug-events","jurisdiction":"US","ingredient":"UMECLIDINIUM BROMIDE","level":"ingredient","rank":117,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"UMECLIDINIUM BROMIDE: 17,015 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,119 were serious (41.8%) and 973 reported a death outcome (5.7%). Most reported reactions: DYSPNOEA (2,264); WRONG TECHNIQUE IN DEVICE USAGE PROCESS (1,554); PRODUCT DOSE OMISSION ISSUE (1,458); DRUG INEFFECTIVE (1,352); PRODUCT COMPLAINT (1,321). A report does not show that the drug caused the event.","value":17015,"unit":"FAERS reports received in the window","reports":17015,"serious":7119,"deaths":973,"serious_pct":41.8,"death_pct":5.7,"reports_q1":2082,"reports_q2":2296,"reports_q3":2289,"reports_q4":2296,"reports_q5":1929,"reports_q6":2001,"reports_q7":1910,"reports_q8":2212,"serious_q1":992,"serious_q2":1040,"serious_q3":960,"serious_q4":981,"serious_q5":753,"serious_q6":743,"serious_q7":820,"serious_q8":830,"topReactions":"DYSPNOEA (2,264); WRONG TECHNIQUE IN DEVICE USAGE PROCESS (1,554); PRODUCT DOSE OMISSION ISSUE (1,458); DRUG INEFFECTIVE (1,352); PRODUCT COMPLAINT (1,321)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:tocilizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"TOCILIZUMAB","level":"ingredient","rank":118,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TOCILIZUMAB: 16,940 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,086 were serious (71.3%) and 4,513 reported a death outcome (26.6%). Most reported reactions: OFF LABEL USE (3,948); DRUG INEFFECTIVE (2,886); RHEUMATOID ARTHRITIS (2,732); PAIN (2,706); JOINT SWELLING (2,452). A report does not show that the drug caused the event.","value":16940,"unit":"FAERS reports received in the window","reports":16940,"serious":12086,"deaths":4513,"serious_pct":71.3,"death_pct":26.6,"reports_q1":2528,"reports_q2":2836,"reports_q3":2242,"reports_q4":1950,"reports_q5":2124,"reports_q6":1949,"reports_q7":1647,"reports_q8":1664,"serious_q1":1689,"serious_q2":2021,"serious_q3":1529,"serious_q4":1394,"serious_q5":1567,"serious_q6":1434,"serious_q7":1232,"serious_q8":1220,"topReactions":"OFF LABEL USE (3,948); DRUG INEFFECTIVE (2,886); RHEUMATOID ARTHRITIS (2,732); PAIN (2,706); JOINT SWELLING (2,452)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pomalidomide","dataset":"drug-events","jurisdiction":"US","ingredient":"POMALIDOMIDE","level":"ingredient","rank":119,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"POMALIDOMIDE: 16,645 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,402 were serious (56.5%) and 1,604 reported a death outcome (9.6%). Most reported reactions: FATIGUE (1,558); OFF LABEL USE (1,363); DEATH (1,072); PLASMA CELL MYELOMA (950); PNEUMONIA (792). A report does not show that the drug caused the event.","value":16645,"unit":"FAERS reports received in the window","reports":16645,"serious":9402,"deaths":1604,"serious_pct":56.5,"death_pct":9.6,"reports_q1":2274,"reports_q2":2153,"reports_q3":2137,"reports_q4":2259,"reports_q5":2116,"reports_q6":2095,"reports_q7":2053,"reports_q8":1558,"serious_q1":1287,"serious_q2":1219,"serious_q3":1083,"serious_q4":1308,"serious_q5":1174,"serious_q6":1196,"serious_q7":1161,"serious_q8":974,"topReactions":"FATIGUE (1,558); OFF LABEL USE (1,363); DEATH (1,072); PLASMA CELL MYELOMA (950); PNEUMONIA (792)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:alprazolam","dataset":"drug-events","jurisdiction":"US","ingredient":"ALPRAZOLAM","level":"ingredient","rank":120,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ALPRAZOLAM: 16,589 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,827 were serious (71.3%) and 2,059 reported a death outcome (12.4%). Most reported reactions: OFF LABEL USE (1,110); FATIGUE (1,044); TOXICITY TO VARIOUS AGENTS (1,027); NAUSEA (1,016); DRUG INEFFECTIVE (1,008). A report does not show that the drug caused the event.","value":16589,"unit":"FAERS reports received in the window","reports":16589,"serious":11827,"deaths":2059,"serious_pct":71.3,"death_pct":12.4,"reports_q1":2112,"reports_q2":2145,"reports_q3":2314,"reports_q4":2176,"reports_q5":2139,"reports_q6":1758,"reports_q7":2079,"reports_q8":1866,"serious_q1":1465,"serious_q2":1550,"serious_q3":1763,"serious_q4":1613,"serious_q5":1452,"serious_q6":1245,"serious_q7":1520,"serious_q8":1219,"topReactions":"OFF LABEL USE (1,110); FATIGUE (1,044); TOXICITY TO VARIOUS AGENTS (1,027); NAUSEA (1,016); DRUG INEFFECTIVE (1,008)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ramipril","dataset":"drug-events","jurisdiction":"US","ingredient":"RAMIPRIL","level":"ingredient","rank":121,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RAMIPRIL: 16,437 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,724 were serious (89.6%) and 3,169 reported a death outcome (19.3%). Most reported reactions: OFF LABEL USE (2,006); FATIGUE (1,600); PAIN (1,563); VOMITING (1,502); NAUSEA (1,498). A report does not show that the drug caused the event.","value":16437,"unit":"FAERS reports received in the window","reports":16437,"serious":14724,"deaths":3169,"serious_pct":89.6,"death_pct":19.3,"reports_q1":2061,"reports_q2":2195,"reports_q3":2984,"reports_q4":1821,"reports_q5":2113,"reports_q6":1794,"reports_q7":1698,"reports_q8":1771,"serious_q1":1947,"serious_q2":2020,"serious_q3":1934,"serious_q4":1760,"serious_q5":2000,"serious_q6":1737,"serious_q7":1619,"serious_q8":1707,"topReactions":"OFF LABEL USE (2,006); FATIGUE (1,600); PAIN (1,563); VOMITING (1,502); NAUSEA (1,498)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:valsartan","dataset":"drug-events","jurisdiction":"US","ingredient":"VALSARTAN","level":"ingredient","rank":122,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VALSARTAN: 16,208 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,851 were serious (73.1%) and 1,215 reported a death outcome (7.5%). Most reported reactions: FATIGUE (1,077); OFF LABEL USE (1,018); DIARRHOEA (943); DIZZINESS (899); ACUTE KIDNEY INJURY (849). Named in open multidistrict litigation MDL-2875. A report does not show that the drug caused the event.","value":16208,"unit":"FAERS reports received in the window","reports":16208,"serious":11851,"deaths":1215,"serious_pct":73.1,"death_pct":7.5,"reports_q1":2338,"reports_q2":1993,"reports_q3":2124,"reports_q4":2080,"reports_q5":2104,"reports_q6":1874,"reports_q7":1789,"reports_q8":1906,"serious_q1":1728,"serious_q2":1531,"serious_q3":1588,"serious_q4":1577,"serious_q5":1436,"serious_q6":1391,"serious_q7":1306,"serious_q8":1294,"topReactions":"FATIGUE (1,077); OFF LABEL USE (1,018); DIARRHOEA (943); DIZZINESS (899); ACUTE KIDNEY INJURY (849)","mdl":"MDL-2875","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lansoprazole","dataset":"drug-events","jurisdiction":"US","ingredient":"LANSOPRAZOLE","level":"ingredient","rank":123,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LANSOPRAZOLE: 16,111 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,720 were serious (91.4%) and 2,354 reported a death outcome (14.6%). Most reported reactions: OFF LABEL USE (1,634); DIARRHOEA (1,412); FATIGUE (1,383); HEADACHE (1,230); NAUSEA (1,188). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":16111,"unit":"FAERS reports received in the window","reports":16111,"serious":14720,"deaths":2354,"serious_pct":91.4,"death_pct":14.6,"reports_q1":2053,"reports_q2":2353,"reports_q3":2113,"reports_q4":1941,"reports_q5":1964,"reports_q6":1947,"reports_q7":1894,"reports_q8":1846,"serious_q1":1864,"serious_q2":2187,"serious_q3":1925,"serious_q4":1758,"serious_q5":1786,"serious_q6":1795,"serious_q7":1745,"serious_q8":1660,"topReactions":"OFF LABEL USE (1,634); DIARRHOEA (1,412); FATIGUE (1,383); HEADACHE (1,230); NAUSEA (1,188)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:levothyroxine-sodium-anhydrous","dataset":"drug-events","jurisdiction":"US","ingredient":"LEVOTHYROXINE SODIUM ANHYDROUS","level":"ingredient","rank":124,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LEVOTHYROXINE SODIUM ANHYDROUS: 15,974 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,610 were serious (60.2%) and 1,227 reported a death outcome (7.7%). Most reported reactions: FATIGUE (1,548); HEADACHE (1,423); NAUSEA (1,254); DIARRHOEA (1,191); DYSPNOEA (1,143). A report does not show that the drug caused the event.","value":15974,"unit":"FAERS reports received in the window","reports":15974,"serious":9610,"deaths":1227,"serious_pct":60.2,"death_pct":7.7,"reports_q1":2069,"reports_q2":1710,"reports_q3":2274,"reports_q4":1863,"reports_q5":2218,"reports_q6":1908,"reports_q7":1903,"reports_q8":2029,"serious_q1":1258,"serious_q2":1158,"serious_q3":1245,"serious_q4":1196,"serious_q5":1202,"serious_q6":1194,"serious_q7":1239,"serious_q8":1118,"topReactions":"FATIGUE (1,548); HEADACHE (1,423); NAUSEA (1,254); DIARRHOEA (1,191); DYSPNOEA (1,143)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:acyclovir","dataset":"drug-events","jurisdiction":"US","ingredient":"ACYCLOVIR","level":"ingredient","rank":125,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ACYCLOVIR: 15,958 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,648 were serious (73.0%) and 2,026 reported a death outcome (12.7%). Most reported reactions: OFF LABEL USE (1,780); FATIGUE (1,228); DIARRHOEA (1,016); DRUG INEFFECTIVE (982); NAUSEA (885). A report does not show that the drug caused the event.","value":15958,"unit":"FAERS reports received in the window","reports":15958,"serious":11648,"deaths":2026,"serious_pct":73,"death_pct":12.7,"reports_q1":2053,"reports_q2":2080,"reports_q3":2083,"reports_q4":2314,"reports_q5":2123,"reports_q6":1795,"reports_q7":1850,"reports_q8":1660,"serious_q1":1475,"serious_q2":1527,"serious_q3":1477,"serious_q4":1691,"serious_q5":1523,"serious_q6":1315,"serious_q7":1389,"serious_q8":1251,"topReactions":"OFF LABEL USE (1,780); FATIGUE (1,228); DIARRHOEA (1,016); DRUG INEFFECTIVE (982); NAUSEA (885)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:hydrocortisone","dataset":"drug-events","jurisdiction":"US","ingredient":"HYDROCORTISONE","level":"ingredient","rank":126,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"HYDROCORTISONE: 15,943 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,606 were serious (79.1%) and 3,676 reported a death outcome (23.1%). Most reported reactions: OFF LABEL USE (2,992); DRUG INEFFECTIVE (2,302); FATIGUE (2,133); RASH (1,826); CONDITION AGGRAVATED (1,752). A report does not show that the drug caused the event.","value":15943,"unit":"FAERS reports received in the window","reports":15943,"serious":12606,"deaths":3676,"serious_pct":79.1,"death_pct":23.1,"reports_q1":2026,"reports_q2":2458,"reports_q3":2062,"reports_q4":1790,"reports_q5":2244,"reports_q6":1902,"reports_q7":1720,"reports_q8":1741,"serious_q1":1655,"serious_q2":2042,"serious_q3":1659,"serious_q4":1403,"serious_q5":1813,"serious_q6":1508,"serious_q7":1274,"serious_q8":1252,"topReactions":"OFF LABEL USE (2,992); DRUG INEFFECTIVE (2,302); FATIGUE (2,133); RASH (1,826); CONDITION AGGRAVATED (1,752)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:calcium","dataset":"drug-events","jurisdiction":"US","ingredient":"CALCIUM","level":"ingredient","rank":127,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CALCIUM: 15,896 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,088 were serious (63.5%) and 1,793 reported a death outcome (11.3%). Most reported reactions: FATIGUE (1,954); OFF LABEL USE (1,815); DIARRHOEA (1,439); DYSPNOEA (1,351); NAUSEA (1,347). A report does not show that the drug caused the event.","value":15896,"unit":"FAERS reports received in the window","reports":15896,"serious":10088,"deaths":1793,"serious_pct":63.5,"death_pct":11.3,"reports_q1":1951,"reports_q2":2093,"reports_q3":2047,"reports_q4":1922,"reports_q5":2301,"reports_q6":1738,"reports_q7":1749,"reports_q8":2095,"serious_q1":1282,"serious_q2":1443,"serious_q3":1417,"serious_q4":1202,"serious_q5":1357,"serious_q6":1162,"serious_q7":1114,"serious_q8":1111,"topReactions":"FATIGUE (1,954); OFF LABEL USE (1,815); DIARRHOEA (1,439); DYSPNOEA (1,351); NAUSEA (1,347)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:hyaluronic-acid","dataset":"drug-events","jurisdiction":"US","ingredient":"HYALURONIC ACID","level":"ingredient","rank":128,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"HYALURONIC ACID: 15,896 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,429 were serious (59.3%) and 2,757 reported a death outcome (17.3%). Most reported reactions: FATIGUE (2,336); OFF LABEL USE (2,090); HEADACHE (1,794); PAIN (1,714); DIARRHOEA (1,674). A report does not show that the drug caused the event.","value":15896,"unit":"FAERS reports received in the window","reports":15896,"serious":9429,"deaths":2757,"serious_pct":59.3,"death_pct":17.3,"reports_q1":1958,"reports_q2":1985,"reports_q3":2106,"reports_q4":1945,"reports_q5":2400,"reports_q6":1777,"reports_q7":1780,"reports_q8":1945,"serious_q1":1108,"serious_q2":1317,"serious_q3":1331,"serious_q4":1134,"serious_q5":1353,"serious_q6":1146,"serious_q7":1054,"serious_q8":986,"topReactions":"FATIGUE (2,336); OFF LABEL USE (2,090); HEADACHE (1,794); PAIN (1,714); DIARRHOEA (1,674)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:botulinum-toxin-type-a","dataset":"drug-events","jurisdiction":"US","ingredient":"BOTULINUM TOXIN TYPE A","level":"ingredient","rank":129,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BOTULINUM TOXIN TYPE A: 15,800 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,240 were serious (39.5%) and 2,018 reported a death outcome (12.8%). Most reported reactions: OFF LABEL USE (4,016); DRUG INEFFECTIVE (3,403); HEADACHE (1,104); PRODUCT USE IN UNAPPROVED INDICATION (1,008); MIGRAINE (872). A report does not show that the drug caused the event.","value":15800,"unit":"FAERS reports received in the window","reports":15800,"serious":6240,"deaths":2018,"serious_pct":39.5,"death_pct":12.8,"reports_q1":2013,"reports_q2":1997,"reports_q3":2301,"reports_q4":1881,"reports_q5":1879,"reports_q6":1894,"reports_q7":2097,"reports_q8":1738,"serious_q1":698,"serious_q2":787,"serious_q3":823,"serious_q4":750,"serious_q5":908,"serious_q6":826,"serious_q7":716,"serious_q8":732,"topReactions":"OFF LABEL USE (4,016); DRUG INEFFECTIVE (3,403); HEADACHE (1,104); PRODUCT USE IN UNAPPROVED INDICATION (1,008); MIGRAINE (872)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:estradiol","dataset":"drug-events","jurisdiction":"US","ingredient":"ESTRADIOL","level":"ingredient","rank":130,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ESTRADIOL: 15,798 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,698 were serious (36.1%) and 211 reported a death outcome (1.3%). Most reported reactions: PRODUCT ADHESION ISSUE (1,914); DRUG INEFFECTIVE (1,175); DEVICE ADHESION ISSUE (1,172); OFF LABEL USE (886); HEADACHE (855). A report does not show that the drug caused the event.","value":15798,"unit":"FAERS reports received in the window","reports":15798,"serious":5698,"deaths":211,"serious_pct":36.1,"death_pct":1.3,"reports_q1":1324,"reports_q2":1594,"reports_q3":1809,"reports_q4":1694,"reports_q5":2074,"reports_q6":2416,"reports_q7":2370,"reports_q8":2517,"serious_q1":598,"serious_q2":600,"serious_q3":760,"serious_q4":723,"serious_q5":726,"serious_q6":725,"serious_q7":755,"serious_q8":811,"topReactions":"PRODUCT ADHESION ISSUE (1,914); DRUG INEFFECTIVE (1,175); DEVICE ADHESION ISSUE (1,172); OFF LABEL USE (886); HEADACHE (855)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:acyclovir-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"ACYCLOVIR SODIUM","level":"ingredient","rank":131,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ACYCLOVIR SODIUM: 15,534 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,327 were serious (72.9%) and 1,948 reported a death outcome (12.5%). Most reported reactions: OFF LABEL USE (1,736); FATIGUE (1,197); DIARRHOEA (985); DRUG INEFFECTIVE (977); NAUSEA (849). A report does not show that the drug caused the event.","value":15534,"unit":"FAERS reports received in the window","reports":15534,"serious":11327,"deaths":1948,"serious_pct":72.9,"death_pct":12.5,"reports_q1":1983,"reports_q2":2018,"reports_q3":2031,"reports_q4":2260,"reports_q5":2078,"reports_q6":1763,"reports_q7":1785,"reports_q8":1616,"serious_q1":1415,"serious_q2":1479,"serious_q3":1436,"serious_q4":1645,"serious_q5":1488,"serious_q6":1293,"serious_q7":1346,"serious_q8":1225,"topReactions":"OFF LABEL USE (1,736); FATIGUE (1,197); DIARRHOEA (985); DRUG INEFFECTIVE (977); NAUSEA (849)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:magnesium","dataset":"drug-events","jurisdiction":"US","ingredient":"MAGNESIUM","level":"ingredient","rank":132,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MAGNESIUM: 15,462 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,945 were serious (57.9%) and 1,433 reported a death outcome (9.3%). Most reported reactions: FATIGUE (1,751); DIARRHOEA (1,482); NAUSEA (1,411); HEADACHE (1,381); OFF LABEL USE (1,283). A report does not show that the drug caused the event.","value":15462,"unit":"FAERS reports received in the window","reports":15462,"serious":8945,"deaths":1433,"serious_pct":57.9,"death_pct":9.3,"reports_q1":1848,"reports_q2":1797,"reports_q3":1910,"reports_q4":1889,"reports_q5":2235,"reports_q6":1782,"reports_q7":1811,"reports_q8":2190,"serious_q1":1096,"serious_q2":1116,"serious_q3":1179,"serious_q4":1129,"serious_q5":1209,"serious_q6":1077,"serious_q7":1052,"serious_q8":1087,"topReactions":"FATIGUE (1,751); DIARRHOEA (1,482); NAUSEA (1,411); HEADACHE (1,381); OFF LABEL USE (1,283)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:clonazepam","dataset":"drug-events","jurisdiction":"US","ingredient":"CLONAZEPAM","level":"ingredient","rank":133,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CLONAZEPAM: 15,349 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,269 were serious (73.4%) and 1,448 reported a death outcome (9.4%). Most reported reactions: OFF LABEL USE (1,563); DRUG INEFFECTIVE (1,352); VOMITING (1,254); PNEUMONIA (1,130); DYSPNOEA (956). A report does not show that the drug caused the event.","value":15349,"unit":"FAERS reports received in the window","reports":15349,"serious":11269,"deaths":1448,"serious_pct":73.4,"death_pct":9.4,"reports_q1":1950,"reports_q2":2002,"reports_q3":1919,"reports_q4":1823,"reports_q5":1899,"reports_q6":1906,"reports_q7":1969,"reports_q8":1881,"serious_q1":1459,"serious_q2":1509,"serious_q3":1434,"serious_q4":1353,"serious_q5":1353,"serious_q6":1454,"serious_q7":1487,"serious_q8":1220,"topReactions":"OFF LABEL USE (1,563); DRUG INEFFECTIVE (1,352); VOMITING (1,254); PNEUMONIA (1,130); DYSPNOEA (956)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lamotrigine","dataset":"drug-events","jurisdiction":"US","ingredient":"LAMOTRIGINE","level":"ingredient","rank":134,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LAMOTRIGINE: 15,330 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,200 were serious (79.6%) and 2,382 reported a death outcome (15.5%). Most reported reactions: DRUG INEFFECTIVE (1,751); OFF LABEL USE (1,731); MATERNAL EXPOSURE DURING PREGNANCY (1,189); RASH (1,138); FATIGUE (1,089). A report does not show that the drug caused the event.","value":15330,"unit":"FAERS reports received in the window","reports":15330,"serious":12200,"deaths":2382,"serious_pct":79.6,"death_pct":15.5,"reports_q1":2007,"reports_q2":1831,"reports_q3":2240,"reports_q4":1870,"reports_q5":1982,"reports_q6":1811,"reports_q7":1862,"reports_q8":1727,"serious_q1":1624,"serious_q2":1491,"serious_q3":1755,"serious_q4":1520,"serious_q5":1592,"serious_q6":1489,"serious_q7":1360,"serious_q8":1369,"topReactions":"DRUG INEFFECTIVE (1,751); OFF LABEL USE (1,731); MATERNAL EXPOSURE DURING PREGNANCY (1,189); RASH (1,138); FATIGUE (1,089)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:metoprolol-succinate","dataset":"drug-events","jurisdiction":"US","ingredient":"METOPROLOL SUCCINATE","level":"ingredient","rank":135,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METOPROLOL SUCCINATE: 15,172 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,120 were serious (53.5%) and 1,148 reported a death outcome (7.6%). Most reported reactions: FATIGUE (1,311); DIARRHOEA (1,086); DYSPNOEA (1,022); NAUSEA (929); OFF LABEL USE (846). A report does not show that the drug caused the event.","value":15172,"unit":"FAERS reports received in the window","reports":15172,"serious":8120,"deaths":1148,"serious_pct":53.5,"death_pct":7.6,"reports_q1":1827,"reports_q2":1696,"reports_q3":2028,"reports_q4":1881,"reports_q5":2134,"reports_q6":1708,"reports_q7":1882,"reports_q8":2016,"serious_q1":998,"serious_q2":988,"serious_q3":1158,"serious_q4":1046,"serious_q5":987,"serious_q6":975,"serious_q7":1047,"serious_q8":921,"topReactions":"FATIGUE (1,311); DIARRHOEA (1,086); DYSPNOEA (1,022); NAUSEA (929); OFF LABEL USE (846)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:insulin-lispro","dataset":"drug-events","jurisdiction":"US","ingredient":"INSULIN LISPRO","level":"ingredient","rank":136,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"INSULIN LISPRO: 15,122 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,160 were serious (40.7%) and 502 reported a death outcome (3.3%). Most reported reactions: BLOOD GLUCOSE INCREASED (3,017); HAEMORRHAGE (1,546); INCORRECT DOSE ADMINISTERED (1,098); NAUSEA (757); VISUAL IMPAIRMENT (740). A report does not show that the drug caused the event.","value":15122,"unit":"FAERS reports received in the window","reports":15122,"serious":6160,"deaths":502,"serious_pct":40.7,"death_pct":3.3,"reports_q1":1613,"reports_q2":1528,"reports_q3":2418,"reports_q4":2910,"reports_q5":2083,"reports_q6":1463,"reports_q7":1568,"reports_q8":1539,"serious_q1":728,"serious_q2":744,"serious_q3":825,"serious_q4":797,"serious_q5":958,"serious_q6":725,"serious_q7":720,"serious_q8":663,"topReactions":"BLOOD GLUCOSE INCREASED (3,017); HAEMORRHAGE (1,546); INCORRECT DOSE ADMINISTERED (1,098); NAUSEA (757); VISUAL IMPAIRMENT (740)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:duloxetine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"DULOXETINE HYDROCHLORIDE","level":"ingredient","rank":137,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DULOXETINE HYDROCHLORIDE: 15,111 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,473 were serious (69.3%) and 1,213 reported a death outcome (8.0%). Most reported reactions: OFF LABEL USE (1,368); DRUG INEFFECTIVE (1,288); NAUSEA (1,247); FATIGUE (1,006); DIARRHOEA (917). A report does not show that the drug caused the event.","value":15111,"unit":"FAERS reports received in the window","reports":15111,"serious":10473,"deaths":1213,"serious_pct":69.3,"death_pct":8,"reports_q1":1792,"reports_q2":1735,"reports_q3":1894,"reports_q4":1827,"reports_q5":2135,"reports_q6":1804,"reports_q7":2003,"reports_q8":1921,"serious_q1":1218,"serious_q2":1225,"serious_q3":1311,"serious_q4":1297,"serious_q5":1478,"serious_q6":1295,"serious_q7":1413,"serious_q8":1236,"topReactions":"OFF LABEL USE (1,368); DRUG INEFFECTIVE (1,288); NAUSEA (1,247); FATIGUE (1,006); DIARRHOEA (917)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ezetimibe","dataset":"drug-events","jurisdiction":"US","ingredient":"EZETIMIBE","level":"ingredient","rank":138,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"EZETIMIBE: 15,003 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,280 were serious (68.5%) and 828 reported a death outcome (5.5%). Most reported reactions: FATIGUE (1,164); DIARRHOEA (972); NAUSEA (926); MYALGIA (870); HEADACHE (780). A report does not show that the drug caused the event.","value":15003,"unit":"FAERS reports received in the window","reports":15003,"serious":10280,"deaths":828,"serious_pct":68.5,"death_pct":5.5,"reports_q1":1617,"reports_q2":1473,"reports_q3":1989,"reports_q4":1871,"reports_q5":2050,"reports_q6":1693,"reports_q7":2319,"reports_q8":1991,"serious_q1":1135,"serious_q2":1066,"serious_q3":1223,"serious_q4":1367,"serious_q5":1411,"serious_q6":1262,"serious_q7":1479,"serious_q8":1337,"topReactions":"FATIGUE (1,164); DIARRHOEA (972); NAUSEA (926); MYALGIA (870); HEADACHE (780)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:oxycodone","dataset":"drug-events","jurisdiction":"US","ingredient":"OXYCODONE","level":"ingredient","rank":139,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OXYCODONE: 14,941 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,887 were serious (79.6%) and 4,683 reported a death outcome (31.3%). Most reported reactions: OFF LABEL USE (2,360); FATIGUE (2,063); PAIN (1,839); DRUG INEFFECTIVE (1,790); NAUSEA (1,719). A report does not show that the drug caused the event.","value":14941,"unit":"FAERS reports received in the window","reports":14941,"serious":11887,"deaths":4683,"serious_pct":79.6,"death_pct":31.3,"reports_q1":1867,"reports_q2":1936,"reports_q3":2054,"reports_q4":1858,"reports_q5":2065,"reports_q6":1743,"reports_q7":1669,"reports_q8":1749,"serious_q1":1521,"serious_q2":1603,"serious_q3":1687,"serious_q4":1419,"serious_q5":1620,"serious_q6":1421,"serious_q7":1322,"serious_q8":1294,"topReactions":"OFF LABEL USE (2,360); FATIGUE (2,063); PAIN (1,839); DRUG INEFFECTIVE (1,790); NAUSEA (1,719)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:esomeprazole-magnesium-trihydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"ESOMEPRAZOLE MAGNESIUM TRIHYDRATE","level":"ingredient","rank":140,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ESOMEPRAZOLE MAGNESIUM TRIHYDRATE: 14,939 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,383 were serious (76.2%) and 1,174 reported a death outcome (7.9%). Most reported reactions: OFF LABEL USE (1,346); DRUG INEFFECTIVE (1,226); NAUSEA (1,197); HEADACHE (1,072); DIARRHOEA (1,047). A report does not show that the drug caused the event.","value":14939,"unit":"FAERS reports received in the window","reports":14939,"serious":11383,"deaths":1174,"serious_pct":76.2,"death_pct":7.9,"reports_q1":1807,"reports_q2":1736,"reports_q3":2430,"reports_q4":1794,"reports_q5":1970,"reports_q6":1686,"reports_q7":1660,"reports_q8":1856,"serious_q1":1452,"serious_q2":1381,"serious_q3":1702,"serious_q4":1402,"serious_q5":1445,"serious_q6":1299,"serious_q7":1296,"serious_q8":1406,"topReactions":"OFF LABEL USE (1,346); DRUG INEFFECTIVE (1,226); NAUSEA (1,197); HEADACHE (1,072); DIARRHOEA (1,047)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ustekinumab","dataset":"drug-events","jurisdiction":"US","ingredient":"USTEKINUMAB","level":"ingredient","rank":141,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"USTEKINUMAB: 14,853 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,909 were serious (66.7%) and 2,797 reported a death outcome (18.8%). Most reported reactions: OFF LABEL USE (2,503); PRODUCT DOSE OMISSION ISSUE (2,479); DRUG INEFFECTIVE (1,850); FATIGUE (1,658); PAIN (1,560). A report does not show that the drug caused the event.","value":14853,"unit":"FAERS reports received in the window","reports":14853,"serious":9909,"deaths":2797,"serious_pct":66.7,"death_pct":18.8,"reports_q1":2327,"reports_q2":2178,"reports_q3":1996,"reports_q4":1924,"reports_q5":1848,"reports_q6":1715,"reports_q7":1230,"reports_q8":1635,"serious_q1":1330,"serious_q2":1361,"serious_q3":1225,"serious_q4":1196,"serious_q5":1343,"serious_q6":1238,"serious_q7":868,"serious_q8":1348,"topReactions":"OFF LABEL USE (2,503); PRODUCT DOSE OMISSION ISSUE (2,479); DRUG INEFFECTIVE (1,850); FATIGUE (1,658); PAIN (1,560)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:oxygen","dataset":"drug-events","jurisdiction":"US","ingredient":"OXYGEN","level":"ingredient","rank":142,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OXYGEN: 14,832 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,463 were serious (50.3%) and 988 reported a death outcome (6.7%). Most reported reactions: DYSPNOEA (2,617); COUGH (2,397); HEADACHE (2,026); DIARRHOEA (1,667); DIZZINESS (1,353). A report does not show that the drug caused the event.","value":14832,"unit":"FAERS reports received in the window","reports":14832,"serious":7463,"deaths":988,"serious_pct":50.3,"death_pct":6.7,"reports_q1":1677,"reports_q2":1821,"reports_q3":2013,"reports_q4":1970,"reports_q5":1835,"reports_q6":1811,"reports_q7":1859,"reports_q8":1846,"serious_q1":855,"serious_q2":947,"serious_q3":1037,"serious_q4":976,"serious_q5":933,"serious_q6":892,"serious_q7":955,"serious_q8":868,"topReactions":"DYSPNOEA (2,617); COUGH (2,397); HEADACHE (2,026); DIARRHOEA (1,667); DIZZINESS (1,353)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:oxaliplatin","dataset":"drug-events","jurisdiction":"US","ingredient":"OXALIPLATIN","level":"ingredient","rank":143,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OXALIPLATIN: 14,784 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 14,319 were serious (96.9%) and 1,540 reported a death outcome (10.4%). Most reported reactions: OFF LABEL USE (1,303); NAUSEA (1,114); DIARRHOEA (1,099); NEUROPATHY PERIPHERAL (1,022); MYELOSUPPRESSION (814). A report does not show that the drug caused the event.","value":14784,"unit":"FAERS reports received in the window","reports":14784,"serious":14319,"deaths":1540,"serious_pct":96.9,"death_pct":10.4,"reports_q1":1714,"reports_q2":1959,"reports_q3":1923,"reports_q4":1776,"reports_q5":1925,"reports_q6":1777,"reports_q7":1898,"reports_q8":1812,"serious_q1":1644,"serious_q2":1829,"serious_q3":1874,"serious_q4":1743,"serious_q5":1869,"serious_q6":1748,"serious_q7":1842,"serious_q8":1770,"topReactions":"OFF LABEL USE (1,303); NAUSEA (1,114); DIARRHOEA (1,099); NEUROPATHY PERIPHERAL (1,022); MYELOSUPPRESSION (814)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:potassium-cation","dataset":"drug-events","jurisdiction":"US","ingredient":"POTASSIUM CATION","level":"ingredient","rank":144,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"POTASSIUM CATION: 14,629 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,415 were serious (64.4%) and 1,528 reported a death outcome (10.4%). Most reported reactions: DIARRHOEA (1,216); DYSPNOEA (1,178); FATIGUE (1,150); NAUSEA (1,103); HEADACHE (1,083). A report does not show that the drug caused the event.","value":14629,"unit":"FAERS reports received in the window","reports":14629,"serious":9415,"deaths":1528,"serious_pct":64.4,"death_pct":10.4,"reports_q1":1841,"reports_q2":1848,"reports_q3":1976,"reports_q4":1954,"reports_q5":1847,"reports_q6":1770,"reports_q7":1748,"reports_q8":1645,"serious_q1":1179,"serious_q2":1252,"serious_q3":1324,"serious_q4":1264,"serious_q5":1164,"serious_q6":1138,"serious_q7":1146,"serious_q8":948,"topReactions":"DIARRHOEA (1,216); DYSPNOEA (1,178); FATIGUE (1,150); NAUSEA (1,103); HEADACHE (1,083)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:rivaroxaban","dataset":"drug-events","jurisdiction":"US","ingredient":"RIVAROXABAN","level":"ingredient","rank":145,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RIVAROXABAN: 14,579 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,496 were serious (78.9%) and 1,181 reported a death outcome (8.1%). Most reported reactions: FATIGUE (836); OFF LABEL USE (801); DYSPNOEA (681); DIARRHOEA (679); DRUG INEFFECTIVE (635). A report does not show that the drug caused the event.","value":14579,"unit":"FAERS reports received in the window","reports":14579,"serious":11496,"deaths":1181,"serious_pct":78.9,"death_pct":8.1,"reports_q1":2013,"reports_q2":2043,"reports_q3":1712,"reports_q4":1782,"reports_q5":1834,"reports_q6":1700,"reports_q7":1719,"reports_q8":1776,"serious_q1":1580,"serious_q2":1631,"serious_q3":1329,"serious_q4":1383,"serious_q5":1438,"serious_q6":1365,"serious_q7":1369,"serious_q8":1401,"topReactions":"FATIGUE (836); OFF LABEL USE (801); DYSPNOEA (681); DIARRHOEA (679); DRUG INEFFECTIVE (635)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:nivolumab","dataset":"drug-events","jurisdiction":"US","ingredient":"NIVOLUMAB","level":"ingredient","rank":146,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"NIVOLUMAB: 14,575 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,332 were serious (84.6%) and 2,592 reported a death outcome (17.8%). Most reported reactions: OFF LABEL USE (1,701); DEATH (1,237); DIARRHOEA (871); MALIGNANT NEOPLASM PROGRESSION (791); FATIGUE (651). A report does not show that the drug caused the event.","value":14575,"unit":"FAERS reports received in the window","reports":14575,"serious":12332,"deaths":2592,"serious_pct":84.6,"death_pct":17.8,"reports_q1":1907,"reports_q2":1848,"reports_q3":2227,"reports_q4":1581,"reports_q5":1578,"reports_q6":1697,"reports_q7":2037,"reports_q8":1700,"serious_q1":1664,"serious_q2":1639,"serious_q3":1604,"serious_q4":1426,"serious_q5":1420,"serious_q6":1488,"serious_q7":1579,"serious_q8":1512,"topReactions":"OFF LABEL USE (1,701); DEATH (1,237); DIARRHOEA (871); MALIGNANT NEOPLASM PROGRESSION (791); FATIGUE (651)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:venetoclax","dataset":"drug-events","jurisdiction":"US","ingredient":"VENETOCLAX","level":"ingredient","rank":147,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VENETOCLAX: 14,304 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 13,577 were serious (94.9%) and 3,626 reported a death outcome (25.3%). Most reported reactions: DEATH (2,106); MYELOSUPPRESSION (1,600); OFF LABEL USE (1,395); NEUTROPENIA (839); PLATELET COUNT DECREASED (711). A report does not show that the drug caused the event.","value":14304,"unit":"FAERS reports received in the window","reports":14304,"serious":13577,"deaths":3626,"serious_pct":94.9,"death_pct":25.3,"reports_q1":1857,"reports_q2":1848,"reports_q3":1725,"reports_q4":1706,"reports_q5":1964,"reports_q6":1902,"reports_q7":1776,"reports_q8":1526,"serious_q1":1774,"serious_q2":1715,"serious_q3":1629,"serious_q4":1628,"serious_q5":1882,"serious_q6":1836,"serious_q7":1694,"serious_q8":1419,"topReactions":"DEATH (2,106); MYELOSUPPRESSION (1,600); OFF LABEL USE (1,395); NEUTROPENIA (839); PLATELET COUNT DECREASED (711)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:levonorgestrel","dataset":"drug-events","jurisdiction":"US","ingredient":"LEVONORGESTREL","level":"ingredient","rank":148,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LEVONORGESTREL: 14,144 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,271 were serious (23.1%) and 20 reported a death outcome (0.1%). Most reported reactions: DEVICE EXPULSION (3,005); DEVICE DISLOCATION (2,208); GENITAL HAEMORRHAGE (976); COMPLICATION OF DEVICE INSERTION (795); PROCEDURAL PAIN (782). A report does not show that the drug caused the event.","value":14144,"unit":"FAERS reports received in the window","reports":14144,"serious":3271,"deaths":20,"serious_pct":23.1,"death_pct":0.1,"reports_q1":2151,"reports_q2":1839,"reports_q3":1512,"reports_q4":2107,"reports_q5":1683,"reports_q6":1636,"reports_q7":1640,"reports_q8":1576,"serious_q1":507,"serious_q2":475,"serious_q3":331,"serious_q4":439,"serious_q5":405,"serious_q6":371,"serious_q7":367,"serious_q8":376,"topReactions":"DEVICE EXPULSION (3,005); DEVICE DISLOCATION (2,208); GENITAL HAEMORRHAGE (976); COMPLICATION OF DEVICE INSERTION (795); PROCEDURAL PAIN (782)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:atorvastatin","dataset":"drug-events","jurisdiction":"US","ingredient":"ATORVASTATIN","level":"ingredient","rank":149,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ATORVASTATIN: 14,136 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,062 were serious (50.0%) and 773 reported a death outcome (5.5%). Most reported reactions: FATIGUE (1,239); DYSPNOEA (1,133); HEADACHE (1,133); DIARRHOEA (1,059); COUGH (1,038). A report does not show that the drug caused the event.","value":14136,"unit":"FAERS reports received in the window","reports":14136,"serious":7062,"deaths":773,"serious_pct":50,"death_pct":5.5,"reports_q1":1770,"reports_q2":1480,"reports_q3":1763,"reports_q4":1788,"reports_q5":2146,"reports_q6":1598,"reports_q7":1724,"reports_q8":1867,"serious_q1":872,"serious_q2":849,"serious_q3":968,"serious_q4":902,"serious_q5":891,"serious_q6":838,"serious_q7":925,"serious_q8":817,"topReactions":"FATIGUE (1,239); DYSPNOEA (1,133); HEADACHE (1,133); DIARRHOEA (1,059); COUGH (1,038)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:atorvastatin-calcium-propylene-glycol-solvate","dataset":"drug-events","jurisdiction":"US","ingredient":"ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE","level":"ingredient","rank":150,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE: 14,136 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,062 were serious (50.0%) and 773 reported a death outcome (5.5%). Most reported reactions: FATIGUE (1,239); DYSPNOEA (1,133); HEADACHE (1,133); DIARRHOEA (1,059); COUGH (1,038). A report does not show that the drug caused the event.","value":14136,"unit":"FAERS reports received in the window","reports":14136,"serious":7062,"deaths":773,"serious_pct":50,"death_pct":5.5,"reports_q1":1770,"reports_q2":1480,"reports_q3":1763,"reports_q4":1788,"reports_q5":2146,"reports_q6":1598,"reports_q7":1724,"reports_q8":1867,"serious_q1":872,"serious_q2":849,"serious_q3":968,"serious_q4":902,"serious_q5":891,"serious_q6":838,"serious_q7":925,"serious_q8":817,"topReactions":"FATIGUE (1,239); DYSPNOEA (1,133); HEADACHE (1,133); DIARRHOEA (1,059); COUGH (1,038)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:fluoxetine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"FLUOXETINE HYDROCHLORIDE","level":"ingredient","rank":151,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FLUOXETINE HYDROCHLORIDE: 14,101 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,967 were serious (70.7%) and 1,145 reported a death outcome (8.1%). Most reported reactions: OFF LABEL USE (997); DRUG INEFFECTIVE (933); NAUSEA (816); FATIGUE (770); HEADACHE (738). A report does not show that the drug caused the event.","value":14101,"unit":"FAERS reports received in the window","reports":14101,"serious":9967,"deaths":1145,"serious_pct":70.7,"death_pct":8.1,"reports_q1":1706,"reports_q2":1765,"reports_q3":1783,"reports_q4":1799,"reports_q5":1746,"reports_q6":1708,"reports_q7":1810,"reports_q8":1784,"serious_q1":1159,"serious_q2":1250,"serious_q3":1266,"serious_q4":1309,"serious_q5":1243,"serious_q6":1249,"serious_q7":1280,"serious_q8":1211,"topReactions":"OFF LABEL USE (997); DRUG INEFFECTIVE (933); NAUSEA (816); FATIGUE (770); HEADACHE (738)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:polyethylene-glycol-3350","dataset":"drug-events","jurisdiction":"US","ingredient":"POLYETHYLENE GLYCOL 3350","level":"ingredient","rank":152,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"POLYETHYLENE GLYCOL 3350: 14,041 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,960 were serious (49.6%) and 970 reported a death outcome (6.9%). Most reported reactions: DRUG INEFFECTIVE (1,321); DIARRHOEA (1,106); OFF LABEL USE (1,013); PRODUCT PRESCRIBING ISSUE (930); FATIGUE (924). A report does not show that the drug caused the event.","value":14041,"unit":"FAERS reports received in the window","reports":14041,"serious":6960,"deaths":970,"serious_pct":49.6,"death_pct":6.9,"reports_q1":1423,"reports_q2":1953,"reports_q3":1756,"reports_q4":1616,"reports_q5":1815,"reports_q6":2078,"reports_q7":1637,"reports_q8":1763,"serious_q1":798,"serious_q2":846,"serious_q3":1004,"serious_q4":899,"serious_q5":929,"serious_q6":800,"serious_q7":853,"serious_q8":831,"topReactions":"DRUG INEFFECTIVE (1,321); DIARRHOEA (1,106); OFF LABEL USE (1,013); PRODUCT PRESCRIBING ISSUE (930); FATIGUE (924)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:venlafaxine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"VENLAFAXINE HYDROCHLORIDE","level":"ingredient","rank":153,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VENLAFAXINE HYDROCHLORIDE: 14,037 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,455 were serious (81.6%) and 1,493 reported a death outcome (10.6%). Most reported reactions: OFF LABEL USE (1,468); DRUG INEFFECTIVE (1,259); NAUSEA (998); FATIGUE (833); HEADACHE (831). A report does not show that the drug caused the event.","value":14037,"unit":"FAERS reports received in the window","reports":14037,"serious":11455,"deaths":1493,"serious_pct":81.6,"death_pct":10.6,"reports_q1":1843,"reports_q2":1796,"reports_q3":1757,"reports_q4":1848,"reports_q5":1798,"reports_q6":1618,"reports_q7":1731,"reports_q8":1646,"serious_q1":1524,"serious_q2":1489,"serious_q3":1456,"serious_q4":1490,"serious_q5":1456,"serious_q6":1315,"serious_q7":1405,"serious_q8":1320,"topReactions":"OFF LABEL USE (1,468); DRUG INEFFECTIVE (1,259); NAUSEA (998); FATIGUE (833); HEADACHE (831)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:epinephrine","dataset":"drug-events","jurisdiction":"US","ingredient":"EPINEPHRINE","level":"ingredient","rank":154,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"EPINEPHRINE: 14,018 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,242 were serious (51.7%) and 629 reported a death outcome (4.5%). Most reported reactions: DRUG INEFFECTIVE (1,585); OFF LABEL USE (1,067); FATIGUE (907); HEADACHE (820); PRODUCT DOSE OMISSION ISSUE (747). A report does not show that the drug caused the event.","value":14018,"unit":"FAERS reports received in the window","reports":14018,"serious":7242,"deaths":629,"serious_pct":51.7,"death_pct":4.5,"reports_q1":1540,"reports_q2":2018,"reports_q3":1822,"reports_q4":1693,"reports_q5":1844,"reports_q6":1622,"reports_q7":1849,"reports_q8":1630,"serious_q1":814,"serious_q2":956,"serious_q3":929,"serious_q4":948,"serious_q5":999,"serious_q6":867,"serious_q7":994,"serious_q8":735,"topReactions":"DRUG INEFFECTIVE (1,585); OFF LABEL USE (1,067); FATIGUE (907); HEADACHE (820); PRODUCT DOSE OMISSION ISSUE (747)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:medroxyprogesterone-acetate","dataset":"drug-events","jurisdiction":"US","ingredient":"MEDROXYPROGESTERONE ACETATE","level":"ingredient","rank":155,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MEDROXYPROGESTERONE ACETATE: 13,872 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,825 were serious (92.5%) and 46 reported a death outcome (0.3%). Most reported reactions: MENINGIOMA (11,243); MENINGIOMA BENIGN (583); OFF LABEL USE (180); HEADACHE (122); NAUSEA (120). Named in open multidistrict litigation MDL-3140. A report does not show that the drug caused the event.","value":13872,"unit":"FAERS reports received in the window","reports":13872,"serious":12825,"deaths":46,"serious_pct":92.5,"death_pct":0.3,"reports_q1":270,"reports_q2":374,"reports_q3":447,"reports_q4":817,"reports_q5":1046,"reports_q6":569,"reports_q7":1618,"reports_q8":8731,"serious_q1":120,"serious_q2":226,"serious_q3":223,"serious_q4":670,"serious_q5":936,"serious_q6":473,"serious_q7":1522,"serious_q8":8655,"topReactions":"MENINGIOMA (11,243); MENINGIOMA BENIGN (583); OFF LABEL USE (180); HEADACHE (122); NAUSEA (120)","mdl":"MDL-3140","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:quetiapine","dataset":"drug-events","jurisdiction":"US","ingredient":"QUETIAPINE","level":"ingredient","rank":156,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"QUETIAPINE: 13,862 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,854 were serious (92.7%) and 2,323 reported a death outcome (16.8%). Most reported reactions: OFF LABEL USE (1,267); TOXICITY TO VARIOUS AGENTS (1,218); DRUG INEFFECTIVE (1,117); INTENTIONAL OVERDOSE (787); SOMNOLENCE (746). A report does not show that the drug caused the event.","value":13862,"unit":"FAERS reports received in the window","reports":13862,"serious":12854,"deaths":2323,"serious_pct":92.7,"death_pct":16.8,"reports_q1":1912,"reports_q2":1644,"reports_q3":1743,"reports_q4":1665,"reports_q5":1740,"reports_q6":1634,"reports_q7":1865,"reports_q8":1659,"serious_q1":1762,"serious_q2":1507,"serious_q3":1634,"serious_q4":1529,"serious_q5":1640,"serious_q6":1523,"serious_q7":1751,"serious_q8":1508,"topReactions":"OFF LABEL USE (1,267); TOXICITY TO VARIOUS AGENTS (1,218); DRUG INEFFECTIVE (1,117); INTENTIONAL OVERDOSE (787); SOMNOLENCE (746)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:olanzapine","dataset":"drug-events","jurisdiction":"US","ingredient":"OLANZAPINE","level":"ingredient","rank":157,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OLANZAPINE: 13,801 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,221 were serious (88.6%) and 1,365 reported a death outcome (9.9%). Most reported reactions: OFF LABEL USE (1,354); DRUG INEFFECTIVE (1,246); TOXICITY TO VARIOUS AGENTS (796); NAUSEA (711); FEBRILE NEUTROPENIA (614). A report does not show that the drug caused the event.","value":13801,"unit":"FAERS reports received in the window","reports":13801,"serious":12221,"deaths":1365,"serious_pct":88.6,"death_pct":9.9,"reports_q1":1727,"reports_q2":1803,"reports_q3":1766,"reports_q4":1768,"reports_q5":1643,"reports_q6":1833,"reports_q7":1653,"reports_q8":1608,"serious_q1":1561,"serious_q2":1632,"serious_q3":1581,"serious_q4":1584,"serious_q5":1413,"serious_q6":1572,"serious_q7":1471,"serious_q8":1407,"topReactions":"OFF LABEL USE (1,354); DRUG INEFFECTIVE (1,246); TOXICITY TO VARIOUS AGENTS (796); NAUSEA (711); FEBRILE NEUTROPENIA (614)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:carvedilol","dataset":"drug-events","jurisdiction":"US","ingredient":"CARVEDILOL","level":"ingredient","rank":158,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CARVEDILOL: 13,540 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,622 were serious (63.7%) and 1,322 reported a death outcome (9.8%). Most reported reactions: FATIGUE (1,010); DIARRHOEA (990); OFF LABEL USE (871); DYSPNOEA (717); NAUSEA (711). A report does not show that the drug caused the event.","value":13540,"unit":"FAERS reports received in the window","reports":13540,"serious":8622,"deaths":1322,"serious_pct":63.7,"death_pct":9.8,"reports_q1":1781,"reports_q2":1655,"reports_q3":1715,"reports_q4":1597,"reports_q5":1841,"reports_q6":1548,"reports_q7":1765,"reports_q8":1638,"serious_q1":1128,"serious_q2":1113,"serious_q3":1148,"serious_q4":998,"serious_q5":1064,"serious_q6":1004,"serious_q7":1181,"serious_q8":986,"topReactions":"FATIGUE (1,010); DIARRHOEA (990); OFF LABEL USE (871); DYSPNOEA (717); NAUSEA (711)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:hydrocortisone-acetate","dataset":"drug-events","jurisdiction":"US","ingredient":"HYDROCORTISONE ACETATE","level":"ingredient","rank":159,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"HYDROCORTISONE ACETATE: 13,520 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,655 were serious (78.8%) and 3,289 reported a death outcome (24.3%). Most reported reactions: OFF LABEL USE (2,679); DRUG INEFFECTIVE (2,055); FATIGUE (1,744); RASH (1,591); CONDITION AGGRAVATED (1,543). A report does not show that the drug caused the event.","value":13520,"unit":"FAERS reports received in the window","reports":13520,"serious":10655,"deaths":3289,"serious_pct":78.8,"death_pct":24.3,"reports_q1":1733,"reports_q2":2024,"reports_q3":1744,"reports_q4":1463,"reports_q5":1899,"reports_q6":1652,"reports_q7":1487,"reports_q8":1518,"serious_q1":1425,"serious_q2":1681,"serious_q3":1384,"serious_q4":1140,"serious_q5":1533,"serious_q6":1302,"serious_q7":1091,"serious_q8":1099,"topReactions":"OFF LABEL USE (2,679); DRUG INEFFECTIVE (2,055); FATIGUE (1,744); RASH (1,591); CONDITION AGGRAVATED (1,543)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:doxycycline-hyclate","dataset":"drug-events","jurisdiction":"US","ingredient":"DOXYCYCLINE HYCLATE","level":"ingredient","rank":160,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DOXYCYCLINE HYCLATE: 13,386 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,124 were serious (75.6%) and 2,256 reported a death outcome (16.9%). Most reported reactions: OFF LABEL USE (1,575); DRUG INEFFECTIVE (1,406); FATIGUE (1,332); NAUSEA (1,126); RASH (1,125). A report does not show that the drug caused the event.","value":13386,"unit":"FAERS reports received in the window","reports":13386,"serious":10124,"deaths":2256,"serious_pct":75.6,"death_pct":16.9,"reports_q1":1677,"reports_q2":1879,"reports_q3":1635,"reports_q4":1583,"reports_q5":1919,"reports_q6":1579,"reports_q7":1620,"reports_q8":1494,"serious_q1":1315,"serious_q2":1545,"serious_q3":1243,"serious_q4":1211,"serious_q5":1384,"serious_q6":1204,"serious_q7":1194,"serious_q8":1028,"topReactions":"OFF LABEL USE (1,575); DRUG INEFFECTIVE (1,406); FATIGUE (1,332); NAUSEA (1,126); RASH (1,125)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:propranolol-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"PROPRANOLOL HYDROCHLORIDE","level":"ingredient","rank":161,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PROPRANOLOL HYDROCHLORIDE: 13,382 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,669 were serious (57.3%) and 909 reported a death outcome (6.8%). Most reported reactions: OFF LABEL USE (3,023); DRUG INEFFECTIVE (1,360); PRODUCT USE IN UNAPPROVED INDICATION (1,305); PRODUCT USE ISSUE (920); NAUSEA (833). A report does not show that the drug caused the event.","value":13382,"unit":"FAERS reports received in the window","reports":13382,"serious":7669,"deaths":909,"serious_pct":57.3,"death_pct":6.8,"reports_q1":3012,"reports_q2":1273,"reports_q3":1252,"reports_q4":2132,"reports_q5":1252,"reports_q6":1243,"reports_q7":1323,"reports_q8":1895,"serious_q1":1022,"serious_q2":980,"serious_q3":954,"serious_q4":966,"serious_q5":881,"serious_q6":954,"serious_q7":993,"serious_q8":919,"topReactions":"OFF LABEL USE (3,023); DRUG INEFFECTIVE (1,360); PRODUCT USE IN UNAPPROVED INDICATION (1,305); PRODUCT USE ISSUE (920); NAUSEA (833)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:menthol","dataset":"drug-events","jurisdiction":"US","ingredient":"MENTHOL","level":"ingredient","rank":162,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MENTHOL: 13,341 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,113 were serious (75.8%) and 2,716 reported a death outcome (20.4%). Most reported reactions: OFF LABEL USE (1,613); DRUG INEFFECTIVE (1,606); NAUSEA (1,419); FATIGUE (1,410); PAIN (1,320). A report does not show that the drug caused the event.","value":13341,"unit":"FAERS reports received in the window","reports":13341,"serious":10113,"deaths":2716,"serious_pct":75.8,"death_pct":20.4,"reports_q1":1650,"reports_q2":1910,"reports_q3":1697,"reports_q4":1689,"reports_q5":1718,"reports_q6":1668,"reports_q7":1597,"reports_q8":1412,"serious_q1":1245,"serious_q2":1532,"serious_q3":1299,"serious_q4":1242,"serious_q5":1334,"serious_q6":1269,"serious_q7":1218,"serious_q8":974,"topReactions":"OFF LABEL USE (1,613); DRUG INEFFECTIVE (1,606); NAUSEA (1,419); FATIGUE (1,410); PAIN (1,320)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:fluorouracil","dataset":"drug-events","jurisdiction":"US","ingredient":"FLUOROURACIL","level":"ingredient","rank":163,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FLUOROURACIL: 13,091 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,377 were serious (94.5%) and 1,396 reported a death outcome (10.7%). Most reported reactions: DIARRHOEA (1,044); OFF LABEL USE (991); NEUROPATHY PERIPHERAL (842); NAUSEA (835); NEUTROPENIA (748). A report does not show that the drug caused the event.","value":13091,"unit":"FAERS reports received in the window","reports":13091,"serious":12377,"deaths":1396,"serious_pct":94.5,"death_pct":10.7,"reports_q1":1471,"reports_q2":1532,"reports_q3":1640,"reports_q4":1724,"reports_q5":1730,"reports_q6":1662,"reports_q7":1603,"reports_q8":1729,"serious_q1":1388,"serious_q2":1455,"serious_q3":1579,"serious_q4":1599,"serious_q5":1657,"serious_q6":1594,"serious_q7":1533,"serious_q8":1572,"topReactions":"DIARRHOEA (1,044); OFF LABEL USE (991); NEUROPATHY PERIPHERAL (842); NAUSEA (835); NEUTROPENIA (748)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:formoterol-fumarate","dataset":"drug-events","jurisdiction":"US","ingredient":"FORMOTEROL FUMARATE","level":"ingredient","rank":164,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FORMOTEROL FUMARATE: 12,925 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,991 were serious (54.1%) and 565 reported a death outcome (4.4%). Most reported reactions: DYSPNOEA (1,759); ASTHMA (1,571); COUGH (1,044); PRODUCT DOSE OMISSION ISSUE (1,012); DRUG INEFFECTIVE (924). A report does not show that the drug caused the event.","value":12925,"unit":"FAERS reports received in the window","reports":12925,"serious":6991,"deaths":565,"serious_pct":54.1,"death_pct":4.4,"reports_q1":1854,"reports_q2":1665,"reports_q3":1643,"reports_q4":1631,"reports_q5":1559,"reports_q6":1364,"reports_q7":1675,"reports_q8":1534,"serious_q1":1245,"serious_q2":909,"serious_q3":894,"serious_q4":768,"serious_q5":827,"serious_q6":720,"serious_q7":932,"serious_q8":696,"topReactions":"DYSPNOEA (1,759); ASTHMA (1,571); COUGH (1,044); PRODUCT DOSE OMISSION ISSUE (1,012); DRUG INEFFECTIVE (924)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:mirtazapine","dataset":"drug-events","jurisdiction":"US","ingredient":"MIRTAZAPINE","level":"ingredient","rank":165,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MIRTAZAPINE: 12,919 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,901 were serious (84.4%) and 1,591 reported a death outcome (12.3%). Most reported reactions: OFF LABEL USE (823); DRUG INEFFECTIVE (784); NAUSEA (722); FATIGUE (713); DIARRHOEA (639). A report does not show that the drug caused the event.","value":12919,"unit":"FAERS reports received in the window","reports":12919,"serious":10901,"deaths":1591,"serious_pct":84.4,"death_pct":12.3,"reports_q1":1648,"reports_q2":1448,"reports_q3":1675,"reports_q4":1755,"reports_q5":1680,"reports_q6":1604,"reports_q7":1529,"reports_q8":1580,"serious_q1":1387,"serious_q2":1230,"serious_q3":1410,"serious_q4":1482,"serious_q5":1452,"serious_q6":1353,"serious_q7":1270,"serious_q8":1317,"topReactions":"OFF LABEL USE (823); DRUG INEFFECTIVE (784); NAUSEA (722); FATIGUE (713); DIARRHOEA (639)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:celecoxib","dataset":"drug-events","jurisdiction":"US","ingredient":"CELECOXIB","level":"ingredient","rank":166,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CELECOXIB: 12,724 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,889 were serious (77.7%) and 3,567 reported a death outcome (28.0%). Most reported reactions: OFF LABEL USE (2,273); FATIGUE (2,016); DRUG INEFFECTIVE (2,011); ARTHRALGIA (1,835); NAUSEA (1,767). A report does not show that the drug caused the event.","value":12724,"unit":"FAERS reports received in the window","reports":12724,"serious":9889,"deaths":3567,"serious_pct":77.7,"death_pct":28,"reports_q1":1622,"reports_q2":1850,"reports_q3":1622,"reports_q4":1599,"reports_q5":1844,"reports_q6":1628,"reports_q7":1228,"reports_q8":1331,"serious_q1":1293,"serious_q2":1493,"serious_q3":1317,"serious_q4":1238,"serious_q5":1439,"serious_q6":1315,"serious_q7":889,"serious_q8":905,"topReactions":"OFF LABEL USE (2,273); FATIGUE (2,016); DRUG INEFFECTIVE (2,011); ARTHRALGIA (1,835); NAUSEA (1,767)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lidocaine","dataset":"drug-events","jurisdiction":"US","ingredient":"LIDOCAINE","level":"ingredient","rank":167,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LIDOCAINE: 12,702 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,402 were serious (66.1%) and 980 reported a death outcome (7.7%). Most reported reactions: DRUG INEFFECTIVE (1,017); OFF LABEL USE (996); NAUSEA (866); FATIGUE (790); HEADACHE (767). A report does not show that the drug caused the event.","value":12702,"unit":"FAERS reports received in the window","reports":12702,"serious":8402,"deaths":980,"serious_pct":66.1,"death_pct":7.7,"reports_q1":1561,"reports_q2":1551,"reports_q3":1594,"reports_q4":1677,"reports_q5":1552,"reports_q6":1516,"reports_q7":1667,"reports_q8":1584,"serious_q1":1055,"serious_q2":1014,"serious_q3":1010,"serious_q4":1117,"serious_q5":1039,"serious_q6":1001,"serious_q7":1193,"serious_q8":973,"topReactions":"DRUG INEFFECTIVE (1,017); OFF LABEL USE (996); NAUSEA (866); FATIGUE (790); HEADACHE (767)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:apixaban","dataset":"drug-events","jurisdiction":"US","ingredient":"APIXABAN","level":"ingredient","rank":168,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"APIXABAN: 12,658 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 12,034 were serious (95.1%) and 1,394 reported a death outcome (11.0%). Most reported reactions: OFF LABEL USE (790); DRUG INEFFECTIVE (726); DYSPNOEA (587); FATIGUE (572); ACUTE KIDNEY INJURY (496). A report does not show that the drug caused the event.","value":12658,"unit":"FAERS reports received in the window","reports":12658,"serious":12034,"deaths":1394,"serious_pct":95.1,"death_pct":11,"reports_q1":1385,"reports_q2":1624,"reports_q3":1538,"reports_q4":1458,"reports_q5":1349,"reports_q6":1541,"reports_q7":1701,"reports_q8":2062,"serious_q1":1317,"serious_q2":1511,"serious_q3":1437,"serious_q4":1380,"serious_q5":1289,"serious_q6":1485,"serious_q7":1602,"serious_q8":2013,"topReactions":"OFF LABEL USE (790); DRUG INEFFECTIVE (726); DYSPNOEA (587); FATIGUE (572); ACUTE KIDNEY INJURY (496)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:loratadine","dataset":"drug-events","jurisdiction":"US","ingredient":"LORATADINE","level":"ingredient","rank":169,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LORATADINE: 12,648 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,474 were serious (43.3%) and 446 reported a death outcome (3.5%). Most reported reactions: DRUG INEFFECTIVE (1,276); FATIGUE (928); NAUSEA (769); OFF LABEL USE (753); DIARRHOEA (705). A report does not show that the drug caused the event.","value":12648,"unit":"FAERS reports received in the window","reports":12648,"serious":5474,"deaths":446,"serious_pct":43.3,"death_pct":3.5,"reports_q1":1642,"reports_q2":1640,"reports_q3":1526,"reports_q4":1643,"reports_q5":1649,"reports_q6":1417,"reports_q7":1446,"reports_q8":1685,"serious_q1":700,"serious_q2":770,"serious_q3":729,"serious_q4":698,"serious_q5":684,"serious_q6":589,"serious_q7":661,"serious_q8":643,"topReactions":"DRUG INEFFECTIVE (1,276); FATIGUE (928); NAUSEA (769); OFF LABEL USE (753); DIARRHOEA (705)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:nemolizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"NEMOLIZUMAB","level":"ingredient","rank":170,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"NEMOLIZUMAB: 12,619 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 790 were serious (6.3%) and 117 reported a death outcome (0.9%). Most reported reactions: PRODUCT DOSE OMISSION ISSUE (4,298); DEVICE MALFUNCTION (2,066); INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1,485); PRURITUS (1,268); INCORRECT DOSE ADMINISTERED (1,258). A report does not show that the drug caused the event.","value":12619,"unit":"FAERS reports received in the window","reports":12619,"serious":790,"deaths":117,"serious_pct":6.3,"death_pct":0.9,"reports_q1":3,"reports_q2":152,"reports_q3":564,"reports_q4":1382,"reports_q5":2290,"reports_q6":3036,"reports_q7":2523,"reports_q8":2669,"serious_q1":1,"serious_q2":11,"serious_q3":41,"serious_q4":78,"serious_q5":140,"serious_q6":138,"serious_q7":175,"serious_q8":206,"topReactions":"PRODUCT DOSE OMISSION ISSUE (4,298); DEVICE MALFUNCTION (2,066); INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1,485); PRURITUS (1,268); INCORRECT DOSE ADMINISTERED (1,258)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ruxolitinib","dataset":"drug-events","jurisdiction":"US","ingredient":"RUXOLITINIB","level":"ingredient","rank":171,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RUXOLITINIB: 12,515 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,656 were serious (53.2%) and 1,600 reported a death outcome (12.8%). Most reported reactions: OFF LABEL USE (3,819); FATIGUE (994); DEATH (880); PRODUCT DOSE OMISSION ISSUE (790); DRUG INEFFECTIVE (527). A report does not show that the drug caused the event.","value":12515,"unit":"FAERS reports received in the window","reports":12515,"serious":6656,"deaths":1600,"serious_pct":53.2,"death_pct":12.8,"reports_q1":1477,"reports_q2":1554,"reports_q3":1551,"reports_q4":1521,"reports_q5":1598,"reports_q6":1462,"reports_q7":1743,"reports_q8":1609,"serious_q1":740,"serious_q2":921,"serious_q3":838,"serious_q4":830,"serious_q5":766,"serious_q6":818,"serious_q7":933,"serious_q8":810,"topReactions":"OFF LABEL USE (3,819); FATIGUE (994); DEATH (880); PRODUCT DOSE OMISSION ISSUE (790); DRUG INEFFECTIVE (527)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:azathioprine","dataset":"drug-events","jurisdiction":"US","ingredient":"AZATHIOPRINE","level":"ingredient","rank":172,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AZATHIOPRINE: 12,298 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,010 were serious (89.5%) and 2,365 reported a death outcome (19.2%). Most reported reactions: OFF LABEL USE (2,734); DRUG INEFFECTIVE (1,776); CONDITION AGGRAVATED (1,284); DIARRHOEA (982); ARTHRALGIA (940). A report does not show that the drug caused the event.","value":12298,"unit":"FAERS reports received in the window","reports":12298,"serious":11010,"deaths":2365,"serious_pct":89.5,"death_pct":19.2,"reports_q1":1553,"reports_q2":1778,"reports_q3":1694,"reports_q4":1505,"reports_q5":1658,"reports_q6":1519,"reports_q7":1227,"reports_q8":1364,"serious_q1":1442,"serious_q2":1523,"serious_q3":1580,"serious_q4":1289,"serious_q5":1557,"serious_q6":1370,"serious_q7":1104,"serious_q8":1145,"topReactions":"OFF LABEL USE (2,734); DRUG INEFFECTIVE (1,776); CONDITION AGGRAVATED (1,284); DIARRHOEA (982); ARTHRALGIA (940)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:simvastatin","dataset":"drug-events","jurisdiction":"US","ingredient":"SIMVASTATIN","level":"ingredient","rank":173,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SIMVASTATIN: 12,290 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,544 were serious (69.5%) and 1,256 reported a death outcome (10.2%). Most reported reactions: FATIGUE (936); DIARRHOEA (883); OFF LABEL USE (835); NAUSEA (815); DYSPNOEA (696). A report does not show that the drug caused the event.","value":12290,"unit":"FAERS reports received in the window","reports":12290,"serious":8544,"deaths":1256,"serious_pct":69.5,"death_pct":10.2,"reports_q1":1683,"reports_q2":1500,"reports_q3":1560,"reports_q4":1623,"reports_q5":1742,"reports_q6":1336,"reports_q7":1349,"reports_q8":1497,"serious_q1":1178,"serious_q2":1094,"serious_q3":1044,"serious_q4":1162,"serious_q5":1151,"serious_q6":971,"serious_q7":927,"serious_q8":1017,"topReactions":"FATIGUE (936); DIARRHOEA (883); OFF LABEL USE (835); NAUSEA (815); DYSPNOEA (696)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:tadalafil","dataset":"drug-events","jurisdiction":"US","ingredient":"TADALAFIL","level":"ingredient","rank":174,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TADALAFIL: 12,288 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,842 were serious (55.7%) and 935 reported a death outcome (7.6%). Most reported reactions: HEADACHE (1,400); DYSPNOEA (1,287); DIARRHOEA (1,167); FATIGUE (1,127); NAUSEA (898). A report does not show that the drug caused the event.","value":12288,"unit":"FAERS reports received in the window","reports":12288,"serious":6842,"deaths":935,"serious_pct":55.7,"death_pct":7.6,"reports_q1":1484,"reports_q2":1585,"reports_q3":1643,"reports_q4":1593,"reports_q5":1678,"reports_q6":1542,"reports_q7":1432,"reports_q8":1331,"serious_q1":865,"serious_q2":944,"serious_q3":922,"serious_q4":816,"serious_q5":863,"serious_q6":899,"serious_q7":850,"serious_q8":683,"topReactions":"HEADACHE (1,400); DYSPNOEA (1,287); DIARRHOEA (1,167); FATIGUE (1,127); NAUSEA (898)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:glycerin","dataset":"drug-events","jurisdiction":"US","ingredient":"GLYCERIN","level":"ingredient","rank":175,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"GLYCERIN: 12,272 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,963 were serious (64.9%) and 886 reported a death outcome (7.2%). Most reported reactions: DRUG INEFFECTIVE (1,226); OFF LABEL USE (1,056); NAUSEA (729); HEADACHE (706); FATIGUE (705). A report does not show that the drug caused the event.","value":12272,"unit":"FAERS reports received in the window","reports":12272,"serious":7963,"deaths":886,"serious_pct":64.9,"death_pct":7.2,"reports_q1":1521,"reports_q2":1499,"reports_q3":1497,"reports_q4":1562,"reports_q5":1696,"reports_q6":1476,"reports_q7":1589,"reports_q8":1432,"serious_q1":921,"serious_q2":1026,"serious_q3":981,"serious_q4":1049,"serious_q5":1008,"serious_q6":967,"serious_q7":1114,"serious_q8":897,"topReactions":"DRUG INEFFECTIVE (1,226); OFF LABEL USE (1,056); NAUSEA (729); HEADACHE (706); FATIGUE (705)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:diazepam","dataset":"drug-events","jurisdiction":"US","ingredient":"DIAZEPAM","level":"ingredient","rank":176,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DIAZEPAM: 12,258 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,329 were serious (84.3%) and 1,753 reported a death outcome (14.3%). Most reported reactions: TOXICITY TO VARIOUS AGENTS (1,332); OFF LABEL USE (937); DRUG ABUSE (833); SOMNOLENCE (763); DRUG USE DISORDER (732). A report does not show that the drug caused the event.","value":12258,"unit":"FAERS reports received in the window","reports":12258,"serious":10329,"deaths":1753,"serious_pct":84.3,"death_pct":14.3,"reports_q1":1439,"reports_q2":1569,"reports_q3":1664,"reports_q4":1476,"reports_q5":1656,"reports_q6":1531,"reports_q7":1433,"reports_q8":1490,"serious_q1":1202,"serious_q2":1356,"serious_q3":1370,"serious_q4":1261,"serious_q5":1394,"serious_q6":1266,"serious_q7":1211,"serious_q8":1269,"topReactions":"TOXICITY TO VARIOUS AGENTS (1,332); OFF LABEL USE (937); DRUG ABUSE (833); SOMNOLENCE (763); DRUG USE DISORDER (732)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:valacyclovir-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"VALACYCLOVIR HYDROCHLORIDE","level":"ingredient","rank":177,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VALACYCLOVIR HYDROCHLORIDE: 12,108 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,726 were serious (72.1%) and 882 reported a death outcome (7.3%). Most reported reactions: OFF LABEL USE (983); FATIGUE (709); DRUG INEFFECTIVE (614); FEBRILE NEUTROPENIA (609); NAUSEA (589). A report does not show that the drug caused the event.","value":12108,"unit":"FAERS reports received in the window","reports":12108,"serious":8726,"deaths":882,"serious_pct":72.1,"death_pct":7.3,"reports_q1":1684,"reports_q2":1535,"reports_q3":1530,"reports_q4":1388,"reports_q5":1764,"reports_q6":1436,"reports_q7":1452,"reports_q8":1319,"serious_q1":1185,"serious_q2":1202,"serious_q3":1173,"serious_q4":1033,"serious_q5":1096,"serious_q6":1069,"serious_q7":1075,"serious_q8":893,"topReactions":"OFF LABEL USE (983); FATIGUE (709); DRUG INEFFECTIVE (614); FEBRILE NEUTROPENIA (609); NAUSEA (589)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:aripiprazole","dataset":"drug-events","jurisdiction":"US","ingredient":"ARIPIPRAZOLE","level":"ingredient","rank":178,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ARIPIPRAZOLE: 12,035 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,324 were serious (77.5%) and 767 reported a death outcome (6.4%). Most reported reactions: DRUG INEFFECTIVE (1,026); OFF LABEL USE (885); WEIGHT INCREASED (546); PRODUCT USE IN UNAPPROVED INDICATION (523); NAUSEA (498). A report does not show that the drug caused the event.","value":12035,"unit":"FAERS reports received in the window","reports":12035,"serious":9324,"deaths":767,"serious_pct":77.5,"death_pct":6.4,"reports_q1":1801,"reports_q2":1338,"reports_q3":1415,"reports_q4":1496,"reports_q5":1473,"reports_q6":1302,"reports_q7":1540,"reports_q8":1670,"serious_q1":1122,"serious_q2":1095,"serious_q3":1147,"serious_q4":1160,"serious_q5":1245,"serious_q6":1058,"serious_q7":1252,"serious_q8":1245,"topReactions":"DRUG INEFFECTIVE (1,026); OFF LABEL USE (885); WEIGHT INCREASED (546); PRODUCT USE IN UNAPPROVED INDICATION (523); NAUSEA (498)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:etoposide","dataset":"drug-events","jurisdiction":"US","ingredient":"ETOPOSIDE","level":"ingredient","rank":179,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ETOPOSIDE: 11,982 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,585 were serious (96.7%) and 2,654 reported a death outcome (22.1%). Most reported reactions: OFF LABEL USE (2,070); FEBRILE NEUTROPENIA (1,273); DRUG INEFFECTIVE (1,165); MYELOSUPPRESSION (931); DISEASE PROGRESSION (806). A report does not show that the drug caused the event.","value":11982,"unit":"FAERS reports received in the window","reports":11982,"serious":11585,"deaths":2654,"serious_pct":96.7,"death_pct":22.1,"reports_q1":1766,"reports_q2":1766,"reports_q3":1469,"reports_q4":1407,"reports_q5":1482,"reports_q6":1279,"reports_q7":1366,"reports_q8":1447,"serious_q1":1742,"serious_q2":1592,"serious_q3":1413,"serious_q4":1387,"serious_q5":1462,"serious_q6":1244,"serious_q7":1322,"serious_q8":1423,"topReactions":"OFF LABEL USE (2,070); FEBRILE NEUTROPENIA (1,273); DRUG INEFFECTIVE (1,165); MYELOSUPPRESSION (931); DISEASE PROGRESSION (806)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cisplatin","dataset":"drug-events","jurisdiction":"US","ingredient":"CISPLATIN","level":"ingredient","rank":180,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CISPLATIN: 11,965 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 11,555 were serious (96.6%) and 1,809 reported a death outcome (15.1%). Most reported reactions: MYELOSUPPRESSION (1,483); OFF LABEL USE (1,452); DISEASE PROGRESSION (759); DRUG INEFFECTIVE (730); MALIGNANT NEOPLASM PROGRESSION (672). A report does not show that the drug caused the event.","value":11965,"unit":"FAERS reports received in the window","reports":11965,"serious":11555,"deaths":1809,"serious_pct":96.6,"death_pct":15.1,"reports_q1":1592,"reports_q2":1804,"reports_q3":1516,"reports_q4":1461,"reports_q5":1461,"reports_q6":1374,"reports_q7":1378,"reports_q8":1379,"serious_q1":1535,"serious_q2":1643,"serious_q3":1462,"serious_q4":1436,"serious_q5":1434,"serious_q6":1353,"serious_q7":1334,"serious_q8":1358,"topReactions":"MYELOSUPPRESSION (1,483); OFF LABEL USE (1,452); DISEASE PROGRESSION (759); DRUG INEFFECTIVE (730); MALIGNANT NEOPLASM PROGRESSION (672)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lidocaine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"LIDOCAINE HYDROCHLORIDE","level":"ingredient","rank":181,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LIDOCAINE HYDROCHLORIDE: 11,826 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,021 were serious (67.8%) and 908 reported a death outcome (7.7%). Most reported reactions: DRUG INEFFECTIVE (1,121); OFF LABEL USE (915); NAUSEA (784); HEADACHE (711); FATIGUE (677). A report does not show that the drug caused the event.","value":11826,"unit":"FAERS reports received in the window","reports":11826,"serious":8021,"deaths":908,"serious_pct":67.8,"death_pct":7.7,"reports_q1":1534,"reports_q2":1482,"reports_q3":1494,"reports_q4":1591,"reports_q5":1394,"reports_q6":1402,"reports_q7":1494,"reports_q8":1435,"serious_q1":1046,"serious_q2":997,"serious_q3":994,"serious_q4":1068,"serious_q5":966,"serious_q6":941,"serious_q7":1085,"serious_q8":924,"topReactions":"DRUG INEFFECTIVE (1,121); OFF LABEL USE (915); NAUSEA (784); HEADACHE (711); FATIGUE (677)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dimethicone","dataset":"drug-events","jurisdiction":"US","ingredient":"DIMETHICONE","level":"ingredient","rank":182,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DIMETHICONE: 11,811 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,713 were serious (73.8%) and 2,344 reported a death outcome (19.8%). Most reported reactions: DIARRHOEA (1,796); OFF LABEL USE (1,728); FATIGUE (1,648); NAUSEA (1,575); VOMITING (1,457). A report does not show that the drug caused the event.","value":11811,"unit":"FAERS reports received in the window","reports":11811,"serious":8713,"deaths":2344,"serious_pct":73.8,"death_pct":19.8,"reports_q1":1635,"reports_q2":1559,"reports_q3":1597,"reports_q4":1388,"reports_q5":1602,"reports_q6":1492,"reports_q7":1298,"reports_q8":1240,"serious_q1":1176,"serious_q2":1196,"serious_q3":1171,"serious_q4":1009,"serious_q5":1218,"serious_q6":1132,"serious_q7":913,"serious_q8":898,"topReactions":"DIARRHOEA (1,796); OFF LABEL USE (1,728); FATIGUE (1,648); NAUSEA (1,575); VOMITING (1,457)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:leuprolide-acetate","dataset":"drug-events","jurisdiction":"US","ingredient":"LEUPROLIDE ACETATE","level":"ingredient","rank":183,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LEUPROLIDE ACETATE: 11,799 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,623 were serious (39.2%) and 1,839 reported a death outcome (15.6%). Most reported reactions: INTERCEPTED PRODUCT PREPARATION ERROR (2,827); DEATH (1,560); DEVICE LEAKAGE (1,503); SYRINGE ISSUE (1,424); WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (1,151). A report does not show that the drug caused the event.","value":11799,"unit":"FAERS reports received in the window","reports":11799,"serious":4623,"deaths":1839,"serious_pct":39.2,"death_pct":15.6,"reports_q1":2275,"reports_q2":1998,"reports_q3":2984,"reports_q4":1154,"reports_q5":990,"reports_q6":873,"reports_q7":764,"reports_q8":761,"serious_q1":702,"serious_q2":703,"serious_q3":738,"serious_q4":502,"serious_q5":527,"serious_q6":507,"serious_q7":440,"serious_q8":504,"topReactions":"INTERCEPTED PRODUCT PREPARATION ERROR (2,827); DEATH (1,560); DEVICE LEAKAGE (1,503); SYRINGE ISSUE (1,424); WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (1,151)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:clopidogrel","dataset":"drug-events","jurisdiction":"US","ingredient":"CLOPIDOGREL","level":"ingredient","rank":184,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CLOPIDOGREL: 11,766 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,452 were serious (80.3%) and 1,035 reported a death outcome (8.8%). Most reported reactions: FATIGUE (635); DIARRHOEA (617); DRUG INEFFECTIVE (564); DYSPNOEA (562); OFF LABEL USE (527). A report does not show that the drug caused the event.","value":11766,"unit":"FAERS reports received in the window","reports":11766,"serious":9452,"deaths":1035,"serious_pct":80.3,"death_pct":8.8,"reports_q1":1552,"reports_q2":1364,"reports_q3":1450,"reports_q4":1445,"reports_q5":1776,"reports_q6":1325,"reports_q7":1429,"reports_q8":1425,"serious_q1":1249,"serious_q2":1129,"serious_q3":1157,"serious_q4":1196,"serious_q5":1404,"serious_q6":1077,"serious_q7":1179,"serious_q8":1061,"topReactions":"FATIGUE (635); DIARRHOEA (617); DRUG INEFFECTIVE (564); DYSPNOEA (562); OFF LABEL USE (527)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pancrelipase-lipase","dataset":"drug-events","jurisdiction":"US","ingredient":"PANCRELIPASE LIPASE","level":"ingredient","rank":185,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PANCRELIPASE LIPASE: 11,753 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,594 were serious (81.6%) and 1,105 reported a death outcome (9.4%). Most reported reactions: DIARRHOEA (1,341); DEATH (757); PANCREATIC CARCINOMA (607); WEIGHT DECREASED (576); NAUSEA (495). A report does not show that the drug caused the event.","value":11753,"unit":"FAERS reports received in the window","reports":11753,"serious":9594,"deaths":1105,"serious_pct":81.6,"death_pct":9.4,"reports_q1":1360,"reports_q2":1355,"reports_q3":1457,"reports_q4":1489,"reports_q5":1453,"reports_q6":1539,"reports_q7":1701,"reports_q8":1399,"serious_q1":986,"serious_q2":1104,"serious_q3":1238,"serious_q4":1240,"serious_q5":1120,"serious_q6":1333,"serious_q7":1450,"serious_q8":1123,"topReactions":"DIARRHOEA (1,341); DEATH (757); PANCREATIC CARCINOMA (607); WEIGHT DECREASED (576); NAUSEA (495)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:trimethoprim","dataset":"drug-events","jurisdiction":"US","ingredient":"TRIMETHOPRIM","level":"ingredient","rank":186,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TRIMETHOPRIM: 11,715 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,584 were serious (81.8%) and 1,572 reported a death outcome (13.4%). Most reported reactions: OFF LABEL USE (1,432); FATIGUE (1,010); DIARRHOEA (816); DYSPNOEA (812); NAUSEA (801). A report does not show that the drug caused the event.","value":11715,"unit":"FAERS reports received in the window","reports":11715,"serious":9584,"deaths":1572,"serious_pct":81.8,"death_pct":13.4,"reports_q1":1606,"reports_q2":1674,"reports_q3":1500,"reports_q4":1448,"reports_q5":1526,"reports_q6":1290,"reports_q7":1408,"reports_q8":1263,"serious_q1":1340,"serious_q2":1413,"serious_q3":1232,"serious_q4":1172,"serious_q5":1227,"serious_q6":1070,"serious_q7":1118,"serious_q8":1012,"topReactions":"OFF LABEL USE (1,432); FATIGUE (1,010); DIARRHOEA (816); DYSPNOEA (812); NAUSEA (801)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pancrelipase-amylase","dataset":"drug-events","jurisdiction":"US","ingredient":"PANCRELIPASE AMYLASE","level":"ingredient","rank":187,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PANCRELIPASE AMYLASE: 11,694 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,568 were serious (81.8%) and 1,098 reported a death outcome (9.4%). Most reported reactions: DIARRHOEA (1,338); DEATH (752); PANCREATIC CARCINOMA (606); WEIGHT DECREASED (574); NAUSEA (493). A report does not show that the drug caused the event.","value":11694,"unit":"FAERS reports received in the window","reports":11694,"serious":9568,"deaths":1098,"serious_pct":81.8,"death_pct":9.4,"reports_q1":1350,"reports_q2":1354,"reports_q3":1455,"reports_q4":1483,"reports_q5":1441,"reports_q6":1530,"reports_q7":1695,"reports_q8":1386,"serious_q1":982,"serious_q2":1104,"serious_q3":1238,"serious_q4":1237,"serious_q5":1118,"serious_q6":1327,"serious_q7":1445,"serious_q8":1117,"topReactions":"DIARRHOEA (1,338); DEATH (752); PANCREATIC CARCINOMA (606); WEIGHT DECREASED (574); NAUSEA (493)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pancrelipase-protease","dataset":"drug-events","jurisdiction":"US","ingredient":"PANCRELIPASE PROTEASE","level":"ingredient","rank":188,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PANCRELIPASE PROTEASE: 11,694 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,568 were serious (81.8%) and 1,098 reported a death outcome (9.4%). Most reported reactions: DIARRHOEA (1,338); DEATH (752); PANCREATIC CARCINOMA (606); WEIGHT DECREASED (574); NAUSEA (493). A report does not show that the drug caused the event.","value":11694,"unit":"FAERS reports received in the window","reports":11694,"serious":9568,"deaths":1098,"serious_pct":81.8,"death_pct":9.4,"reports_q1":1350,"reports_q2":1354,"reports_q3":1455,"reports_q4":1483,"reports_q5":1441,"reports_q6":1530,"reports_q7":1695,"reports_q8":1386,"serious_q1":982,"serious_q2":1104,"serious_q3":1238,"serious_q4":1237,"serious_q5":1118,"serious_q6":1327,"serious_q7":1445,"serious_q8":1117,"topReactions":"DIARRHOEA (1,338); DEATH (752); PANCREATIC CARCINOMA (606); WEIGHT DECREASED (574); NAUSEA (493)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:fentanyl","dataset":"drug-events","jurisdiction":"US","ingredient":"FENTANYL","level":"ingredient","rank":189,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FENTANYL: 11,693 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,142 were serious (86.7%) and 3,664 reported a death outcome (31.3%). Most reported reactions: DRUG ABUSE (1,931); TOXICITY TO VARIOUS AGENTS (1,374); OVERDOSE (706); DRUG DIVERSION (697); DRUG INEFFECTIVE (648). A report does not show that the drug caused the event.","value":11693,"unit":"FAERS reports received in the window","reports":11693,"serious":10142,"deaths":3664,"serious_pct":86.7,"death_pct":31.3,"reports_q1":1329,"reports_q2":1643,"reports_q3":2276,"reports_q4":1299,"reports_q5":1364,"reports_q6":1269,"reports_q7":1179,"reports_q8":1334,"serious_q1":1178,"serious_q2":1410,"serious_q3":2144,"serious_q4":1162,"serious_q5":1204,"serious_q6":963,"serious_q7":964,"serious_q8":1117,"topReactions":"DRUG ABUSE (1,931); TOXICITY TO VARIOUS AGENTS (1,374); OVERDOSE (706); DRUG DIVERSION (697); DRUG INEFFECTIVE (648)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:losartan-potassium","dataset":"drug-events","jurisdiction":"US","ingredient":"LOSARTAN POTASSIUM","level":"ingredient","rank":190,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LOSARTAN POTASSIUM: 11,687 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,331 were serious (45.6%) and 540 reported a death outcome (4.6%). Most reported reactions: FATIGUE (1,043); DIARRHOEA (795); DYSPNOEA (737); HEADACHE (708); PRODUCT DOSE OMISSION ISSUE (694). Named in open multidistrict litigation MDL-2875. A report does not show that the drug caused the event.","value":11687,"unit":"FAERS reports received in the window","reports":11687,"serious":5331,"deaths":540,"serious_pct":45.6,"death_pct":4.6,"reports_q1":1311,"reports_q2":1328,"reports_q3":1408,"reports_q4":1431,"reports_q5":1753,"reports_q6":1336,"reports_q7":1419,"reports_q8":1701,"serious_q1":595,"serious_q2":683,"serious_q3":680,"serious_q4":683,"serious_q5":685,"serious_q6":674,"serious_q7":670,"serious_q8":661,"topReactions":"FATIGUE (1,043); DIARRHOEA (795); DYSPNOEA (737); HEADACHE (708); PRODUCT DOSE OMISSION ISSUE (694)","mdl":"MDL-2875","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:amoxicillin","dataset":"drug-events","jurisdiction":"US","ingredient":"AMOXICILLIN","level":"ingredient","rank":191,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AMOXICILLIN: 11,667 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,152 were serious (78.4%) and 669 reported a death outcome (5.7%). Most reported reactions: OFF LABEL USE (802); DIARRHOEA (685); DRUG INEFFECTIVE (658); FATIGUE (601); NAUSEA (579). A report does not show that the drug caused the event.","value":11667,"unit":"FAERS reports received in the window","reports":11667,"serious":9152,"deaths":669,"serious_pct":78.4,"death_pct":5.7,"reports_q1":1524,"reports_q2":1496,"reports_q3":1516,"reports_q4":1450,"reports_q5":1404,"reports_q6":1363,"reports_q7":1483,"reports_q8":1431,"serious_q1":1228,"serious_q2":1130,"serious_q3":1194,"serious_q4":1136,"serious_q5":1120,"serious_q6":1065,"serious_q7":1181,"serious_q8":1098,"topReactions":"OFF LABEL USE (802); DIARRHOEA (685); DRUG INEFFECTIVE (658); FATIGUE (601); NAUSEA (579)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dulaglutide","dataset":"drug-events","jurisdiction":"US","ingredient":"DULAGLUTIDE","level":"ingredient","rank":192,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DULAGLUTIDE: 11,630 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,728 were serious (40.7%) and 296 reported a death outcome (2.5%). Most reported reactions: NAUSEA (1,802); VOMITING (1,556); IMPAIRED GASTRIC EMPTYING (1,516); DIARRHOEA (1,284); INJECTION SITE PAIN (1,089). Named in open multidistrict litigation MDL-3094. A report does not show that the drug caused the event.","value":11630,"unit":"FAERS reports received in the window","reports":11630,"serious":4728,"deaths":296,"serious_pct":40.7,"death_pct":2.5,"reports_q1":1838,"reports_q2":1451,"reports_q3":1531,"reports_q4":1341,"reports_q5":1918,"reports_q6":1082,"reports_q7":1129,"reports_q8":1340,"serious_q1":650,"serious_q2":481,"serious_q3":492,"serious_q4":423,"serious_q5":1044,"serious_q6":431,"serious_q7":533,"serious_q8":674,"topReactions":"NAUSEA (1,802); VOMITING (1,556); IMPAIRED GASTRIC EMPTYING (1,516); DIARRHOEA (1,284); INJECTION SITE PAIN (1,089)","mdl":"MDL-3094","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cabozantinib-s-malate","dataset":"drug-events","jurisdiction":"US","ingredient":"CABOZANTINIB S-MALATE","level":"ingredient","rank":193,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CABOZANTINIB S-MALATE: 11,582 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,301 were serious (45.8%) and 861 reported a death outcome (7.4%). Most reported reactions: OFF LABEL USE (2,863); DIARRHOEA (1,755); FATIGUE (1,432); MALIGNANT NEOPLASM PROGRESSION (963); NAUSEA (908). A report does not show that the drug caused the event.","value":11582,"unit":"FAERS reports received in the window","reports":11582,"serious":5301,"deaths":861,"serious_pct":45.8,"death_pct":7.4,"reports_q1":532,"reports_q2":508,"reports_q3":4881,"reports_q4":439,"reports_q5":374,"reports_q6":396,"reports_q7":3697,"reports_q8":755,"serious_q1":425,"serious_q2":434,"serious_q3":1420,"serious_q4":368,"serious_q5":298,"serious_q6":335,"serious_q7":1333,"serious_q8":688,"topReactions":"OFF LABEL USE (2,863); DIARRHOEA (1,755); FATIGUE (1,432); MALIGNANT NEOPLASM PROGRESSION (963); NAUSEA (908)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:trastuzumab","dataset":"drug-events","jurisdiction":"US","ingredient":"TRASTUZUMAB","level":"ingredient","rank":194,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TRASTUZUMAB: 11,457 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,721 were serious (76.1%) and 945 reported a death outcome (8.2%). Most reported reactions: MYELOSUPPRESSION (1,320); OFF LABEL USE (1,264); DIARRHOEA (926); NAUSEA (739); DISEASE PROGRESSION (640). Named in open multidistrict litigation MDL-2700. A report does not show that the drug caused the event.","value":11457,"unit":"FAERS reports received in the window","reports":11457,"serious":8721,"deaths":945,"serious_pct":76.1,"death_pct":8.2,"reports_q1":3602,"reports_q2":1339,"reports_q3":1113,"reports_q4":1128,"reports_q5":1171,"reports_q6":1110,"reports_q7":978,"reports_q8":1016,"serious_q1":1330,"serious_q2":1230,"serious_q3":1040,"serious_q4":1059,"serious_q5":1111,"serious_q6":1065,"serious_q7":915,"serious_q8":971,"topReactions":"MYELOSUPPRESSION (1,320); OFF LABEL USE (1,264); DIARRHOEA (926); NAUSEA (739); DISEASE PROGRESSION (640)","mdl":"MDL-2700","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lidocaine-hydrochloride-anhydrous","dataset":"drug-events","jurisdiction":"US","ingredient":"LIDOCAINE HYDROCHLORIDE ANHYDROUS","level":"ingredient","rank":195,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LIDOCAINE HYDROCHLORIDE ANHYDROUS: 11,412 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,933 were serious (69.5%) and 902 reported a death outcome (7.9%). Most reported reactions: DRUG INEFFECTIVE (957); OFF LABEL USE (903); NAUSEA (772); HEADACHE (705); FATIGUE (661). A report does not show that the drug caused the event.","value":11412,"unit":"FAERS reports received in the window","reports":11412,"serious":7933,"deaths":902,"serious_pct":69.5,"death_pct":7.9,"reports_q1":1464,"reports_q2":1427,"reports_q3":1433,"reports_q4":1536,"reports_q5":1358,"reports_q6":1349,"reports_q7":1454,"reports_q8":1391,"serious_q1":1028,"serious_q2":988,"serious_q3":982,"serious_q4":1061,"serious_q5":957,"serious_q6":929,"serious_q7":1074,"serious_q8":914,"topReactions":"DRUG INEFFECTIVE (957); OFF LABEL USE (903); NAUSEA (772); HEADACHE (705); FATIGUE (661)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:alcohol","dataset":"drug-events","jurisdiction":"US","ingredient":"ALCOHOL","level":"ingredient","rank":196,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ALCOHOL: 11,348 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,604 were serious (67.0%) and 3,879 reported a death outcome (34.2%). Most reported reactions: ADVERSE DRUG REACTION (1,301); TOXICITY TO VARIOUS AGENTS (1,140); DRUG INEFFECTIVE (1,030); RASH (928); OFF LABEL USE (925). A report does not show that the drug caused the event.","value":11348,"unit":"FAERS reports received in the window","reports":11348,"serious":7604,"deaths":3879,"serious_pct":67,"death_pct":34.2,"reports_q1":1928,"reports_q2":1282,"reports_q3":1557,"reports_q4":1563,"reports_q5":1725,"reports_q6":839,"reports_q7":1368,"reports_q8":1086,"serious_q1":743,"serious_q2":1168,"serious_q3":1397,"serious_q4":744,"serious_q5":907,"serious_q6":743,"serious_q7":1199,"serious_q8":703,"topReactions":"ADVERSE DRUG REACTION (1,301); TOXICITY TO VARIOUS AGENTS (1,140); DRUG INEFFECTIVE (1,030); RASH (928); OFF LABEL USE (925)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:abaloparatide","dataset":"drug-events","jurisdiction":"US","ingredient":"ABALOPARATIDE","level":"ingredient","rank":197,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ABALOPARATIDE: 11,334 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,005 were serious (26.5%) and 144 reported a death outcome (1.3%). Most reported reactions: HEADACHE (2,056); DIZZINESS (1,645); NAUSEA (1,518); FATIGUE (1,461); ARTHRALGIA (1,129). A report does not show that the drug caused the event.","value":11334,"unit":"FAERS reports received in the window","reports":11334,"serious":3005,"deaths":144,"serious_pct":26.5,"death_pct":1.3,"reports_q1":197,"reports_q2":271,"reports_q3":316,"reports_q4":414,"reports_q5":4839,"reports_q6":737,"reports_q7":340,"reports_q8":4220,"serious_q1":167,"serious_q2":236,"serious_q3":270,"serious_q4":377,"serious_q5":528,"serious_q6":506,"serious_q7":311,"serious_q8":610,"topReactions":"HEADACHE (2,056); DIZZINESS (1,645); NAUSEA (1,518); FATIGUE (1,461); ARTHRALGIA (1,129)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:esomeprazole-magnesium","dataset":"drug-events","jurisdiction":"US","ingredient":"ESOMEPRAZOLE MAGNESIUM","level":"ingredient","rank":198,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ESOMEPRAZOLE MAGNESIUM: 11,096 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,136 were serious (82.3%) and 972 reported a death outcome (8.8%). Most reported reactions: OFF LABEL USE (993); DRUG INEFFECTIVE (909); NAUSEA (905); HEADACHE (863); DIARRHOEA (801). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":11096,"unit":"FAERS reports received in the window","reports":11096,"serious":9136,"deaths":972,"serious_pct":82.3,"death_pct":8.8,"reports_q1":1411,"reports_q2":1300,"reports_q3":1603,"reports_q4":1375,"reports_q5":1431,"reports_q6":1300,"reports_q7":1244,"reports_q8":1432,"serious_q1":1182,"serious_q2":1114,"serious_q3":1304,"serious_q4":1138,"serious_q5":1096,"serious_q6":1082,"serious_q7":1042,"serious_q8":1178,"topReactions":"OFF LABEL USE (993); DRUG INEFFECTIVE (909); NAUSEA (905); HEADACHE (863); DIARRHOEA (801)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:benzalkonium-chloride","dataset":"drug-events","jurisdiction":"US","ingredient":"BENZALKONIUM CHLORIDE","level":"ingredient","rank":199,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BENZALKONIUM CHLORIDE: 11,078 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,635 were serious (68.9%) and 880 reported a death outcome (7.9%). Most reported reactions: DRUG INEFFECTIVE (943); OFF LABEL USE (885); NAUSEA (760); HEADACHE (703); FATIGUE (651). A report does not show that the drug caused the event.","value":11078,"unit":"FAERS reports received in the window","reports":11078,"serious":7635,"deaths":880,"serious_pct":68.9,"death_pct":7.9,"reports_q1":1420,"reports_q2":1376,"reports_q3":1380,"reports_q4":1498,"reports_q5":1314,"reports_q6":1327,"reports_q7":1430,"reports_q8":1333,"serious_q1":983,"serious_q2":941,"serious_q3":933,"serious_q4":1028,"serious_q5":923,"serious_q6":912,"serious_q7":1054,"serious_q8":861,"topReactions":"DRUG INEFFECTIVE (943); OFF LABEL USE (885); NAUSEA (760); HEADACHE (703); FATIGUE (651)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:topiramate","dataset":"drug-events","jurisdiction":"US","ingredient":"TOPIRAMATE","level":"ingredient","rank":200,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TOPIRAMATE: 11,062 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,005 were serious (63.3%) and 1,712 reported a death outcome (15.5%). Most reported reactions: OFF LABEL USE (2,170); DRUG INEFFECTIVE (1,663); PRODUCT USE IN UNAPPROVED INDICATION (990); NAUSEA (973); HEADACHE (956). A report does not show that the drug caused the event.","value":11062,"unit":"FAERS reports received in the window","reports":11062,"serious":7005,"deaths":1712,"serious_pct":63.3,"death_pct":15.5,"reports_q1":2301,"reports_q2":1241,"reports_q3":1214,"reports_q4":1006,"reports_q5":2333,"reports_q6":1094,"reports_q7":934,"reports_q8":939,"serious_q1":938,"serious_q2":994,"serious_q3":945,"serious_q4":795,"serious_q5":1026,"serious_q6":858,"serious_q7":724,"serious_q8":725,"topReactions":"OFF LABEL USE (2,170); DRUG INEFFECTIVE (1,663); PRODUCT USE IN UNAPPROVED INDICATION (990); NAUSEA (973); HEADACHE (956)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:azithromycin-dihydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"AZITHROMYCIN DIHYDRATE","level":"ingredient","rank":201,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AZITHROMYCIN DIHYDRATE: 11,022 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,198 were serious (74.4%) and 999 reported a death outcome (9.1%). Most reported reactions: DRUG INEFFECTIVE (1,352); OFF LABEL USE (1,310); DYSPNOEA (871); COUGH (627); PNEUMONIA (626). A report does not show that the drug caused the event.","value":11022,"unit":"FAERS reports received in the window","reports":11022,"serious":8198,"deaths":999,"serious_pct":74.4,"death_pct":9.1,"reports_q1":1381,"reports_q2":1446,"reports_q3":1498,"reports_q4":1296,"reports_q5":1437,"reports_q6":1298,"reports_q7":1380,"reports_q8":1286,"serious_q1":1047,"serious_q2":1056,"serious_q3":1139,"serious_q4":972,"serious_q5":1060,"serious_q6":948,"serious_q7":1039,"serious_q8":937,"topReactions":"DRUG INEFFECTIVE (1,352); OFF LABEL USE (1,310); DYSPNOEA (871); COUGH (627); PNEUMONIA (626)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:hydroxyzine-dihydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"HYDROXYZINE DIHYDROCHLORIDE","level":"ingredient","rank":202,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"HYDROXYZINE DIHYDROCHLORIDE: 11,014 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,944 were serious (54.0%) and 1,026 reported a death outcome (9.3%). Most reported reactions: PRURITUS (890); DRUG INEFFECTIVE (836); OFF LABEL USE (821); NAUSEA (745); FATIGUE (607). A report does not show that the drug caused the event.","value":11014,"unit":"FAERS reports received in the window","reports":11014,"serious":5944,"deaths":1026,"serious_pct":54,"death_pct":9.3,"reports_q1":1128,"reports_q2":1425,"reports_q3":1436,"reports_q4":1271,"reports_q5":1491,"reports_q6":1279,"reports_q7":1566,"reports_q8":1418,"serious_q1":581,"serious_q2":685,"serious_q3":847,"serious_q4":678,"serious_q5":824,"serious_q6":680,"serious_q7":938,"serious_q8":711,"topReactions":"PRURITUS (890); DRUG INEFFECTIVE (836); OFF LABEL USE (821); NAUSEA (745); FATIGUE (607)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sildenafil-citrate","dataset":"drug-events","jurisdiction":"US","ingredient":"SILDENAFIL CITRATE","level":"ingredient","rank":203,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SILDENAFIL CITRATE: 10,985 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,599 were serious (60.1%) and 1,027 reported a death outcome (9.3%). Most reported reactions: DYSPNOEA (1,131); HEADACHE (1,131); DIARRHOEA (910); FATIGUE (886); COUGH (811). A report does not show that the drug caused the event.","value":10985,"unit":"FAERS reports received in the window","reports":10985,"serious":6599,"deaths":1027,"serious_pct":60.1,"death_pct":9.3,"reports_q1":1402,"reports_q2":1436,"reports_q3":1469,"reports_q4":1439,"reports_q5":1503,"reports_q6":1348,"reports_q7":1242,"reports_q8":1146,"serious_q1":882,"serious_q2":886,"serious_q3":860,"serious_q4":818,"serious_q5":903,"serious_q6":827,"serious_q7":763,"serious_q8":660,"topReactions":"DYSPNOEA (1,131); HEADACHE (1,131); DIARRHOEA (910); FATIGUE (886); COUGH (811)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:alendronate-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"ALENDRONATE SODIUM","level":"ingredient","rank":204,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ALENDRONATE SODIUM: 10,852 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,514 were serious (78.5%) and 4,011 reported a death outcome (37.0%). Most reported reactions: FATIGUE (2,339); OFF LABEL USE (2,152); RHEUMATOID ARTHRITIS (2,068); PAIN (2,066); SYSTEMIC LUPUS ERYTHEMATOSUS (2,054). Named in open multidistrict litigation MDL-2243. A report does not show that the drug caused the event.","value":10852,"unit":"FAERS reports received in the window","reports":10852,"serious":8514,"deaths":4011,"serious_pct":78.5,"death_pct":37,"reports_q1":1551,"reports_q2":1749,"reports_q3":1355,"reports_q4":1181,"reports_q5":1637,"reports_q6":1272,"reports_q7":981,"reports_q8":1126,"serious_q1":1186,"serious_q2":1476,"serious_q3":1124,"serious_q4":928,"serious_q5":1222,"serious_q6":1053,"serious_q7":721,"serious_q8":804,"topReactions":"FATIGUE (2,339); OFF LABEL USE (2,152); RHEUMATOID ARTHRITIS (2,068); PAIN (2,066); SYSTEMIC LUPUS ERYTHEMATOSUS (2,054)","mdl":"MDL-2243","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:estradiol-hemihydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"ESTRADIOL HEMIHYDRATE","level":"ingredient","rank":205,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ESTRADIOL HEMIHYDRATE: 10,764 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,033 were serious (37.5%) and 148 reported a death outcome (1.4%). Most reported reactions: DEVICE ADHESION ISSUE (1,007); DRUG INEFFECTIVE (741); HEADACHE (618); OFF LABEL USE (596); PRODUCT ADHESION ISSUE (583). A report does not show that the drug caused the event.","value":10764,"unit":"FAERS reports received in the window","reports":10764,"serious":4033,"deaths":148,"serious_pct":37.5,"death_pct":1.4,"reports_q1":990,"reports_q2":1058,"reports_q3":1060,"reports_q4":1150,"reports_q5":1464,"reports_q6":1767,"reports_q7":1469,"reports_q8":1806,"serious_q1":388,"serious_q2":423,"serious_q3":508,"serious_q4":518,"serious_q5":487,"serious_q6":548,"serious_q7":567,"serious_q8":594,"topReactions":"DEVICE ADHESION ISSUE (1,007); DRUG INEFFECTIVE (741); HEADACHE (618); OFF LABEL USE (596); PRODUCT ADHESION ISSUE (583)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:bortezomib","dataset":"drug-events","jurisdiction":"US","ingredient":"BORTEZOMIB","level":"ingredient","rank":206,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BORTEZOMIB: 10,736 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,749 were serious (90.8%) and 1,326 reported a death outcome (12.4%). Most reported reactions: PLASMA CELL MYELOMA (1,343); OFF LABEL USE (1,231); DRUG INEFFECTIVE (861); NEUROPATHY PERIPHERAL (678); INTENTIONAL PRODUCT USE ISSUE (538). A report does not show that the drug caused the event.","value":10736,"unit":"FAERS reports received in the window","reports":10736,"serious":9749,"deaths":1326,"serious_pct":90.8,"death_pct":12.4,"reports_q1":1561,"reports_q2":1707,"reports_q3":1237,"reports_q4":1205,"reports_q5":1228,"reports_q6":1239,"reports_q7":1239,"reports_q8":1320,"serious_q1":1319,"serious_q2":1550,"serious_q3":1112,"serious_q4":1081,"serious_q5":1139,"serious_q6":1147,"serious_q7":1154,"serious_q8":1247,"topReactions":"PLASMA CELL MYELOMA (1,343); OFF LABEL USE (1,231); DRUG INEFFECTIVE (861); NEUROPATHY PERIPHERAL (678); INTENTIONAL PRODUCT USE ISSUE (538)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:citalopram-hydrobromide","dataset":"drug-events","jurisdiction":"US","ingredient":"CITALOPRAM HYDROBROMIDE","level":"ingredient","rank":207,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CITALOPRAM HYDROBROMIDE: 10,683 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,301 were serious (77.7%) and 1,686 reported a death outcome (15.8%). Most reported reactions: OFF LABEL USE (866); FATIGUE (820); DRUG INEFFECTIVE (686); NAUSEA (655); HEADACHE (622). A report does not show that the drug caused the event.","value":10683,"unit":"FAERS reports received in the window","reports":10683,"serious":8301,"deaths":1686,"serious_pct":77.7,"death_pct":15.8,"reports_q1":1284,"reports_q2":1356,"reports_q3":1426,"reports_q4":1902,"reports_q5":1210,"reports_q6":1103,"reports_q7":1211,"reports_q8":1191,"serious_q1":990,"serious_q2":1035,"serious_q3":1093,"serious_q4":1645,"serious_q5":905,"serious_q6":831,"serious_q7":944,"serious_q8":858,"topReactions":"OFF LABEL USE (866); FATIGUE (820); DRUG INEFFECTIVE (686); NAUSEA (655); HEADACHE (622)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:melatonin","dataset":"drug-events","jurisdiction":"US","ingredient":"MELATONIN","level":"ingredient","rank":208,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MELATONIN: 10,564 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,935 were serious (65.6%) and 932 reported a death outcome (8.8%). Most reported reactions: FATIGUE (859); OFF LABEL USE (844); NAUSEA (643); DIARRHOEA (609); HEADACHE (609). A report does not show that the drug caused the event.","value":10564,"unit":"FAERS reports received in the window","reports":10564,"serious":6935,"deaths":932,"serious_pct":65.6,"death_pct":8.8,"reports_q1":1247,"reports_q2":1222,"reports_q3":1433,"reports_q4":1384,"reports_q5":1486,"reports_q6":1246,"reports_q7":1398,"reports_q8":1148,"serious_q1":795,"serious_q2":807,"serious_q3":978,"serious_q4":921,"serious_q5":938,"serious_q6":880,"serious_q7":934,"serious_q8":682,"topReactions":"FATIGUE (859); OFF LABEL USE (844); NAUSEA (643); DIARRHOEA (609); HEADACHE (609)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:candesartan-cilexetil","dataset":"drug-events","jurisdiction":"US","ingredient":"CANDESARTAN CILEXETIL","level":"ingredient","rank":209,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CANDESARTAN CILEXETIL: 10,562 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 10,061 were serious (95.3%) and 2,610 reported a death outcome (24.7%). Most reported reactions: OFF LABEL USE (1,886); FATIGUE (1,323); PAIN (1,275); HEADACHE (1,224); DRUG INEFFECTIVE (1,217). A report does not show that the drug caused the event.","value":10562,"unit":"FAERS reports received in the window","reports":10562,"serious":10061,"deaths":2610,"serious_pct":95.3,"death_pct":24.7,"reports_q1":1395,"reports_q2":1349,"reports_q3":1490,"reports_q4":1126,"reports_q5":1388,"reports_q6":1257,"reports_q7":1301,"reports_q8":1256,"serious_q1":1267,"serious_q2":1295,"serious_q3":1413,"serious_q4":1094,"serious_q5":1333,"serious_q6":1206,"serious_q7":1235,"serious_q8":1218,"topReactions":"OFF LABEL USE (1,886); FATIGUE (1,323); PAIN (1,275); HEADACHE (1,224); DRUG INEFFECTIVE (1,217)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sulfamethoxazole","dataset":"drug-events","jurisdiction":"US","ingredient":"SULFAMETHOXAZOLE","level":"ingredient","rank":210,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SULFAMETHOXAZOLE: 10,529 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,491 were serious (80.6%) and 1,407 reported a death outcome (13.4%). Most reported reactions: OFF LABEL USE (1,277); FATIGUE (932); DIARRHOEA (747); NAUSEA (740); DYSPNOEA (693). A report does not show that the drug caused the event.","value":10529,"unit":"FAERS reports received in the window","reports":10529,"serious":8491,"deaths":1407,"serious_pct":80.6,"death_pct":13.4,"reports_q1":1420,"reports_q2":1502,"reports_q3":1359,"reports_q4":1340,"reports_q5":1361,"reports_q6":1156,"reports_q7":1285,"reports_q8":1106,"serious_q1":1171,"serious_q2":1252,"serious_q3":1109,"serious_q4":1070,"serious_q5":1072,"serious_q6":947,"serious_q7":1006,"serious_q8":864,"topReactions":"OFF LABEL USE (1,277); FATIGUE (932); DIARRHOEA (747); NAUSEA (740); DYSPNOEA (693)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:esomeprazole","dataset":"drug-events","jurisdiction":"US","ingredient":"ESOMEPRAZOLE","level":"ingredient","rank":211,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ESOMEPRAZOLE: 10,513 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,961 were serious (85.2%) and 957 reported a death outcome (9.1%). Most reported reactions: OFF LABEL USE (926); NAUSEA (830); HEADACHE (804); DIARRHOEA (727); DRUG INEFFECTIVE (715). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":10513,"unit":"FAERS reports received in the window","reports":10513,"serious":8961,"deaths":957,"serious_pct":85.2,"death_pct":9.1,"reports_q1":1346,"reports_q2":1262,"reports_q3":1530,"reports_q4":1301,"reports_q5":1304,"reports_q6":1231,"reports_q7":1182,"reports_q8":1357,"serious_q1":1161,"serious_q2":1105,"serious_q3":1290,"serious_q4":1121,"serious_q5":1066,"serious_q6":1051,"serious_q7":1026,"serious_q8":1141,"topReactions":"OFF LABEL USE (926); NAUSEA (830); HEADACHE (804); DIARRHOEA (727); DRUG INEFFECTIVE (715)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:leflunomide","dataset":"drug-events","jurisdiction":"US","ingredient":"LEFLUNOMIDE","level":"ingredient","rank":212,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LEFLUNOMIDE: 10,347 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,237 were serious (89.3%) and 4,175 reported a death outcome (40.3%). Most reported reactions: OFF LABEL USE (2,538); RHEUMATOID ARTHRITIS (2,506); PAIN (2,320); RASH (2,269); ARTHRALGIA (2,220). A report does not show that the drug caused the event.","value":10347,"unit":"FAERS reports received in the window","reports":10347,"serious":9237,"deaths":4175,"serious_pct":89.3,"death_pct":40.3,"reports_q1":1395,"reports_q2":1771,"reports_q3":1431,"reports_q4":1160,"reports_q5":1514,"reports_q6":1231,"reports_q7":824,"reports_q8":1021,"serious_q1":1270,"serious_q2":1565,"serious_q3":1297,"serious_q4":1015,"serious_q5":1388,"serious_q6":1094,"serious_q7":713,"serious_q8":895,"topReactions":"OFF LABEL USE (2,538); RHEUMATOID ARTHRITIS (2,506); PAIN (2,320); RASH (2,269); ARTHRALGIA (2,220)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cytarabine","dataset":"drug-events","jurisdiction":"US","ingredient":"CYTARABINE","level":"ingredient","rank":213,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CYTARABINE: 10,308 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,886 were serious (95.9%) and 2,094 reported a death outcome (20.3%). Most reported reactions: FEBRILE NEUTROPENIA (1,467); OFF LABEL USE (1,275); MYELOSUPPRESSION (1,061); PYREXIA (765); DRUG INEFFECTIVE (745). A report does not show that the drug caused the event.","value":10308,"unit":"FAERS reports received in the window","reports":10308,"serious":9886,"deaths":2094,"serious_pct":95.9,"death_pct":20.3,"reports_q1":1745,"reports_q2":1483,"reports_q3":1046,"reports_q4":1290,"reports_q5":1410,"reports_q6":1046,"reports_q7":1086,"reports_q8":1202,"serious_q1":1649,"serious_q2":1296,"serious_q3":1022,"serious_q4":1270,"serious_q5":1388,"serious_q6":1027,"serious_q7":1056,"serious_q8":1178,"topReactions":"FEBRILE NEUTROPENIA (1,467); OFF LABEL USE (1,275); MYELOSUPPRESSION (1,061); PYREXIA (765); DRUG INEFFECTIVE (745)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:naproxen","dataset":"drug-events","jurisdiction":"US","ingredient":"NAPROXEN","level":"ingredient","rank":214,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"NAPROXEN: 10,153 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,578 were serious (84.5%) and 2,376 reported a death outcome (23.4%). Most reported reactions: OFF LABEL USE (1,837); PAIN (1,520); NAUSEA (1,515); DRUG INEFFECTIVE (1,510); RASH (1,402). A report does not show that the drug caused the event.","value":10153,"unit":"FAERS reports received in the window","reports":10153,"serious":8578,"deaths":2376,"serious_pct":84.5,"death_pct":23.4,"reports_q1":1274,"reports_q2":1498,"reports_q3":1370,"reports_q4":1147,"reports_q5":1596,"reports_q6":1247,"reports_q7":948,"reports_q8":1073,"serious_q1":1071,"serious_q2":1284,"serious_q3":1156,"serious_q4":969,"serious_q5":1344,"serious_q6":1081,"serious_q7":776,"serious_q8":897,"topReactions":"OFF LABEL USE (1,837); PAIN (1,520); NAUSEA (1,515); DRUG INEFFECTIVE (1,510); RASH (1,402)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ocrelizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"OCRELIZUMAB","level":"ingredient","rank":215,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OCRELIZUMAB: 10,129 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,288 were serious (52.2%) and 236 reported a death outcome (2.3%). Most reported reactions: COVID-19 (889); FATIGUE (854); MULTIPLE SCLEROSIS (602); OFF LABEL USE (512); DRUG INEFFECTIVE (458). A report does not show that the drug caused the event.","value":10129,"unit":"FAERS reports received in the window","reports":10129,"serious":5288,"deaths":236,"serious_pct":52.2,"death_pct":2.3,"reports_q1":1827,"reports_q2":1788,"reports_q3":1372,"reports_q4":1084,"reports_q5":1051,"reports_q6":1042,"reports_q7":997,"reports_q8":968,"serious_q1":816,"serious_q2":796,"serious_q3":554,"serious_q4":572,"serious_q5":583,"serious_q6":662,"serious_q7":660,"serious_q8":645,"topReactions":"COVID-19 (889); FATIGUE (854); MULTIPLE SCLEROSIS (602); OFF LABEL USE (512); DRUG INEFFECTIVE (458)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:azithromycin-monohydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"AZITHROMYCIN MONOHYDRATE","level":"ingredient","rank":216,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AZITHROMYCIN MONOHYDRATE: 10,120 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,562 were serious (74.7%) and 926 reported a death outcome (9.2%). Most reported reactions: DRUG INEFFECTIVE (1,305); OFF LABEL USE (1,178); DYSPNOEA (789); CONDITION AGGRAVATED (585); COUGH (578). A report does not show that the drug caused the event.","value":10120,"unit":"FAERS reports received in the window","reports":10120,"serious":7562,"deaths":926,"serious_pct":74.7,"death_pct":9.2,"reports_q1":1276,"reports_q2":1324,"reports_q3":1377,"reports_q4":1177,"reports_q5":1333,"reports_q6":1183,"reports_q7":1272,"reports_q8":1178,"serious_q1":975,"serious_q2":983,"serious_q3":1056,"serious_q4":881,"serious_q5":982,"serious_q6":864,"serious_q7":968,"serious_q8":853,"topReactions":"DRUG INEFFECTIVE (1,305); OFF LABEL USE (1,178); DYSPNOEA (789); CONDITION AGGRAVATED (585); COUGH (578)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:apremilast","dataset":"drug-events","jurisdiction":"US","ingredient":"APREMILAST","level":"ingredient","rank":217,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"APREMILAST: 10,099 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,928 were serious (58.7%) and 3,098 reported a death outcome (30.7%). Most reported reactions: PAIN (1,815); RASH (1,678); DIARRHOEA (1,671); PSORIATIC ARTHROPATHY (1,661); OFF LABEL USE (1,646). A report does not show that the drug caused the event.","value":10099,"unit":"FAERS reports received in the window","reports":10099,"serious":5928,"deaths":3098,"serious_pct":58.7,"death_pct":30.7,"reports_q1":1442,"reports_q2":1501,"reports_q3":1341,"reports_q4":1247,"reports_q5":1293,"reports_q6":1054,"reports_q7":848,"reports_q8":1373,"serious_q1":760,"serious_q2":949,"serious_q3":791,"serious_q4":679,"serious_q5":793,"serious_q6":684,"serious_q7":421,"serious_q8":851,"topReactions":"PAIN (1,815); RASH (1,678); DIARRHOEA (1,671); PSORIATIC ARTHROPATHY (1,661); OFF LABEL USE (1,646)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:zolpidem-tartrate","dataset":"drug-events","jurisdiction":"US","ingredient":"ZOLPIDEM TARTRATE","level":"ingredient","rank":218,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ZOLPIDEM TARTRATE: 10,032 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,955 were serious (69.3%) and 897 reported a death outcome (8.9%). Most reported reactions: DRUG INEFFECTIVE (719); TOXICITY TO VARIOUS AGENTS (647); FATIGUE (640); NAUSEA (639); OFF LABEL USE (589). A report does not show that the drug caused the event.","value":10032,"unit":"FAERS reports received in the window","reports":10032,"serious":6955,"deaths":897,"serious_pct":69.3,"death_pct":8.9,"reports_q1":1342,"reports_q2":1105,"reports_q3":1381,"reports_q4":1344,"reports_q5":1222,"reports_q6":1099,"reports_q7":1264,"reports_q8":1275,"serious_q1":958,"serious_q2":763,"serious_q3":988,"serious_q4":953,"serious_q5":833,"serious_q6":766,"serious_q7":915,"serious_q8":779,"topReactions":"DRUG INEFFECTIVE (719); TOXICITY TO VARIOUS AGENTS (647); FATIGUE (640); NAUSEA (639); OFF LABEL USE (589)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cetirizine","dataset":"drug-events","jurisdiction":"US","ingredient":"CETIRIZINE","level":"ingredient","rank":219,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CETIRIZINE: 9,932 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,686 were serious (77.4%) and 2,221 reported a death outcome (22.4%). Most reported reactions: OFF LABEL USE (1,579); FATIGUE (1,533); RASH (1,425); PAIN (1,285); URTICARIA (1,214). A report does not show that the drug caused the event.","value":9932,"unit":"FAERS reports received in the window","reports":9932,"serious":7686,"deaths":2221,"serious_pct":77.4,"death_pct":22.4,"reports_q1":1256,"reports_q2":1385,"reports_q3":1350,"reports_q4":1141,"reports_q5":1374,"reports_q6":1195,"reports_q7":1152,"reports_q8":1079,"serious_q1":989,"serious_q2":1069,"serious_q3":1060,"serious_q4":872,"serious_q5":1071,"serious_q6":950,"serious_q7":856,"serious_q8":819,"topReactions":"OFF LABEL USE (1,579); FATIGUE (1,533); RASH (1,425); PAIN (1,285); URTICARIA (1,214)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:risperidone","dataset":"drug-events","jurisdiction":"US","ingredient":"RISPERIDONE","level":"ingredient","rank":220,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RISPERIDONE: 9,798 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,921 were serious (80.8%) and 689 reported a death outcome (7.0%). Most reported reactions: OFF LABEL USE (1,139); DRUG INEFFECTIVE (922); WEIGHT INCREASED (542); SOMNOLENCE (471); DRUG INTERACTION (459). A report does not show that the drug caused the event.","value":9798,"unit":"FAERS reports received in the window","reports":9798,"serious":7921,"deaths":689,"serious_pct":80.8,"death_pct":7,"reports_q1":1238,"reports_q2":1476,"reports_q3":1205,"reports_q4":1224,"reports_q5":1225,"reports_q6":1194,"reports_q7":1137,"reports_q8":1099,"serious_q1":983,"serious_q2":1234,"serious_q3":961,"serious_q4":1002,"serious_q5":982,"serious_q6":924,"serious_q7":884,"serious_q8":951,"topReactions":"OFF LABEL USE (1,139); DRUG INEFFECTIVE (922); WEIGHT INCREASED (542); SOMNOLENCE (471); DRUG INTERACTION (459)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:macitentan","dataset":"drug-events","jurisdiction":"US","ingredient":"MACITENTAN","level":"ingredient","rank":221,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MACITENTAN: 9,758 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,636 were serious (57.8%) and 836 reported a death outcome (8.6%). Most reported reactions: HEADACHE (1,218); DYSPNOEA (1,154); DIARRHOEA (886); FATIGUE (762); NAUSEA (761). A report does not show that the drug caused the event.","value":9758,"unit":"FAERS reports received in the window","reports":9758,"serious":5636,"deaths":836,"serious_pct":57.8,"death_pct":8.6,"reports_q1":1442,"reports_q2":1298,"reports_q3":1380,"reports_q4":1375,"reports_q5":1233,"reports_q6":1113,"reports_q7":1000,"reports_q8":917,"serious_q1":881,"serious_q2":783,"serious_q3":809,"serious_q4":758,"serious_q5":706,"serious_q6":613,"serious_q7":561,"serious_q8":525,"topReactions":"HEADACHE (1,218); DYSPNOEA (1,154); DIARRHOEA (886); FATIGUE (762); NAUSEA (761)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:mesalamine","dataset":"drug-events","jurisdiction":"US","ingredient":"MESALAMINE","level":"ingredient","rank":222,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MESALAMINE: 9,747 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,939 were serious (91.7%) and 1,110 reported a death outcome (11.4%). Most reported reactions: OFF LABEL USE (1,879); COLITIS ULCERATIVE (1,818); DRUG INEFFECTIVE (1,235); HAEMATOCHEZIA (987); DIARRHOEA (954). A report does not show that the drug caused the event.","value":9747,"unit":"FAERS reports received in the window","reports":9747,"serious":8939,"deaths":1110,"serious_pct":91.7,"death_pct":11.4,"reports_q1":1321,"reports_q2":1305,"reports_q3":1330,"reports_q4":1242,"reports_q5":1226,"reports_q6":1231,"reports_q7":1186,"reports_q8":906,"serious_q1":1206,"serious_q2":1217,"serious_q3":1212,"serious_q4":1139,"serious_q5":1117,"serious_q6":1145,"serious_q7":1097,"serious_q8":806,"topReactions":"OFF LABEL USE (1,879); COLITIS ULCERATIVE (1,818); DRUG INEFFECTIVE (1,235); HAEMATOCHEZIA (987); DIARRHOEA (954)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:gemcitabine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"GEMCITABINE HYDROCHLORIDE","level":"ingredient","rank":223,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"GEMCITABINE HYDROCHLORIDE: 9,739 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 9,357 were serious (96.1%) and 1,403 reported a death outcome (14.4%). Most reported reactions: OFF LABEL USE (1,170); MYELOSUPPRESSION (921); DISEASE PROGRESSION (907); DRUG INEFFECTIVE (778); MALIGNANT NEOPLASM PROGRESSION (574). A report does not show that the drug caused the event.","value":9739,"unit":"FAERS reports received in the window","reports":9739,"serious":9357,"deaths":1403,"serious_pct":96.1,"death_pct":14.4,"reports_q1":1199,"reports_q2":1404,"reports_q3":1263,"reports_q4":1196,"reports_q5":1222,"reports_q6":1139,"reports_q7":1083,"reports_q8":1233,"serious_q1":1160,"serious_q2":1295,"serious_q3":1213,"serious_q4":1165,"serious_q5":1151,"serious_q6":1115,"serious_q7":1060,"serious_q8":1198,"topReactions":"OFF LABEL USE (1,170); MYELOSUPPRESSION (921); DISEASE PROGRESSION (907); DRUG INEFFECTIVE (778); MALIGNANT NEOPLASM PROGRESSION (574)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:vancomycin","dataset":"drug-events","jurisdiction":"US","ingredient":"VANCOMYCIN","level":"ingredient","rank":224,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VANCOMYCIN: 9,733 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,951 were serious (92.0%) and 1,793 reported a death outcome (18.4%). Most reported reactions: DRUG INEFFECTIVE (2,004); OFF LABEL USE (1,028); ACUTE KIDNEY INJURY (821); DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (555); CONDITION AGGRAVATED (517). A report does not show that the drug caused the event.","value":9733,"unit":"FAERS reports received in the window","reports":9733,"serious":8951,"deaths":1793,"serious_pct":92,"death_pct":18.4,"reports_q1":1176,"reports_q2":1489,"reports_q3":1167,"reports_q4":1238,"reports_q5":1338,"reports_q6":1246,"reports_q7":1096,"reports_q8":983,"serious_q1":1092,"serious_q2":1373,"serious_q3":1045,"serious_q4":1151,"serious_q5":1256,"serious_q6":1122,"serious_q7":1013,"serious_q8":899,"topReactions":"DRUG INEFFECTIVE (2,004); OFF LABEL USE (1,028); ACUTE KIDNEY INJURY (821); DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (555); CONDITION AGGRAVATED (517)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sarilumab","dataset":"drug-events","jurisdiction":"US","ingredient":"SARILUMAB","level":"ingredient","rank":225,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SARILUMAB: 9,682 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,635 were serious (37.5%) and 1,404 reported a death outcome (14.5%). Most reported reactions: ARTHRALGIA (2,241); PAIN (2,138); DRUG INEFFECTIVE (1,706); JOINT SWELLING (1,535); CONDITION AGGRAVATED (1,325). A report does not show that the drug caused the event.","value":9682,"unit":"FAERS reports received in the window","reports":9682,"serious":3635,"deaths":1404,"serious_pct":37.5,"death_pct":14.5,"reports_q1":1006,"reports_q2":1306,"reports_q3":1213,"reports_q4":1258,"reports_q5":1310,"reports_q6":1108,"reports_q7":1015,"reports_q8":1466,"serious_q1":475,"serious_q2":555,"serious_q3":510,"serious_q4":471,"serious_q5":511,"serious_q6":414,"serious_q7":327,"serious_q8":372,"topReactions":"ARTHRALGIA (2,241); PAIN (2,138); DRUG INEFFECTIVE (1,706); JOINT SWELLING (1,535); CONDITION AGGRAVATED (1,325)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:minoxidil","dataset":"drug-events","jurisdiction":"US","ingredient":"MINOXIDIL","level":"ingredient","rank":226,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MINOXIDIL: 9,637 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,126 were serious (32.4%) and 268 reported a death outcome (2.8%). Most reported reactions: ADVERSE DRUG REACTION (1,196); DRUG INEFFECTIVE (890); OFF LABEL USE (594); HEADACHE (550); FATIGUE (527). A report does not show that the drug caused the event.","value":9637,"unit":"FAERS reports received in the window","reports":9637,"serious":3126,"deaths":268,"serious_pct":32.4,"death_pct":2.8,"reports_q1":1942,"reports_q2":788,"reports_q3":834,"reports_q4":1562,"reports_q5":1600,"reports_q6":782,"reports_q7":979,"reports_q8":1150,"serious_q1":368,"serious_q2":422,"serious_q3":366,"serious_q4":408,"serious_q5":357,"serious_q6":344,"serious_q7":438,"serious_q8":423,"topReactions":"ADVERSE DRUG REACTION (1,196); DRUG INEFFECTIVE (890); OFF LABEL USE (594); HEADACHE (550); FATIGUE (527)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:doxycycline","dataset":"drug-events","jurisdiction":"US","ingredient":"DOXYCYCLINE","level":"ingredient","rank":227,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DOXYCYCLINE: 9,599 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,745 were serious (80.7%) and 1,263 reported a death outcome (13.2%). Most reported reactions: OFF LABEL USE (1,065); DRUG INEFFECTIVE (1,039); RASH (721); FATIGUE (720); CONDITION AGGRAVATED (685). A report does not show that the drug caused the event.","value":9599,"unit":"FAERS reports received in the window","reports":9599,"serious":7745,"deaths":1263,"serious_pct":80.7,"death_pct":13.2,"reports_q1":1226,"reports_q2":1375,"reports_q3":1199,"reports_q4":1110,"reports_q5":1347,"reports_q6":1100,"reports_q7":1173,"reports_q8":1069,"serious_q1":1051,"serious_q2":1170,"serious_q3":950,"serious_q4":896,"serious_q5":1057,"serious_q6":889,"serious_q7":926,"serious_q8":806,"topReactions":"OFF LABEL USE (1,065); DRUG INEFFECTIVE (1,039); RASH (721); FATIGUE (720); CONDITION AGGRAVATED (685)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:copper","dataset":"drug-events","jurisdiction":"US","ingredient":"COPPER","level":"ingredient","rank":228,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"COPPER: 9,566 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,125 were serious (64.0%) and 72 reported a death outcome (0.8%). Most reported reactions: COMPLICATION OF DEVICE REMOVAL (4,531); DEVICE BREAKAGE (4,468); FOREIGN BODY IN REPRODUCTIVE TRACT (3,885); COMPLICATION OF DEVICE INSERTION (2,503); PAIN (2,076). A report does not show that the drug caused the event.","value":9566,"unit":"FAERS reports received in the window","reports":9566,"serious":6125,"deaths":72,"serious_pct":64,"death_pct":0.8,"reports_q1":213,"reports_q2":566,"reports_q3":1459,"reports_q4":1264,"reports_q5":708,"reports_q6":580,"reports_q7":4611,"reports_q8":165,"serious_q1":171,"serious_q2":486,"serious_q3":906,"serious_q4":1184,"serious_q5":609,"serious_q6":508,"serious_q7":2123,"serious_q8":138,"topReactions":"COMPLICATION OF DEVICE REMOVAL (4,531); DEVICE BREAKAGE (4,468); FOREIGN BODY IN REPRODUCTIVE TRACT (3,885); COMPLICATION OF DEVICE INSERTION (2,503); PAIN (2,076)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:petrolatum","dataset":"drug-events","jurisdiction":"US","ingredient":"PETROLATUM","level":"ingredient","rank":229,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PETROLATUM: 9,506 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,758 were serious (71.1%) and 807 reported a death outcome (8.5%). Most reported reactions: DRUG INEFFECTIVE (1,003); OFF LABEL USE (900); NAUSEA (638); FATIGUE (595); HEADACHE (586). A report does not show that the drug caused the event.","value":9506,"unit":"FAERS reports received in the window","reports":9506,"serious":6758,"deaths":807,"serious_pct":71.1,"death_pct":8.5,"reports_q1":1197,"reports_q2":1147,"reports_q3":1128,"reports_q4":1239,"reports_q5":1166,"reports_q6":1140,"reports_q7":1257,"reports_q8":1232,"serious_q1":834,"serious_q2":825,"serious_q3":803,"serious_q4":879,"serious_q5":816,"serious_q6":810,"serious_q7":972,"serious_q8":819,"topReactions":"DRUG INEFFECTIVE (1,003); OFF LABEL USE (900); NAUSEA (638); FATIGUE (595); HEADACHE (586)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:capecitabine","dataset":"drug-events","jurisdiction":"US","ingredient":"CAPECITABINE","level":"ingredient","rank":230,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CAPECITABINE: 9,437 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,547 were serious (90.6%) and 1,267 reported a death outcome (13.4%). Most reported reactions: DIARRHOEA (1,090); NAUSEA (835); OFF LABEL USE (706); MALIGNANT NEOPLASM PROGRESSION (596); FATIGUE (561). A report does not show that the drug caused the event.","value":9437,"unit":"FAERS reports received in the window","reports":9437,"serious":8547,"deaths":1267,"serious_pct":90.6,"death_pct":13.4,"reports_q1":1483,"reports_q2":1217,"reports_q3":1414,"reports_q4":1070,"reports_q5":1177,"reports_q6":1038,"reports_q7":1111,"reports_q8":927,"serious_q1":1242,"serious_q2":1127,"serious_q3":1259,"serious_q4":1012,"serious_q5":1109,"serious_q6":996,"serious_q7":960,"serious_q8":842,"topReactions":"DIARRHOEA (1,090); NAUSEA (835); OFF LABEL USE (706); MALIGNANT NEOPLASM PROGRESSION (596); FATIGUE (561)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ciprofloxacin-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"CIPROFLOXACIN HYDROCHLORIDE","level":"ingredient","rank":231,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CIPROFLOXACIN HYDROCHLORIDE: 9,410 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,281 were serious (88.0%) and 711 reported a death outcome (7.6%). Most reported reactions: VOMITING (793); PNEUMONIA (785); DYSPNOEA (780); OFF LABEL USE (780); DRUG HYPERSENSITIVITY (762). A report does not show that the drug caused the event.","value":9410,"unit":"FAERS reports received in the window","reports":9410,"serious":8281,"deaths":711,"serious_pct":88,"death_pct":7.6,"reports_q1":1280,"reports_q2":1341,"reports_q3":1091,"reports_q4":1210,"reports_q5":1328,"reports_q6":1139,"reports_q7":985,"reports_q8":1036,"serious_q1":1114,"serious_q2":1183,"serious_q3":970,"serious_q4":1054,"serious_q5":1154,"serious_q6":1020,"serious_q7":877,"serious_q8":909,"topReactions":"VOMITING (793); PNEUMONIA (785); DYSPNOEA (780); OFF LABEL USE (780); DRUG HYPERSENSITIVITY (762)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:polymyxin-b-sulfate","dataset":"drug-events","jurisdiction":"US","ingredient":"POLYMYXIN B SULFATE","level":"ingredient","rank":232,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"POLYMYXIN B SULFATE: 9,230 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,582 were serious (71.3%) and 797 reported a death outcome (8.6%). Most reported reactions: DRUG INEFFECTIVE (915); OFF LABEL USE (777); DYSPNOEA (587); NAUSEA (576); FATIGUE (554). A report does not show that the drug caused the event.","value":9230,"unit":"FAERS reports received in the window","reports":9230,"serious":6582,"deaths":797,"serious_pct":71.3,"death_pct":8.6,"reports_q1":1175,"reports_q2":1106,"reports_q3":1092,"reports_q4":1226,"reports_q5":1111,"reports_q6":1107,"reports_q7":1245,"reports_q8":1168,"serious_q1":840,"serious_q2":781,"serious_q3":771,"serious_q4":855,"serious_q5":801,"serious_q6":785,"serious_q7":960,"serious_q8":789,"topReactions":"DRUG INEFFECTIVE (915); OFF LABEL USE (777); DYSPNOEA (587); NAUSEA (576); FATIGUE (554)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:iron","dataset":"drug-events","jurisdiction":"US","ingredient":"IRON","level":"ingredient","rank":233,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"IRON: 9,178 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,828 were serious (63.5%) and 577 reported a death outcome (6.3%). Most reported reactions: OFF LABEL USE (928); FATIGUE (884); DIARRHOEA (712); NAUSEA (619); HEADACHE (593). A report does not show that the drug caused the event.","value":9178,"unit":"FAERS reports received in the window","reports":9178,"serious":5828,"deaths":577,"serious_pct":63.5,"death_pct":6.3,"reports_q1":1011,"reports_q2":1132,"reports_q3":1168,"reports_q4":1158,"reports_q5":1251,"reports_q6":1070,"reports_q7":1182,"reports_q8":1206,"serious_q1":624,"serious_q2":747,"serious_q3":749,"serious_q4":780,"serious_q5":776,"serious_q6":717,"serious_q7":772,"serious_q8":663,"topReactions":"OFF LABEL USE (928); FATIGUE (884); DIARRHOEA (712); NAUSEA (619); HEADACHE (593)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:diclofenac","dataset":"drug-events","jurisdiction":"US","ingredient":"DICLOFENAC","level":"ingredient","rank":234,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DICLOFENAC: 9,085 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,579 were serious (83.4%) and 2,724 reported a death outcome (30.0%). Most reported reactions: OFF LABEL USE (1,844); PAIN (1,475); FATIGUE (1,471); ARTHRALGIA (1,342); JOINT SWELLING (1,334). A report does not show that the drug caused the event.","value":9085,"unit":"FAERS reports received in the window","reports":9085,"serious":7579,"deaths":2724,"serious_pct":83.4,"death_pct":30,"reports_q1":1221,"reports_q2":1137,"reports_q3":1292,"reports_q4":974,"reports_q5":1554,"reports_q6":1060,"reports_q7":957,"reports_q8":890,"serious_q1":997,"serious_q2":997,"serious_q3":1125,"serious_q4":800,"serious_q5":1259,"serious_q6":921,"serious_q7":700,"serious_q8":780,"topReactions":"OFF LABEL USE (1,844); PAIN (1,475); FATIGUE (1,471); ARTHRALGIA (1,342); JOINT SWELLING (1,334)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:buprenorphine","dataset":"drug-events","jurisdiction":"US","ingredient":"BUPRENORPHINE","level":"ingredient","rank":235,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BUPRENORPHINE: 9,017 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,594 were serious (62.0%) and 2,311 reported a death outcome (25.6%). Most reported reactions: OFF LABEL USE (1,045); DRUG INEFFECTIVE (871); NAUSEA (770); MATERNAL EXPOSURE DURING PREGNANCY (742); CONFUSIONAL STATE (723). Named in open multidistrict litigation MDL-3092. A report does not show that the drug caused the event.","value":9017,"unit":"FAERS reports received in the window","reports":9017,"serious":5594,"deaths":2311,"serious_pct":62,"death_pct":25.6,"reports_q1":971,"reports_q2":1471,"reports_q3":1021,"reports_q4":1245,"reports_q5":1243,"reports_q6":1230,"reports_q7":856,"reports_q8":980,"serious_q1":686,"serious_q2":778,"serious_q3":721,"serious_q4":730,"serious_q5":919,"serious_q6":630,"serious_q7":594,"serious_q8":536,"topReactions":"OFF LABEL USE (1,045); DRUG INEFFECTIVE (871); NAUSEA (770); MATERNAL EXPOSURE DURING PREGNANCY (742); CONFUSIONAL STATE (723)","mdl":"MDL-3092","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:salmeterol-xinafoate","dataset":"drug-events","jurisdiction":"US","ingredient":"SALMETEROL XINAFOATE","level":"ingredient","rank":236,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SALMETEROL XINAFOATE: 9,010 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,891 were serious (43.2%) and 405 reported a death outcome (4.5%). Most reported reactions: PRODUCT DOSE OMISSION ISSUE (1,632); DYSPNOEA (1,353); ASTHMA (1,269); OFF LABEL USE (878); COUGH (841). A report does not show that the drug caused the event.","value":9010,"unit":"FAERS reports received in the window","reports":9010,"serious":3891,"deaths":405,"serious_pct":43.2,"death_pct":4.5,"reports_q1":999,"reports_q2":1706,"reports_q3":1016,"reports_q4":866,"reports_q5":935,"reports_q6":1178,"reports_q7":1482,"reports_q8":828,"serious_q1":600,"serious_q2":584,"serious_q3":557,"serious_q4":411,"serious_q5":490,"serious_q6":479,"serious_q7":418,"serious_q8":352,"topReactions":"PRODUCT DOSE OMISSION ISSUE (1,632); DYSPNOEA (1,353); ASTHMA (1,269); OFF LABEL USE (878); COUGH (841)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sulfasalazine","dataset":"drug-events","jurisdiction":"US","ingredient":"SULFASALAZINE","level":"ingredient","rank":237,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SULFASALAZINE: 9,006 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,298 were serious (92.1%) and 3,569 reported a death outcome (39.6%). Most reported reactions: OFF LABEL USE (2,409); RHEUMATOID ARTHRITIS (2,258); RASH (2,099); PAIN (2,074); DRUG INEFFECTIVE (2,066). A report does not show that the drug caused the event.","value":9006,"unit":"FAERS reports received in the window","reports":9006,"serious":8298,"deaths":3569,"serious_pct":92.1,"death_pct":39.6,"reports_q1":1373,"reports_q2":1625,"reports_q3":1309,"reports_q4":1048,"reports_q5":1222,"reports_q6":1001,"reports_q7":696,"reports_q8":732,"serious_q1":1273,"serious_q2":1486,"serious_q3":1227,"serious_q4":944,"serious_q5":1144,"serious_q6":932,"serious_q7":627,"serious_q8":665,"topReactions":"OFF LABEL USE (2,409); RHEUMATOID ARTHRITIS (2,258); RASH (2,099); PAIN (2,074); DRUG INEFFECTIVE (2,066)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:biotin","dataset":"drug-events","jurisdiction":"US","ingredient":"BIOTIN","level":"ingredient","rank":238,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BIOTIN: 8,974 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,212 were serious (35.8%) and 279 reported a death outcome (3.1%). Most reported reactions: ADVERSE DRUG REACTION (1,199); DRUG INEFFECTIVE (801); OFF LABEL USE (572); FATIGUE (539); HEADACHE (533). A report does not show that the drug caused the event.","value":8974,"unit":"FAERS reports received in the window","reports":8974,"serious":3212,"deaths":279,"serious_pct":35.8,"death_pct":3.1,"reports_q1":1856,"reports_q2":749,"reports_q3":723,"reports_q4":1443,"reports_q5":1534,"reports_q6":683,"reports_q7":875,"reports_q8":1111,"serious_q1":401,"serious_q2":443,"serious_q3":371,"serious_q4":416,"serious_q5":364,"serious_q6":348,"serious_q7":440,"serious_q8":429,"topReactions":"ADVERSE DRUG REACTION (1,199); DRUG INEFFECTIVE (801); OFF LABEL USE (572); FATIGUE (539); HEADACHE (533)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:letrozole","dataset":"drug-events","jurisdiction":"US","ingredient":"LETROZOLE","level":"ingredient","rank":239,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LETROZOLE: 8,926 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,741 were serious (86.7%) and 797 reported a death outcome (8.9%). Most reported reactions: FATIGUE (1,004); NEUTROPENIA (900); MALIGNANT NEOPLASM PROGRESSION (835); DIARRHOEA (825); NAUSEA (792). A report does not show that the drug caused the event.","value":8926,"unit":"FAERS reports received in the window","reports":8926,"serious":7741,"deaths":797,"serious_pct":86.7,"death_pct":8.9,"reports_q1":1222,"reports_q2":1101,"reports_q3":1139,"reports_q4":1108,"reports_q5":1176,"reports_q6":1111,"reports_q7":993,"reports_q8":1076,"serious_q1":956,"serious_q2":936,"serious_q3":978,"serious_q4":975,"serious_q5":1050,"serious_q6":1005,"serious_q7":882,"serious_q8":959,"topReactions":"FATIGUE (1,004); NEUTROPENIA (900); MALIGNANT NEOPLASM PROGRESSION (835); DIARRHOEA (825); NAUSEA (792)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:menthol-unspecified-form","dataset":"drug-events","jurisdiction":"US","ingredient":"MENTHOL, UNSPECIFIED FORM","level":"ingredient","rank":240,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MENTHOL, UNSPECIFIED FORM: 8,895 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,327 were serious (71.1%) and 762 reported a death outcome (8.6%). Most reported reactions: DRUG INEFFECTIVE (849); OFF LABEL USE (758); NAUSEA (579); FATIGUE (537); HEADACHE (513). A report does not show that the drug caused the event.","value":8895,"unit":"FAERS reports received in the window","reports":8895,"serious":6327,"deaths":762,"serious_pct":71.1,"death_pct":8.6,"reports_q1":1097,"reports_q2":1073,"reports_q3":1034,"reports_q4":1176,"reports_q5":1063,"reports_q6":1077,"reports_q7":1214,"reports_q8":1161,"serious_q1":780,"serious_q2":758,"serious_q3":718,"serious_q4":817,"serious_q5":774,"serious_q6":765,"serious_q7":933,"serious_q8":782,"topReactions":"DRUG INEFFECTIVE (849); OFF LABEL USE (758); NAUSEA (579); FATIGUE (537); HEADACHE (513)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:prilocaine","dataset":"drug-events","jurisdiction":"US","ingredient":"PRILOCAINE","level":"ingredient","rank":241,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PRILOCAINE: 8,762 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,162 were serious (70.3%) and 745 reported a death outcome (8.5%). Most reported reactions: DRUG INEFFECTIVE (835); OFF LABEL USE (757); NAUSEA (572); FATIGUE (555); HEADACHE (493). A report does not show that the drug caused the event.","value":8762,"unit":"FAERS reports received in the window","reports":8762,"serious":6162,"deaths":745,"serious_pct":70.3,"death_pct":8.5,"reports_q1":1067,"reports_q2":1038,"reports_q3":1029,"reports_q4":1171,"reports_q5":1048,"reports_q6":1058,"reports_q7":1197,"reports_q8":1154,"serious_q1":761,"serious_q2":737,"serious_q3":703,"serious_q4":806,"serious_q5":748,"serious_q6":736,"serious_q7":910,"serious_q8":761,"topReactions":"DRUG INEFFECTIVE (835); OFF LABEL USE (757); NAUSEA (572); FATIGUE (555); HEADACHE (493)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ribociclib-succinate","dataset":"drug-events","jurisdiction":"US","ingredient":"RIBOCICLIB SUCCINATE","level":"ingredient","rank":242,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RIBOCICLIB SUCCINATE: 8,759 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,519 were serious (85.8%) and 808 reported a death outcome (9.2%). Most reported reactions: NEUTROPENIA (1,160); FATIGUE (1,002); NAUSEA (908); MALIGNANT NEOPLASM PROGRESSION (741); OFF LABEL USE (596). A report does not show that the drug caused the event.","value":8759,"unit":"FAERS reports received in the window","reports":8759,"serious":7519,"deaths":808,"serious_pct":85.8,"death_pct":9.2,"reports_q1":903,"reports_q2":956,"reports_q3":974,"reports_q4":1265,"reports_q5":1207,"reports_q6":1127,"reports_q7":1086,"reports_q8":1241,"serious_q1":801,"serious_q2":807,"serious_q3":823,"serious_q4":1092,"serious_q5":1043,"serious_q6":976,"serious_q7":925,"serious_q8":1052,"topReactions":"NEUTROPENIA (1,160); FATIGUE (1,002); NAUSEA (908); MALIGNANT NEOPLASM PROGRESSION (741); OFF LABEL USE (596)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:durvalumab","dataset":"drug-events","jurisdiction":"US","ingredient":"DURVALUMAB","level":"ingredient","rank":243,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DURVALUMAB: 8,682 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,482 were serious (97.7%) and 3,078 reported a death outcome (35.5%). Most reported reactions: DEATH (1,940); MALIGNANT NEOPLASM PROGRESSION (607); OFF LABEL USE (325); DIARRHOEA (314); ASTHENIA (267). A report does not show that the drug caused the event.","value":8682,"unit":"FAERS reports received in the window","reports":8682,"serious":8482,"deaths":3078,"serious_pct":97.7,"death_pct":35.5,"reports_q1":906,"reports_q2":1087,"reports_q3":810,"reports_q4":955,"reports_q5":987,"reports_q6":1248,"reports_q7":1293,"reports_q8":1396,"serious_q1":876,"serious_q2":1063,"serious_q3":782,"serious_q4":930,"serious_q5":975,"serious_q6":1222,"serious_q7":1266,"serious_q8":1368,"topReactions":"DEATH (1,940); MALIGNANT NEOPLASM PROGRESSION (607); OFF LABEL USE (325); DIARRHOEA (314); ASTHENIA (267)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:bacitracin-zinc","dataset":"drug-events","jurisdiction":"US","ingredient":"BACITRACIN ZINC","level":"ingredient","rank":244,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BACITRACIN ZINC: 8,649 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,144 were serious (71.0%) and 752 reported a death outcome (8.7%). Most reported reactions: DRUG INEFFECTIVE (831); OFF LABEL USE (738); NAUSEA (563); FATIGUE (534); HEADACHE (507). A report does not show that the drug caused the event.","value":8649,"unit":"FAERS reports received in the window","reports":8649,"serious":6144,"deaths":752,"serious_pct":71,"death_pct":8.7,"reports_q1":1079,"reports_q2":1035,"reports_q3":1011,"reports_q4":1162,"reports_q5":1036,"reports_q6":1039,"reports_q7":1175,"reports_q8":1112,"serious_q1":769,"serious_q2":732,"serious_q3":704,"serious_q4":811,"serious_q5":749,"serious_q6":733,"serious_q7":900,"serious_q8":746,"topReactions":"DRUG INEFFECTIVE (831); OFF LABEL USE (738); NAUSEA (563); FATIGUE (534); HEADACHE (507)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:fish-oil","dataset":"drug-events","jurisdiction":"US","ingredient":"FISH OIL","level":"ingredient","rank":245,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FISH OIL: 8,644 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,117 were serious (47.6%) and 866 reported a death outcome (10.0%). Most reported reactions: FATIGUE (1,101); DIARRHOEA (905); HEADACHE (802); ARTHRALGIA (754); PAIN (745). A report does not show that the drug caused the event.","value":8644,"unit":"FAERS reports received in the window","reports":8644,"serious":4117,"deaths":866,"serious_pct":47.6,"death_pct":10,"reports_q1":1191,"reports_q2":1045,"reports_q3":1031,"reports_q4":1034,"reports_q5":1280,"reports_q6":919,"reports_q7":1068,"reports_q8":1076,"serious_q1":591,"serious_q2":603,"serious_q3":532,"serious_q4":515,"serious_q5":514,"serious_q6":470,"serious_q7":480,"serious_q8":412,"topReactions":"FATIGUE (1,101); DIARRHOEA (905); HEADACHE (802); ARTHRALGIA (754); PAIN (745)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:palbociclib","dataset":"drug-events","jurisdiction":"US","ingredient":"PALBOCICLIB","level":"ingredient","rank":246,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PALBOCICLIB: 8,596 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,702 were serious (66.3%) and 1,279 reported a death outcome (14.9%). Most reported reactions: FATIGUE (1,180); DEATH (1,038); WHITE BLOOD CELL COUNT DECREASED (759); NAUSEA (655); NEUTROPENIA (647). A report does not show that the drug caused the event.","value":8596,"unit":"FAERS reports received in the window","reports":8596,"serious":5702,"deaths":1279,"serious_pct":66.3,"death_pct":14.9,"reports_q1":1357,"reports_q2":1329,"reports_q3":1433,"reports_q4":1184,"reports_q5":1073,"reports_q6":1037,"reports_q7":569,"reports_q8":614,"serious_q1":814,"serious_q2":851,"serious_q3":900,"serious_q4":803,"serious_q5":683,"serious_q6":682,"serious_q7":471,"serious_q8":498,"topReactions":"FATIGUE (1,180); DEATH (1,038); WHITE BLOOD CELL COUNT DECREASED (759); NAUSEA (655); NEUTROPENIA (647)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:triamcinolone-acetonide","dataset":"drug-events","jurisdiction":"US","ingredient":"TRIAMCINOLONE ACETONIDE","level":"ingredient","rank":247,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TRIAMCINOLONE ACETONIDE: 8,497 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,087 were serious (48.1%) and 1,860 reported a death outcome (21.9%). Most reported reactions: OFF LABEL USE (1,268); RASH (1,179); DRUG INEFFECTIVE (1,170); PRURITUS (1,134); FATIGUE (902). A report does not show that the drug caused the event.","value":8497,"unit":"FAERS reports received in the window","reports":8497,"serious":4087,"deaths":1860,"serious_pct":48.1,"death_pct":21.9,"reports_q1":980,"reports_q2":1136,"reports_q3":1097,"reports_q4":889,"reports_q5":1140,"reports_q6":1009,"reports_q7":1044,"reports_q8":1202,"serious_q1":526,"serious_q2":643,"serious_q3":597,"serious_q4":422,"serious_q5":543,"serious_q6":505,"serious_q7":418,"serious_q8":433,"topReactions":"OFF LABEL USE (1,268); RASH (1,179); DRUG INEFFECTIVE (1,170); PRURITUS (1,134); FATIGUE (902)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:docetaxel","dataset":"drug-events","jurisdiction":"US","ingredient":"DOCETAXEL","level":"ingredient","rank":248,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DOCETAXEL: 8,473 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,902 were serious (93.3%) and 977 reported a death outcome (11.5%). Most reported reactions: MYELOSUPPRESSION (1,118); OFF LABEL USE (645); DIARRHOEA (614); NAUSEA (550); DISEASE PROGRESSION (530). Named in open multidistrict litigation MDL-2740, MDL-3023. A report does not show that the drug caused the event.","value":8473,"unit":"FAERS reports received in the window","reports":8473,"serious":7902,"deaths":977,"serious_pct":93.3,"death_pct":11.5,"reports_q1":1409,"reports_q2":1168,"reports_q3":1130,"reports_q4":990,"reports_q5":1138,"reports_q6":880,"reports_q7":793,"reports_q8":965,"serious_q1":1128,"serious_q2":1130,"serious_q3":1081,"serious_q4":924,"serious_q5":1084,"serious_q6":842,"serious_q7":778,"serious_q8":935,"topReactions":"MYELOSUPPRESSION (1,118); OFF LABEL USE (645); DIARRHOEA (614); NAUSEA (550); DISEASE PROGRESSION (530)","mdl":"MDL-2740; MDL-3023","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:docetaxel-anhydrous","dataset":"drug-events","jurisdiction":"US","ingredient":"DOCETAXEL ANHYDROUS","level":"ingredient","rank":249,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DOCETAXEL ANHYDROUS: 8,452 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,901 were serious (93.5%) and 975 reported a death outcome (11.5%). Most reported reactions: MYELOSUPPRESSION (1,118); OFF LABEL USE (631); DIARRHOEA (613); NAUSEA (549); DISEASE PROGRESSION (530). A report does not show that the drug caused the event.","value":8452,"unit":"FAERS reports received in the window","reports":8452,"serious":7901,"deaths":975,"serious_pct":93.5,"death_pct":11.5,"reports_q1":1407,"reports_q2":1167,"reports_q3":1129,"reports_q4":984,"reports_q5":1134,"reports_q6":874,"reports_q7":792,"reports_q8":965,"serious_q1":1127,"serious_q2":1129,"serious_q3":1081,"serious_q4":927,"serious_q5":1084,"serious_q6":841,"serious_q7":777,"serious_q8":935,"topReactions":"MYELOSUPPRESSION (1,118); OFF LABEL USE (631); DIARRHOEA (613); NAUSEA (549); DISEASE PROGRESSION (530)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:tetracaine","dataset":"drug-events","jurisdiction":"US","ingredient":"TETRACAINE","level":"ingredient","rank":250,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TETRACAINE: 8,430 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,004 were serious (71.2%) and 718 reported a death outcome (8.5%). Most reported reactions: DRUG INEFFECTIVE (820); OFF LABEL USE (724); NAUSEA (547); FATIGUE (514); HEADACHE (483). A report does not show that the drug caused the event.","value":8430,"unit":"FAERS reports received in the window","reports":8430,"serious":6004,"deaths":718,"serious_pct":71.2,"death_pct":8.5,"reports_q1":1049,"reports_q2":1010,"reports_q3":984,"reports_q4":1130,"reports_q5":994,"reports_q6":1014,"reports_q7":1154,"reports_q8":1095,"serious_q1":751,"serious_q2":718,"serious_q3":682,"serious_q4":786,"serious_q5":724,"serious_q6":720,"serious_q7":888,"serious_q8":735,"topReactions":"DRUG INEFFECTIVE (820); OFF LABEL USE (724); NAUSEA (547); FATIGUE (514); HEADACHE (483)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:baclofen","dataset":"drug-events","jurisdiction":"US","ingredient":"BACLOFEN","level":"ingredient","rank":251,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BACLOFEN: 8,427 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,704 were serious (67.7%) and 738 reported a death outcome (8.8%). Most reported reactions: OFF LABEL USE (629); DRUG INEFFECTIVE (607); FATIGUE (488); NAUSEA (421); TOXICITY TO VARIOUS AGENTS (390). A report does not show that the drug caused the event.","value":8427,"unit":"FAERS reports received in the window","reports":8427,"serious":5704,"deaths":738,"serious_pct":67.7,"death_pct":8.8,"reports_q1":1126,"reports_q2":1121,"reports_q3":1098,"reports_q4":1011,"reports_q5":1139,"reports_q6":929,"reports_q7":1023,"reports_q8":980,"serious_q1":746,"serious_q2":761,"serious_q3":751,"serious_q4":687,"serious_q5":755,"serious_q6":630,"serious_q7":720,"serious_q8":654,"topReactions":"OFF LABEL USE (629); DRUG INEFFECTIVE (607); FATIGUE (488); NAUSEA (421); TOXICITY TO VARIOUS AGENTS (390)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:fluconazole","dataset":"drug-events","jurisdiction":"US","ingredient":"FLUCONAZOLE","level":"ingredient","rank":252,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FLUCONAZOLE: 8,423 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,926 were serious (82.2%) and 1,228 reported a death outcome (14.6%). Most reported reactions: OFF LABEL USE (1,045); DRUG INEFFECTIVE (971); HEADACHE (542); NAUSEA (451); FATIGUE (416). A report does not show that the drug caused the event.","value":8423,"unit":"FAERS reports received in the window","reports":8423,"serious":6926,"deaths":1228,"serious_pct":82.2,"death_pct":14.6,"reports_q1":1081,"reports_q2":1233,"reports_q3":1109,"reports_q4":974,"reports_q5":1148,"reports_q6":1071,"reports_q7":976,"reports_q8":831,"serious_q1":911,"serious_q2":1010,"serious_q3":917,"serious_q4":811,"serious_q5":964,"serious_q6":891,"serious_q7":769,"serious_q8":653,"topReactions":"OFF LABEL USE (1,045); DRUG INEFFECTIVE (971); HEADACHE (542); NAUSEA (451); FATIGUE (416)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:insulin-aspart","dataset":"drug-events","jurisdiction":"US","ingredient":"INSULIN ASPART","level":"ingredient","rank":253,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"INSULIN ASPART: 8,411 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,564 were serious (66.2%) and 562 reported a death outcome (6.7%). Most reported reactions: BLOOD GLUCOSE INCREASED (961); NAUSEA (573); OFF LABEL USE (504); DRUG INEFFECTIVE (459); DIARRHOEA (429). A report does not show that the drug caused the event.","value":8411,"unit":"FAERS reports received in the window","reports":8411,"serious":5564,"deaths":562,"serious_pct":66.2,"death_pct":6.7,"reports_q1":835,"reports_q2":1166,"reports_q3":933,"reports_q4":893,"reports_q5":1047,"reports_q6":1559,"reports_q7":843,"reports_q8":1135,"serious_q1":581,"serious_q2":665,"serious_q3":685,"serious_q4":610,"serious_q5":731,"serious_q6":1030,"serious_q7":663,"serious_q8":599,"topReactions":"BLOOD GLUCOSE INCREASED (961); NAUSEA (573); OFF LABEL USE (504); DRUG INEFFECTIVE (459); DIARRHOEA (429)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lidocaine-hcl","dataset":"drug-events","jurisdiction":"US","ingredient":"LIDOCAINE HCL","level":"ingredient","rank":254,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LIDOCAINE HCL: 8,408 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,987 were serious (71.2%) and 718 reported a death outcome (8.5%). Most reported reactions: DRUG INEFFECTIVE (820); OFF LABEL USE (717); NAUSEA (546); FATIGUE (512); HEADACHE (483). A report does not show that the drug caused the event.","value":8408,"unit":"FAERS reports received in the window","reports":8408,"serious":5987,"deaths":718,"serious_pct":71.2,"death_pct":8.5,"reports_q1":1045,"reports_q2":1009,"reports_q3":980,"reports_q4":1124,"reports_q5":994,"reports_q6":1010,"reports_q7":1152,"reports_q8":1094,"serious_q1":748,"serious_q2":717,"serious_q3":680,"serious_q4":781,"serious_q5":724,"serious_q6":717,"serious_q7":886,"serious_q8":734,"topReactions":"DRUG INEFFECTIVE (820); OFF LABEL USE (717); NAUSEA (546); FATIGUE (512); HEADACHE (483)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pemetrexed-disodium-heptahydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"PEMETREXED DISODIUM HEPTAHYDRATE","level":"ingredient","rank":255,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PEMETREXED DISODIUM HEPTAHYDRATE: 8,367 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 8,171 were serious (97.7%) and 1,072 reported a death outcome (12.8%). Most reported reactions: MYELOSUPPRESSION (488); OFF LABEL USE (454); PANCYTOPENIA (426); MALIGNANT NEOPLASM PROGRESSION (420); ANAEMIA (372). A report does not show that the drug caused the event.","value":8367,"unit":"FAERS reports received in the window","reports":8367,"serious":8171,"deaths":1072,"serious_pct":97.7,"death_pct":12.8,"reports_q1":950,"reports_q2":1226,"reports_q3":1048,"reports_q4":947,"reports_q5":972,"reports_q6":1110,"reports_q7":996,"reports_q8":1118,"serious_q1":906,"serious_q2":1179,"serious_q3":1026,"serious_q4":931,"serious_q5":952,"serious_q6":1093,"serious_q7":976,"serious_q8":1108,"topReactions":"MYELOSUPPRESSION (488); OFF LABEL USE (454); PANCYTOPENIA (426); MALIGNANT NEOPLASM PROGRESSION (420); ANAEMIA (372)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:isotretinoin","dataset":"drug-events","jurisdiction":"US","ingredient":"ISOTRETINOIN","level":"ingredient","rank":256,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ISOTRETINOIN: 8,365 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 2,474 were serious (29.6%) and 47 reported a death outcome (0.6%). Most reported reactions: ADVERSE DRUG REACTION (738); DEPRESSION (524); EXPOSURE DURING PREGNANCY (478); PRODUCT DOSE OMISSION ISSUE (425); DRY SKIN (393). A report does not show that the drug caused the event.","value":8365,"unit":"FAERS reports received in the window","reports":8365,"serious":2474,"deaths":47,"serious_pct":29.6,"death_pct":0.6,"reports_q1":1495,"reports_q2":1431,"reports_q3":915,"reports_q4":800,"reports_q5":679,"reports_q6":1416,"reports_q7":743,"reports_q8":886,"serious_q1":336,"serious_q2":324,"serious_q3":301,"serious_q4":304,"serious_q5":237,"serious_q6":321,"serious_q7":301,"serious_q8":350,"topReactions":"ADVERSE DRUG REACTION (738); DEPRESSION (524); EXPOSURE DURING PREGNANCY (478); PRODUCT DOSE OMISSION ISSUE (425); DRY SKIN (393)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ferrous-sulfate","dataset":"drug-events","jurisdiction":"US","ingredient":"FERROUS SULFATE","level":"ingredient","rank":257,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FERROUS SULFATE: 8,239 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,352 were serious (65.0%) and 706 reported a death outcome (8.6%). Most reported reactions: FATIGUE (727); DIARRHOEA (623); OFF LABEL USE (557); NAUSEA (493); DYSPNOEA (483). A report does not show that the drug caused the event.","value":8239,"unit":"FAERS reports received in the window","reports":8239,"serious":5352,"deaths":706,"serious_pct":65,"death_pct":8.6,"reports_q1":1040,"reports_q2":1041,"reports_q3":1081,"reports_q4":1078,"reports_q5":1078,"reports_q6":992,"reports_q7":1057,"reports_q8":872,"serious_q1":685,"serious_q2":718,"serious_q3":709,"serious_q4":713,"serious_q5":677,"serious_q6":682,"serious_q7":640,"serious_q8":528,"topReactions":"FATIGUE (727); DIARRHOEA (623); OFF LABEL USE (557); NAUSEA (493); DYSPNOEA (483)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:belimumab","dataset":"drug-events","jurisdiction":"US","ingredient":"BELIMUMAB","level":"ingredient","rank":258,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BELIMUMAB: 8,108 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,758 were serious (46.3%) and 121 reported a death outcome (1.5%). Most reported reactions: SYSTEMIC LUPUS ERYTHEMATOSUS (1,828); PRODUCT DOSE OMISSION ISSUE (1,638); OFF LABEL USE (586); WRONG TECHNIQUE IN DEVICE USAGE PROCESS (535); PRODUCT COMPLAINT (527). A report does not show that the drug caused the event.","value":8108,"unit":"FAERS reports received in the window","reports":8108,"serious":3758,"deaths":121,"serious_pct":46.3,"death_pct":1.5,"reports_q1":946,"reports_q2":838,"reports_q3":1032,"reports_q4":1100,"reports_q5":2294,"reports_q6":770,"reports_q7":558,"reports_q8":570,"serious_q1":384,"serious_q2":326,"serious_q3":320,"serious_q4":576,"serious_q5":1272,"serious_q6":316,"serious_q7":323,"serious_q8":241,"topReactions":"SYSTEMIC LUPUS ERYTHEMATOSUS (1,828); PRODUCT DOSE OMISSION ISSUE (1,638); OFF LABEL USE (586); WRONG TECHNIQUE IN DEVICE USAGE PROCESS (535); PRODUCT COMPLAINT (527)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:levofloxacin","dataset":"drug-events","jurisdiction":"US","ingredient":"LEVOFLOXACIN","level":"ingredient","rank":259,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LEVOFLOXACIN: 8,091 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,136 were serious (88.2%) and 1,025 reported a death outcome (12.7%). Most reported reactions: OFF LABEL USE (711); DRUG INEFFECTIVE (630); NAUSEA (444); DYSPNOEA (442); FATIGUE (401). A report does not show that the drug caused the event.","value":8091,"unit":"FAERS reports received in the window","reports":8091,"serious":7136,"deaths":1025,"serious_pct":88.2,"death_pct":12.7,"reports_q1":1069,"reports_q2":1112,"reports_q3":1042,"reports_q4":1006,"reports_q5":1093,"reports_q6":968,"reports_q7":969,"reports_q8":832,"serious_q1":958,"serious_q2":995,"serious_q3":898,"serious_q4":871,"serious_q5":963,"serious_q6":832,"serious_q7":868,"serious_q8":751,"topReactions":"OFF LABEL USE (711); DRUG INEFFECTIVE (630); NAUSEA (444); DYSPNOEA (442); FATIGUE (401)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:cyclobenzaprine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"CYCLOBENZAPRINE HYDROCHLORIDE","level":"ingredient","rank":260,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CYCLOBENZAPRINE HYDROCHLORIDE: 8,088 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,770 were serious (59.0%) and 1,067 reported a death outcome (13.2%). Most reported reactions: OFF LABEL USE (971); FATIGUE (824); PAIN (821); NAUSEA (792); HEADACHE (770). A report does not show that the drug caused the event.","value":8088,"unit":"FAERS reports received in the window","reports":8088,"serious":4770,"deaths":1067,"serious_pct":59,"death_pct":13.2,"reports_q1":875,"reports_q2":1046,"reports_q3":975,"reports_q4":1029,"reports_q5":1159,"reports_q6":876,"reports_q7":993,"reports_q8":1135,"serious_q1":520,"serious_q2":662,"serious_q3":600,"serious_q4":620,"serious_q5":693,"serious_q6":553,"serious_q7":607,"serious_q8":515,"topReactions":"OFF LABEL USE (971); FATIGUE (824); PAIN (821); NAUSEA (792); HEADACHE (770)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:nintedanib-esylate","dataset":"drug-events","jurisdiction":"US","ingredient":"NINTEDANIB ESYLATE","level":"ingredient","rank":261,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"NINTEDANIB ESYLATE: 8,054 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,645 were serious (70.1%) and 1,632 reported a death outcome (20.3%). Most reported reactions: DIARRHOEA (2,231); COUGH (978); NAUSEA (944); DEATH (928); DYSPNOEA (900). A report does not show that the drug caused the event.","value":8054,"unit":"FAERS reports received in the window","reports":8054,"serious":5645,"deaths":1632,"serious_pct":70.1,"death_pct":20.3,"reports_q1":985,"reports_q2":844,"reports_q3":865,"reports_q4":917,"reports_q5":997,"reports_q6":1137,"reports_q7":1092,"reports_q8":1217,"serious_q1":596,"serious_q2":589,"serious_q3":603,"serious_q4":607,"serious_q5":714,"serious_q6":869,"serious_q7":832,"serious_q8":835,"topReactions":"DIARRHOEA (2,231); COUGH (978); NAUSEA (944); DEATH (928); DYSPNOEA (900)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:benralizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"BENRALIZUMAB","level":"ingredient","rank":262,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BENRALIZUMAB: 8,015 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,166 were serious (76.9%) and 845 reported a death outcome (10.5%). Most reported reactions: ASTHMA (869); DEATH (722); DYSPNOEA (699); PNEUMONIA (614); PRODUCT DOSE OMISSION ISSUE (499). A report does not show that the drug caused the event.","value":8015,"unit":"FAERS reports received in the window","reports":8015,"serious":6166,"deaths":845,"serious_pct":76.9,"death_pct":10.5,"reports_q1":1365,"reports_q2":935,"reports_q3":954,"reports_q4":847,"reports_q5":944,"reports_q6":801,"reports_q7":1114,"reports_q8":1055,"serious_q1":1193,"serious_q2":734,"serious_q3":729,"serious_q4":582,"serious_q5":677,"serious_q6":584,"serious_q7":856,"serious_q8":811,"topReactions":"ASTHMA (869); DEATH (722); DYSPNOEA (699); PNEUMONIA (614); PRODUCT DOSE OMISSION ISSUE (499)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:levodopa","dataset":"drug-events","jurisdiction":"US","ingredient":"LEVODOPA","level":"ingredient","rank":263,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LEVODOPA: 7,946 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,442 were serious (68.5%) and 1,369 reported a death outcome (17.2%). Most reported reactions: DEATH (980); HALLUCINATION (918); FALL (767); DRUG INEFFECTIVE (640); DYSKINESIA (500). A report does not show that the drug caused the event.","value":7946,"unit":"FAERS reports received in the window","reports":7946,"serious":5442,"deaths":1369,"serious_pct":68.5,"death_pct":17.2,"reports_q1":862,"reports_q2":958,"reports_q3":1158,"reports_q4":1087,"reports_q5":1030,"reports_q6":1044,"reports_q7":1049,"reports_q8":758,"serious_q1":577,"serious_q2":722,"serious_q3":724,"serious_q4":713,"serious_q5":708,"serious_q6":751,"serious_q7":673,"serious_q8":574,"topReactions":"DEATH (980); HALLUCINATION (918); FALL (767); DRUG INEFFECTIVE (640); DYSKINESIA (500)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:citalopram","dataset":"drug-events","jurisdiction":"US","ingredient":"CITALOPRAM","level":"ingredient","rank":264,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CITALOPRAM: 7,861 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,554 were serious (83.4%) and 1,394 reported a death outcome (17.7%). Most reported reactions: ACCIDENTAL OVERDOSE (568); OFF LABEL USE (541); FATIGUE (530); NAUSEA (435); DRUG INEFFECTIVE (433). A report does not show that the drug caused the event.","value":7861,"unit":"FAERS reports received in the window","reports":7861,"serious":6554,"deaths":1394,"serious_pct":83.4,"death_pct":17.7,"reports_q1":975,"reports_q2":927,"reports_q3":1006,"reports_q4":1585,"reports_q5":863,"reports_q6":797,"reports_q7":891,"reports_q8":817,"serious_q1":777,"serious_q2":732,"serious_q3":826,"serious_q4":1443,"serious_q5":716,"serious_q6":665,"serious_q7":749,"serious_q8":646,"topReactions":"ACCIDENTAL OVERDOSE (568); OFF LABEL USE (541); FATIGUE (530); NAUSEA (435); DRUG INEFFECTIVE (433)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:human-immunoglobulin-g","dataset":"drug-events","jurisdiction":"US","ingredient":"HUMAN IMMUNOGLOBULIN G","level":"ingredient","rank":265,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"HUMAN IMMUNOGLOBULIN G: 7,757 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,162 were serious (92.3%) and 1,023 reported a death outcome (13.2%). Most reported reactions: OFF LABEL USE (2,016); DRUG INEFFECTIVE (964); HEADACHE (584); FATIGUE (569); PNEUMONIA (491). A report does not show that the drug caused the event.","value":7757,"unit":"FAERS reports received in the window","reports":7757,"serious":7162,"deaths":1023,"serious_pct":92.3,"death_pct":13.2,"reports_q1":836,"reports_q2":922,"reports_q3":1635,"reports_q4":748,"reports_q5":910,"reports_q6":856,"reports_q7":1138,"reports_q8":712,"serious_q1":738,"serious_q2":833,"serious_q3":1549,"serious_q4":686,"serious_q5":840,"serious_q6":804,"serious_q7":1060,"serious_q8":652,"topReactions":"OFF LABEL USE (2,016); DRUG INEFFECTIVE (964); HEADACHE (584); FATIGUE (569); PNEUMONIA (491)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:montelukast","dataset":"drug-events","jurisdiction":"US","ingredient":"MONTELUKAST","level":"ingredient","rank":266,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MONTELUKAST: 7,601 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,682 were serious (48.4%) and 337 reported a death outcome (4.4%). Most reported reactions: DYSPNOEA (797); ASTHMA (793); HEADACHE (635); COUGH (626); DRUG INEFFECTIVE (572). A report does not show that the drug caused the event.","value":7601,"unit":"FAERS reports received in the window","reports":7601,"serious":3682,"deaths":337,"serious_pct":48.4,"death_pct":4.4,"reports_q1":918,"reports_q2":952,"reports_q3":923,"reports_q4":859,"reports_q5":1062,"reports_q6":880,"reports_q7":1004,"reports_q8":1003,"serious_q1":481,"serious_q2":514,"serious_q3":480,"serious_q4":421,"serious_q5":493,"serious_q6":436,"serious_q7":469,"serious_q8":388,"topReactions":"DYSPNOEA (797); ASTHMA (793); HEADACHE (635); COUGH (626); DRUG INEFFECTIVE (572)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ambrisentan","dataset":"drug-events","jurisdiction":"US","ingredient":"AMBRISENTAN","level":"ingredient","rank":267,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AMBRISENTAN: 7,574 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,762 were serious (62.9%) and 699 reported a death outcome (9.2%). Most reported reactions: HEADACHE (907); DYSPNOEA (886); DIARRHOEA (614); DEATH (527); NAUSEA (516). A report does not show that the drug caused the event.","value":7574,"unit":"FAERS reports received in the window","reports":7574,"serious":4762,"deaths":699,"serious_pct":62.9,"death_pct":9.2,"reports_q1":1226,"reports_q2":1161,"reports_q3":1191,"reports_q4":947,"reports_q5":868,"reports_q6":763,"reports_q7":722,"reports_q8":696,"serious_q1":796,"serious_q2":741,"serious_q3":759,"serious_q4":560,"serious_q5":558,"serious_q6":450,"serious_q7":476,"serious_q8":422,"topReactions":"HEADACHE (907); DYSPNOEA (886); DIARRHOEA (614); DEATH (527); NAUSEA (516)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:methylphenidate-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"METHYLPHENIDATE HYDROCHLORIDE","level":"ingredient","rank":268,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METHYLPHENIDATE HYDROCHLORIDE: 7,503 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,416 were serious (58.9%) and 273 reported a death outcome (3.6%). Most reported reactions: DRUG INEFFECTIVE (843); OFF LABEL USE (598); FATIGUE (362); NAUSEA (342); PRODUCT DOSE OMISSION ISSUE (336). A report does not show that the drug caused the event.","value":7503,"unit":"FAERS reports received in the window","reports":7503,"serious":4416,"deaths":273,"serious_pct":58.9,"death_pct":3.6,"reports_q1":1071,"reports_q2":865,"reports_q3":993,"reports_q4":939,"reports_q5":974,"reports_q6":884,"reports_q7":873,"reports_q8":904,"serious_q1":589,"serious_q2":547,"serious_q3":602,"serious_q4":521,"serious_q5":457,"serious_q6":573,"serious_q7":572,"serious_q8":555,"topReactions":"DRUG INEFFECTIVE (843); OFF LABEL USE (598); FATIGUE (362); NAUSEA (342); PRODUCT DOSE OMISSION ISSUE (336)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ciprofloxacin","dataset":"drug-events","jurisdiction":"US","ingredient":"CIPROFLOXACIN","level":"ingredient","rank":269,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CIPROFLOXACIN: 7,482 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,875 were serious (91.9%) and 609 reported a death outcome (8.1%). Most reported reactions: DRUG INEFFECTIVE (571); OFF LABEL USE (559); PAIN (538); DYSPNOEA (520); VOMITING (517). A report does not show that the drug caused the event.","value":7482,"unit":"FAERS reports received in the window","reports":7482,"serious":6875,"deaths":609,"serious_pct":91.9,"death_pct":8.1,"reports_q1":1025,"reports_q2":1082,"reports_q3":864,"reports_q4":949,"reports_q5":1067,"reports_q6":892,"reports_q7":765,"reports_q8":838,"serious_q1":943,"serious_q2":991,"serious_q3":793,"serious_q4":862,"serious_q5":980,"serious_q6":831,"serious_q7":711,"serious_q8":764,"topReactions":"DRUG INEFFECTIVE (571); OFF LABEL USE (559); PAIN (538); DYSPNOEA (520); VOMITING (517)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:buprenorphine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"BUPRENORPHINE HYDROCHLORIDE","level":"ingredient","rank":270,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"BUPRENORPHINE HYDROCHLORIDE: 7,440 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,272 were serious (70.9%) and 1,641 reported a death outcome (22.1%). Most reported reactions: DRUG ABUSE (636); NAUSEA (592); OFF LABEL USE (568); DEATH (535); DRUG INEFFECTIVE (495). Named in open multidistrict litigation MDL-3092. A report does not show that the drug caused the event.","value":7440,"unit":"FAERS reports received in the window","reports":7440,"serious":5272,"deaths":1641,"serious_pct":70.9,"death_pct":22.1,"reports_q1":824,"reports_q2":1188,"reports_q3":714,"reports_q4":945,"reports_q5":1009,"reports_q6":1238,"reports_q7":798,"reports_q8":724,"serious_q1":661,"serious_q2":697,"serious_q3":560,"serious_q4":767,"serious_q5":816,"serious_q6":648,"serious_q7":607,"serious_q8":516,"topReactions":"DRUG ABUSE (636); NAUSEA (592); OFF LABEL USE (568); DEATH (535); DRUG INEFFECTIVE (495)","mdl":"MDL-3092","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pemetrexed-disodium","dataset":"drug-events","jurisdiction":"US","ingredient":"PEMETREXED DISODIUM","level":"ingredient","rank":271,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PEMETREXED DISODIUM: 7,412 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,237 were serious (97.6%) and 972 reported a death outcome (13.1%). Most reported reactions: MYELOSUPPRESSION (468); OFF LABEL USE (418); MALIGNANT NEOPLASM PROGRESSION (379); PANCYTOPENIA (365); ANAEMIA (346). A report does not show that the drug caused the event.","value":7412,"unit":"FAERS reports received in the window","reports":7412,"serious":7237,"deaths":972,"serious_pct":97.6,"death_pct":13.1,"reports_q1":842,"reports_q2":1073,"reports_q3":928,"reports_q4":834,"reports_q5":839,"reports_q6":1015,"reports_q7":886,"reports_q8":995,"serious_q1":808,"serious_q2":1028,"serious_q3":907,"serious_q4":820,"serious_q5":821,"serious_q6":999,"serious_q7":869,"serious_q8":985,"topReactions":"MYELOSUPPRESSION (468); OFF LABEL USE (418); MALIGNANT NEOPLASM PROGRESSION (379); PANCYTOPENIA (365); ANAEMIA (346)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pemetrexed-disodium-hemipentahydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"PEMETREXED DISODIUM HEMIPENTAHYDRATE","level":"ingredient","rank":272,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PEMETREXED DISODIUM HEMIPENTAHYDRATE: 7,412 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,237 were serious (97.6%) and 972 reported a death outcome (13.1%). Most reported reactions: MYELOSUPPRESSION (468); OFF LABEL USE (418); MALIGNANT NEOPLASM PROGRESSION (379); PANCYTOPENIA (365); ANAEMIA (346). A report does not show that the drug caused the event.","value":7412,"unit":"FAERS reports received in the window","reports":7412,"serious":7237,"deaths":972,"serious_pct":97.6,"death_pct":13.1,"reports_q1":842,"reports_q2":1073,"reports_q3":928,"reports_q4":834,"reports_q5":839,"reports_q6":1015,"reports_q7":886,"reports_q8":995,"serious_q1":808,"serious_q2":1028,"serious_q3":907,"serious_q4":820,"serious_q5":821,"serious_q6":999,"serious_q7":869,"serious_q8":985,"topReactions":"MYELOSUPPRESSION (468); OFF LABEL USE (418); MALIGNANT NEOPLASM PROGRESSION (379); PANCYTOPENIA (365); ANAEMIA (346)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:fexofenadine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"FEXOFENADINE HYDROCHLORIDE","level":"ingredient","rank":273,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FEXOFENADINE HYDROCHLORIDE: 7,401 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,743 were serious (50.6%) and 234 reported a death outcome (3.2%). Most reported reactions: DRUG INEFFECTIVE (597); NO ADVERSE EVENT (508); PRURITUS (468); FATIGUE (388); OFF LABEL USE (380). A report does not show that the drug caused the event.","value":7401,"unit":"FAERS reports received in the window","reports":7401,"serious":3743,"deaths":234,"serious_pct":50.6,"death_pct":3.2,"reports_q1":815,"reports_q2":862,"reports_q3":711,"reports_q4":1008,"reports_q5":983,"reports_q6":876,"reports_q7":1030,"reports_q8":1116,"serious_q1":403,"serious_q2":392,"serious_q3":362,"serious_q4":536,"serious_q5":514,"serious_q6":476,"serious_q7":526,"serious_q8":534,"topReactions":"DRUG INEFFECTIVE (597); NO ADVERSE EVENT (508); PRURITUS (468); FATIGUE (388); OFF LABEL USE (380)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:tazobactam-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"TAZOBACTAM SODIUM","level":"ingredient","rank":274,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TAZOBACTAM SODIUM: 7,375 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,165 were serious (97.2%) and 1,412 reported a death outcome (19.1%). Most reported reactions: DRUG INEFFECTIVE (1,025); OFF LABEL USE (640); ACUTE KIDNEY INJURY (635); PYREXIA (384); CONDITION AGGRAVATED (367). A report does not show that the drug caused the event.","value":7375,"unit":"FAERS reports received in the window","reports":7375,"serious":7165,"deaths":1412,"serious_pct":97.2,"death_pct":19.1,"reports_q1":874,"reports_q2":1061,"reports_q3":941,"reports_q4":923,"reports_q5":1047,"reports_q6":852,"reports_q7":892,"reports_q8":785,"serious_q1":853,"serious_q2":1024,"serious_q3":914,"serious_q4":896,"serious_q5":1026,"serious_q6":824,"serious_q7":861,"serious_q8":767,"topReactions":"DRUG INEFFECTIVE (1,025); OFF LABEL USE (640); ACUTE KIDNEY INJURY (635); PYREXIA (384); CONDITION AGGRAVATED (367)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:clonidine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"CLONIDINE HYDROCHLORIDE","level":"ingredient","rank":275,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CLONIDINE HYDROCHLORIDE: 7,374 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,550 were serious (61.7%) and 973 reported a death outcome (13.2%). Most reported reactions: OFF LABEL USE (789); HEADACHE (711); HYPERTENSION (588); NAUSEA (588); FATIGUE (586). A report does not show that the drug caused the event.","value":7374,"unit":"FAERS reports received in the window","reports":7374,"serious":4550,"deaths":973,"serious_pct":61.7,"death_pct":13.2,"reports_q1":902,"reports_q2":934,"reports_q3":945,"reports_q4":999,"reports_q5":905,"reports_q6":894,"reports_q7":954,"reports_q8":841,"serious_q1":535,"serious_q2":627,"serious_q3":596,"serious_q4":640,"serious_q5":534,"serious_q6":549,"serious_q7":586,"serious_q8":483,"topReactions":"OFF LABEL USE (789); HEADACHE (711); HYPERTENSION (588); NAUSEA (588); FATIGUE (586)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:foscarbidopa","dataset":"drug-events","jurisdiction":"US","ingredient":"FOSCARBIDOPA","level":"ingredient","rank":276,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FOSCARBIDOPA: 7,371 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,221 were serious (84.4%) and 1,155 reported a death outcome (15.7%). Most reported reactions: ON AND OFF PHENOMENON (959); FALL (905); HALLUCINATION (737); DEATH (587); DYSKINESIA (582). A report does not show that the drug caused the event.","value":7371,"unit":"FAERS reports received in the window","reports":7371,"serious":6221,"deaths":1155,"serious_pct":84.4,"death_pct":15.7,"reports_q1":10,"reports_q2":364,"reports_q3":626,"reports_q4":1048,"reports_q5":1224,"reports_q6":1353,"reports_q7":1447,"reports_q8":1299,"serious_q1":8,"serious_q2":341,"serious_q3":522,"serious_q4":860,"serious_q5":1027,"serious_q6":1117,"serious_q7":1230,"serious_q8":1116,"topReactions":"ON AND OFF PHENOMENON (959); FALL (905); HALLUCINATION (737); DEATH (587); DYSKINESIA (582)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:foslevodopa","dataset":"drug-events","jurisdiction":"US","ingredient":"FOSLEVODOPA","level":"ingredient","rank":277,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"FOSLEVODOPA: 7,371 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,221 were serious (84.4%) and 1,155 reported a death outcome (15.7%). Most reported reactions: ON AND OFF PHENOMENON (959); FALL (905); HALLUCINATION (737); DEATH (587); DYSKINESIA (582). A report does not show that the drug caused the event.","value":7371,"unit":"FAERS reports received in the window","reports":7371,"serious":6221,"deaths":1155,"serious_pct":84.4,"death_pct":15.7,"reports_q1":10,"reports_q2":364,"reports_q3":626,"reports_q4":1048,"reports_q5":1224,"reports_q6":1353,"reports_q7":1447,"reports_q8":1299,"serious_q1":8,"serious_q2":341,"serious_q3":522,"serious_q4":860,"serious_q5":1027,"serious_q6":1117,"serious_q7":1230,"serious_q8":1116,"topReactions":"ON AND OFF PHENOMENON (959); FALL (905); HALLUCINATION (737); DEATH (587); DYSKINESIA (582)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:metronidazole","dataset":"drug-events","jurisdiction":"US","ingredient":"METRONIDAZOLE","level":"ingredient","rank":278,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METRONIDAZOLE: 7,340 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,274 were serious (85.5%) and 723 reported a death outcome (9.9%). Most reported reactions: DRUG INEFFECTIVE (948); OFF LABEL USE (900); NAUSEA (510); HEADACHE (448); VOMITING (381). A report does not show that the drug caused the event.","value":7340,"unit":"FAERS reports received in the window","reports":7340,"serious":6274,"deaths":723,"serious_pct":85.5,"death_pct":9.9,"reports_q1":879,"reports_q2":942,"reports_q3":977,"reports_q4":976,"reports_q5":1018,"reports_q6":886,"reports_q7":862,"reports_q8":800,"serious_q1":752,"serious_q2":815,"serious_q3":809,"serious_q4":840,"serious_q5":890,"serious_q6":763,"serious_q7":745,"serious_q8":660,"topReactions":"DRUG INEFFECTIVE (948); OFF LABEL USE (900); NAUSEA (510); HEADACHE (448); VOMITING (381)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:loperamide-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"LOPERAMIDE HYDROCHLORIDE","level":"ingredient","rank":279,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LOPERAMIDE HYDROCHLORIDE: 7,317 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,826 were serious (52.3%) and 417 reported a death outcome (5.7%). Most reported reactions: DIARRHOEA (1,539); NAUSEA (837); FATIGUE (710); OFF LABEL USE (647); CONSTIPATION (548). A report does not show that the drug caused the event.","value":7317,"unit":"FAERS reports received in the window","reports":7317,"serious":3826,"deaths":417,"serious_pct":52.3,"death_pct":5.7,"reports_q1":934,"reports_q2":837,"reports_q3":1103,"reports_q4":916,"reports_q5":938,"reports_q6":787,"reports_q7":1022,"reports_q8":780,"serious_q1":479,"serious_q2":475,"serious_q3":499,"serious_q4":483,"serious_q5":569,"serious_q6":403,"serious_q7":482,"serious_q8":436,"topReactions":"DIARRHOEA (1,539); NAUSEA (837); FATIGUE (710); OFF LABEL USE (647); CONSTIPATION (548)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:mycophenolate-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"MYCOPHENOLATE SODIUM","level":"ingredient","rank":280,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MYCOPHENOLATE SODIUM: 7,290 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,324 were serious (86.7%) and 925 reported a death outcome (12.7%). Most reported reactions: OFF LABEL USE (956); DRUG INEFFECTIVE (572); DIARRHOEA (364); ACUTE KIDNEY INJURY (306); DEATH (273). A report does not show that the drug caused the event.","value":7290,"unit":"FAERS reports received in the window","reports":7290,"serious":6324,"deaths":925,"serious_pct":86.7,"death_pct":12.7,"reports_q1":775,"reports_q2":1125,"reports_q3":1023,"reports_q4":929,"reports_q5":1148,"reports_q6":730,"reports_q7":828,"reports_q8":732,"serious_q1":668,"serious_q2":976,"serious_q3":898,"serious_q4":816,"serious_q5":1004,"serious_q6":649,"serious_q7":685,"serious_q8":628,"topReactions":"OFF LABEL USE (956); DRUG INEFFECTIVE (572); DIARRHOEA (364); ACUTE KIDNEY INJURY (306); DEATH (273)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:piperacillin-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"PIPERACILLIN SODIUM","level":"ingredient","rank":281,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PIPERACILLIN SODIUM: 7,275 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 7,081 were serious (97.3%) and 1,384 reported a death outcome (19.0%). Most reported reactions: DRUG INEFFECTIVE (1,021); OFF LABEL USE (638); ACUTE KIDNEY INJURY (633); PYREXIA (383); CONDITION AGGRAVATED (363). A report does not show that the drug caused the event.","value":7275,"unit":"FAERS reports received in the window","reports":7275,"serious":7081,"deaths":1384,"serious_pct":97.3,"death_pct":19,"reports_q1":859,"reports_q2":1031,"reports_q3":923,"reports_q4":909,"reports_q5":1038,"reports_q6":846,"reports_q7":886,"reports_q8":783,"serious_q1":841,"serious_q2":996,"serious_q3":898,"serious_q4":888,"serious_q5":1017,"serious_q6":819,"serious_q7":856,"serious_q8":766,"topReactions":"DRUG INEFFECTIVE (1,021); OFF LABEL USE (638); ACUTE KIDNEY INJURY (633); PYREXIA (383); CONDITION AGGRAVATED (363)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:amphetamine-sulfate","dataset":"drug-events","jurisdiction":"US","ingredient":"AMPHETAMINE SULFATE","level":"ingredient","rank":282,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"AMPHETAMINE SULFATE: 7,259 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,897 were serious (53.7%) and 799 reported a death outcome (11.0%). Most reported reactions: DRUG INEFFECTIVE (714); TOXICITY TO VARIOUS AGENTS (562); FATIGUE (495); DRUG ABUSE (452); NAUSEA (433). A report does not show that the drug caused the event.","value":7259,"unit":"FAERS reports received in the window","reports":7259,"serious":3897,"deaths":799,"serious_pct":53.7,"death_pct":11,"reports_q1":865,"reports_q2":1057,"reports_q3":961,"reports_q4":972,"reports_q5":865,"reports_q6":947,"reports_q7":791,"reports_q8":801,"serious_q1":396,"serious_q2":634,"serious_q3":512,"serious_q4":552,"serious_q5":486,"serious_q6":553,"serious_q7":393,"serious_q8":371,"topReactions":"DRUG INEFFECTIVE (714); TOXICITY TO VARIOUS AGENTS (562); FATIGUE (495); DRUG ABUSE (452); NAUSEA (433)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:docusate-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"DOCUSATE SODIUM","level":"ingredient","rank":283,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DOCUSATE SODIUM: 7,236 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,018 were serious (69.3%) and 875 reported a death outcome (12.1%). Most reported reactions: FATIGUE (749); OFF LABEL USE (647); NAUSEA (565); CONSTIPATION (558); HEADACHE (546). A report does not show that the drug caused the event.","value":7236,"unit":"FAERS reports received in the window","reports":7236,"serious":5018,"deaths":875,"serious_pct":69.3,"death_pct":12.1,"reports_q1":875,"reports_q2":868,"reports_q3":928,"reports_q4":942,"reports_q5":1021,"reports_q6":877,"reports_q7":908,"reports_q8":817,"serious_q1":598,"serious_q2":634,"serious_q3":666,"serious_q4":653,"serious_q5":701,"serious_q6":613,"serious_q7":618,"serious_q8":535,"topReactions":"FATIGUE (749); OFF LABEL USE (647); NAUSEA (565); CONSTIPATION (558); HEADACHE (546)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ibrutinib","dataset":"drug-events","jurisdiction":"US","ingredient":"IBRUTINIB","level":"ingredient","rank":284,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"IBRUTINIB: 7,218 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,873 were serious (95.2%) and 1,282 reported a death outcome (17.8%). Most reported reactions: DEATH (833); OFF LABEL USE (600); ATRIAL FIBRILLATION (342); DIARRHOEA (311); FATIGUE (288). A report does not show that the drug caused the event.","value":7218,"unit":"FAERS reports received in the window","reports":7218,"serious":6873,"deaths":1282,"serious_pct":95.2,"death_pct":17.8,"reports_q1":1052,"reports_q2":1101,"reports_q3":1095,"reports_q4":836,"reports_q5":874,"reports_q6":786,"reports_q7":778,"reports_q8":696,"serious_q1":971,"serious_q2":995,"serious_q3":1061,"serious_q4":810,"serious_q5":843,"serious_q6":760,"serious_q7":751,"serious_q8":682,"topReactions":"DEATH (833); OFF LABEL USE (600); ATRIAL FIBRILLATION (342); DIARRHOEA (311); FATIGUE (288)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:meloxicam","dataset":"drug-events","jurisdiction":"US","ingredient":"MELOXICAM","level":"ingredient","rank":285,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MELOXICAM: 7,183 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,867 were serious (53.8%) and 764 reported a death outcome (10.6%). Most reported reactions: FATIGUE (735); DRUG INEFFECTIVE (698); NAUSEA (694); DIARRHOEA (627); ARTHRALGIA (614). A report does not show that the drug caused the event.","value":7183,"unit":"FAERS reports received in the window","reports":7183,"serious":3867,"deaths":764,"serious_pct":53.8,"death_pct":10.6,"reports_q1":890,"reports_q2":887,"reports_q3":830,"reports_q4":929,"reports_q5":1084,"reports_q6":834,"reports_q7":817,"reports_q8":912,"serious_q1":493,"serious_q2":505,"serious_q3":458,"serious_q4":502,"serious_q5":551,"serious_q6":489,"serious_q7":463,"serious_q8":406,"topReactions":"FATIGUE (735); DRUG INEFFECTIVE (698); NAUSEA (694); DIARRHOEA (627); ARTHRALGIA (614)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sacubitril","dataset":"drug-events","jurisdiction":"US","ingredient":"SACUBITRIL","level":"ingredient","rank":286,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SACUBITRIL: 7,157 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,458 were serious (76.3%) and 674 reported a death outcome (9.4%). Most reported reactions: HYPOTENSION (573); FATIGUE (488); DIZZINESS (448); DYSPNOEA (438); OFF LABEL USE (425). A report does not show that the drug caused the event.","value":7157,"unit":"FAERS reports received in the window","reports":7157,"serious":5458,"deaths":674,"serious_pct":76.3,"death_pct":9.4,"reports_q1":1160,"reports_q2":980,"reports_q3":1011,"reports_q4":910,"reports_q5":874,"reports_q6":797,"reports_q7":711,"reports_q8":714,"serious_q1":884,"serious_q2":746,"serious_q3":763,"serious_q4":710,"serious_q5":608,"serious_q6":626,"serious_q7":564,"serious_q8":557,"topReactions":"HYPOTENSION (573); FATIGUE (488); DIZZINESS (448); DYSPNOEA (438); OFF LABEL USE (425)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ofatumumab","dataset":"drug-events","jurisdiction":"US","ingredient":"OFATUMUMAB","level":"ingredient","rank":287,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"OFATUMUMAB: 7,142 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,083 were serious (71.2%) and 141 reported a death outcome (2.0%). Most reported reactions: FATIGUE (906); HEADACHE (679); MULTIPLE SCLEROSIS (583); PYREXIA (582); PAIN (547). A report does not show that the drug caused the event.","value":7142,"unit":"FAERS reports received in the window","reports":7142,"serious":5083,"deaths":141,"serious_pct":71.2,"death_pct":2,"reports_q1":1200,"reports_q2":1018,"reports_q3":1040,"reports_q4":958,"reports_q5":815,"reports_q6":805,"reports_q7":770,"reports_q8":536,"serious_q1":747,"serious_q2":739,"serious_q3":799,"serious_q4":694,"serious_q5":595,"serious_q6":546,"serious_q7":576,"serious_q8":387,"topReactions":"FATIGUE (906); HEADACHE (679); MULTIPLE SCLEROSIS (583); PYREXIA (582); PAIN (547)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:erenumab","dataset":"drug-events","jurisdiction":"US","ingredient":"ERENUMAB","level":"ingredient","rank":288,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ERENUMAB: 7,125 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,750 were serious (52.6%) and 2,148 reported a death outcome (30.1%). Most reported reactions: DEVICE DIFFICULT TO USE (2,007); DRUG DOSE OMISSION BY DEVICE (1,563); MIGRAINE (1,454); OFF LABEL USE (1,382); HEADACHE (1,120). A report does not show that the drug caused the event.","value":7125,"unit":"FAERS reports received in the window","reports":7125,"serious":3750,"deaths":2148,"serious_pct":52.6,"death_pct":30.1,"reports_q1":1724,"reports_q2":842,"reports_q3":880,"reports_q4":622,"reports_q5":858,"reports_q6":730,"reports_q7":612,"reports_q8":857,"serious_q1":384,"serious_q2":489,"serious_q3":598,"serious_q4":341,"serious_q5":571,"serious_q6":465,"serious_q7":360,"serious_q8":542,"topReactions":"DEVICE DIFFICULT TO USE (2,007); DRUG DOSE OMISSION BY DEVICE (1,563); MIGRAINE (1,454); OFF LABEL USE (1,382); HEADACHE (1,120)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:caffeine","dataset":"drug-events","jurisdiction":"US","ingredient":"CAFFEINE","level":"ingredient","rank":289,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"CAFFEINE: 7,122 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,501 were serious (49.2%) and 1,529 reported a death outcome (21.5%). Most reported reactions: PRODUCT USE IN UNAPPROVED INDICATION (2,245); DRUG EFFECTIVE FOR UNAPPROVED INDICATION (1,933); FATIGUE (713); HEADACHE (698); NAUSEA (641). A report does not show that the drug caused the event.","value":7122,"unit":"FAERS reports received in the window","reports":7122,"serious":3501,"deaths":1529,"serious_pct":49.2,"death_pct":21.5,"reports_q1":962,"reports_q2":2210,"reports_q3":1286,"reports_q4":599,"reports_q5":598,"reports_q6":546,"reports_q7":491,"reports_q8":430,"serious_q1":604,"serious_q2":689,"serious_q3":533,"serious_q4":349,"serious_q5":385,"serious_q6":355,"serious_q7":326,"serious_q8":260,"topReactions":"PRODUCT USE IN UNAPPROVED INDICATION (2,245); DRUG EFFECTIVE FOR UNAPPROVED INDICATION (1,933); FATIGUE (713); HEADACHE (698); NAUSEA (641)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:torsemide","dataset":"drug-events","jurisdiction":"US","ingredient":"TORSEMIDE","level":"ingredient","rank":290,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"TORSEMIDE: 7,100 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,939 were serious (69.6%) and 660 reported a death outcome (9.3%). Most reported reactions: DYSPNOEA (680); DIARRHOEA (514); HEADACHE (464); FATIGUE (462); NAUSEA (457). A report does not show that the drug caused the event.","value":7100,"unit":"FAERS reports received in the window","reports":7100,"serious":4939,"deaths":660,"serious_pct":69.6,"death_pct":9.3,"reports_q1":864,"reports_q2":913,"reports_q3":881,"reports_q4":1007,"reports_q5":953,"reports_q6":840,"reports_q7":825,"reports_q8":817,"serious_q1":613,"serious_q2":665,"serious_q3":598,"serious_q4":712,"serious_q5":646,"serious_q6":588,"serious_q7":557,"serious_q8":560,"topReactions":"DYSPNOEA (680); DIARRHOEA (514); HEADACHE (464); FATIGUE (462); NAUSEA (457)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ravulizumab","dataset":"drug-events","jurisdiction":"US","ingredient":"RAVULIZUMAB","level":"ingredient","rank":291,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RAVULIZUMAB: 7,058 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,269 were serious (74.7%) and 688 reported a death outcome (9.7%). Most reported reactions: FATIGUE (826); DEATH (480); ASTHENIA (448); DRUG INEFFECTIVE (335); HEADACHE (314). A report does not show that the drug caused the event.","value":7058,"unit":"FAERS reports received in the window","reports":7058,"serious":5269,"deaths":688,"serious_pct":74.7,"death_pct":9.7,"reports_q1":1322,"reports_q2":679,"reports_q3":724,"reports_q4":730,"reports_q5":745,"reports_q6":891,"reports_q7":842,"reports_q8":1125,"serious_q1":250,"serious_q2":554,"serious_q3":606,"serious_q4":630,"serious_q5":663,"serious_q6":798,"serious_q7":733,"serious_q8":1035,"topReactions":"FATIGUE (826); DEATH (480); ASTHENIA (448); DRUG INEFFECTIVE (335); HEADACHE (314)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pseudoephedrine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"PSEUDOEPHEDRINE HYDROCHLORIDE","level":"ingredient","rank":292,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PSEUDOEPHEDRINE HYDROCHLORIDE: 7,047 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,404 were serious (62.5%) and 2,389 reported a death outcome (33.9%). Most reported reactions: DRUG INEFFECTIVE (1,427); OFF LABEL USE (1,379); PAIN (1,353); RASH (1,343); SYSTEMIC LUPUS ERYTHEMATOSUS (1,319). A report does not show that the drug caused the event.","value":7047,"unit":"FAERS reports received in the window","reports":7047,"serious":4404,"deaths":2389,"serious_pct":62.5,"death_pct":33.9,"reports_q1":1075,"reports_q2":1000,"reports_q3":871,"reports_q4":865,"reports_q5":1162,"reports_q6":708,"reports_q7":590,"reports_q8":776,"serious_q1":586,"serious_q2":799,"serious_q3":588,"serious_q4":495,"serious_q5":657,"serious_q6":516,"serious_q7":379,"serious_q8":384,"topReactions":"DRUG INEFFECTIVE (1,427); OFF LABEL USE (1,379); PAIN (1,353); RASH (1,343); SYSTEMIC LUPUS ERYTHEMATOSUS (1,319)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:sitagliptin-phosphate","dataset":"drug-events","jurisdiction":"US","ingredient":"SITAGLIPTIN PHOSPHATE","level":"ingredient","rank":293,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"SITAGLIPTIN PHOSPHATE: 6,961 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,258 were serious (75.5%) and 585 reported a death outcome (8.4%). Most reported reactions: NAUSEA (576); DIARRHOEA (526); VOMITING (484); PRODUCT DOSE OMISSION ISSUE (438); FATIGUE (425). A report does not show that the drug caused the event.","value":6961,"unit":"FAERS reports received in the window","reports":6961,"serious":5258,"deaths":585,"serious_pct":75.5,"death_pct":8.4,"reports_q1":940,"reports_q2":910,"reports_q3":859,"reports_q4":931,"reports_q5":1016,"reports_q6":758,"reports_q7":769,"reports_q8":778,"serious_q1":723,"serious_q2":690,"serious_q3":622,"serious_q4":731,"serious_q5":773,"serious_q6":598,"serious_q7":569,"serious_q8":552,"topReactions":"NAUSEA (576); DIARRHOEA (526); VOMITING (484); PRODUCT DOSE OMISSION ISSUE (438); FATIGUE (425)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:galcanezumab","dataset":"drug-events","jurisdiction":"US","ingredient":"GALCANEZUMAB","level":"ingredient","rank":294,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"GALCANEZUMAB: 6,915 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 1,021 were serious (14.8%) and 18 reported a death outcome (0.3%). Most reported reactions: INJECTION SITE PAIN (2,303); MIGRAINE (595); INCORRECT DOSE ADMINISTERED BY DEVICE (545); INJECTION SITE HAEMORRHAGE (487); INCORRECT DOSE ADMINISTERED (446). A report does not show that the drug caused the event.","value":6915,"unit":"FAERS reports received in the window","reports":6915,"serious":1021,"deaths":18,"serious_pct":14.8,"death_pct":0.3,"reports_q1":833,"reports_q2":730,"reports_q3":936,"reports_q4":942,"reports_q5":984,"reports_q6":808,"reports_q7":747,"reports_q8":935,"serious_q1":113,"serious_q2":123,"serious_q3":118,"serious_q4":140,"serious_q5":131,"serious_q6":122,"serious_q7":121,"serious_q8":153,"topReactions":"INJECTION SITE PAIN (2,303); MIGRAINE (595); INCORRECT DOSE ADMINISTERED BY DEVICE (545); INJECTION SITE HAEMORRHAGE (487); INCORRECT DOSE ADMINISTERED (446)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:thiamine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"THIAMINE HYDROCHLORIDE","level":"ingredient","rank":295,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"THIAMINE HYDROCHLORIDE: 6,914 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,300 were serious (62.2%) and 732 reported a death outcome (10.6%). Most reported reactions: FATIGUE (758); OFF LABEL USE (651); NAUSEA (568); DYSPNOEA (558); DRUG INEFFECTIVE (528). A report does not show that the drug caused the event.","value":6914,"unit":"FAERS reports received in the window","reports":6914,"serious":4300,"deaths":732,"serious_pct":62.2,"death_pct":10.6,"reports_q1":824,"reports_q2":780,"reports_q3":832,"reports_q4":872,"reports_q5":1016,"reports_q6":787,"reports_q7":935,"reports_q8":868,"serious_q1":497,"serious_q2":501,"serious_q3":565,"serious_q4":560,"serious_q5":593,"serious_q6":490,"serious_q7":584,"serious_q8":510,"topReactions":"FATIGUE (758); OFF LABEL USE (651); NAUSEA (568); DYSPNOEA (558); DRUG INEFFECTIVE (528)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:isopropyl-alcohol","dataset":"drug-events","jurisdiction":"US","ingredient":"ISOPROPYL ALCOHOL","level":"ingredient","rank":296,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ISOPROPYL ALCOHOL: 6,906 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,712 were serious (97.2%) and 3,852 reported a death outcome (55.8%). Most reported reactions: TOXICITY TO VARIOUS AGENTS (1,130); INJURY (909); PEMPHIGUS (881); CONFUSIONAL STATE (878); JOINT SWELLING (876). A report does not show that the drug caused the event.","value":6906,"unit":"FAERS reports received in the window","reports":6906,"serious":6712,"deaths":3852,"serious_pct":97.2,"death_pct":55.8,"reports_q1":697,"reports_q2":1115,"reports_q3":1315,"reports_q4":681,"reports_q5":806,"reports_q6":642,"reports_q7":1074,"reports_q8":576,"serious_q1":662,"serious_q2":1075,"serious_q3":1283,"serious_q4":656,"serious_q5":787,"serious_q6":629,"serious_q7":1063,"serious_q8":557,"topReactions":"TOXICITY TO VARIOUS AGENTS (1,130); INJURY (909); PEMPHIGUS (881); CONFUSIONAL STATE (878); JOINT SWELLING (876)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:morphine","dataset":"drug-events","jurisdiction":"US","ingredient":"MORPHINE","level":"ingredient","rank":297,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"MORPHINE: 6,870 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 6,223 were serious (90.6%) and 1,824 reported a death outcome (26.6%). Most reported reactions: OFF LABEL USE (834); NAUSEA (714); DRUG INEFFECTIVE (666); PAIN (588); FATIGUE (535). A report does not show that the drug caused the event.","value":6870,"unit":"FAERS reports received in the window","reports":6870,"serious":6223,"deaths":1824,"serious_pct":90.6,"death_pct":26.6,"reports_q1":1064,"reports_q2":1034,"reports_q3":1028,"reports_q4":812,"reports_q5":778,"reports_q6":707,"reports_q7":735,"reports_q8":712,"serious_q1":957,"serious_q2":961,"serious_q3":944,"serious_q4":705,"serious_q5":726,"serious_q6":636,"serious_q7":678,"serious_q8":616,"topReactions":"OFF LABEL USE (834); NAUSEA (714); DRUG INEFFECTIVE (666); PAIN (588); FATIGUE (535)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:metoclopramide-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"METOCLOPRAMIDE HYDROCHLORIDE","level":"ingredient","rank":298,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"METOCLOPRAMIDE HYDROCHLORIDE: 6,838 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,821 were serious (85.1%) and 777 reported a death outcome (11.4%). Most reported reactions: NAUSEA (866); OFF LABEL USE (719); VOMITING (596); DIARRHOEA (580); FATIGUE (528). A report does not show that the drug caused the event.","value":6838,"unit":"FAERS reports received in the window","reports":6838,"serious":5821,"deaths":777,"serious_pct":85.1,"death_pct":11.4,"reports_q1":998,"reports_q2":854,"reports_q3":906,"reports_q4":811,"reports_q5":867,"reports_q6":778,"reports_q7":801,"reports_q8":823,"serious_q1":761,"serious_q2":754,"serious_q3":799,"serious_q4":704,"serious_q5":691,"serious_q6":686,"serious_q7":713,"serious_q8":713,"topReactions":"NAUSEA (866); OFF LABEL USE (719); VOMITING (596); DIARRHOEA (580); FATIGUE (528)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:zoledronic-acid","dataset":"drug-events","jurisdiction":"US","ingredient":"ZOLEDRONIC ACID","level":"ingredient","rank":299,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ZOLEDRONIC ACID: 6,792 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 5,747 were serious (84.6%) and 578 reported a death outcome (8.5%). Most reported reactions: FATIGUE (562); ARTHRALGIA (493); NAUSEA (478); OFF LABEL USE (397); PAIN (392). A report does not show that the drug caused the event.","value":6792,"unit":"FAERS reports received in the window","reports":6792,"serious":5747,"deaths":578,"serious_pct":84.6,"death_pct":8.5,"reports_q1":803,"reports_q2":816,"reports_q3":831,"reports_q4":1006,"reports_q5":903,"reports_q6":806,"reports_q7":795,"reports_q8":832,"serious_q1":623,"serious_q2":690,"serious_q3":718,"serious_q4":863,"serious_q5":768,"serious_q6":697,"serious_q7":673,"serious_q8":715,"topReactions":"FATIGUE (562); ARTHRALGIA (493); NAUSEA (478); OFF LABEL USE (397); PAIN (392)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:lutetium-lu-177-vipivotide-tetraxetan","dataset":"drug-events","jurisdiction":"US","ingredient":"LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN","level":"ingredient","rank":300,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN: 6,764 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 1,539 were serious (22.8%) and 639 reported a death outcome (9.4%). Most reported reactions: GENERAL PHYSICAL HEALTH DETERIORATION (4,644); DEATH (454); ILL-DEFINED DISORDER (355); PROSTATIC SPECIFIC ANTIGEN INCREASED (183); MALIGNANT NEOPLASM PROGRESSION (173). A report does not show that the drug caused the event.","value":6764,"unit":"FAERS reports received in the window","reports":6764,"serious":1539,"deaths":639,"serious_pct":22.8,"death_pct":9.4,"reports_q1":906,"reports_q2":900,"reports_q3":878,"reports_q4":800,"reports_q5":834,"reports_q6":945,"reports_q7":772,"reports_q8":729,"serious_q1":196,"serious_q2":200,"serious_q3":208,"serious_q4":183,"serious_q5":196,"serious_q6":202,"serious_q7":176,"serious_q8":178,"topReactions":"GENERAL PHYSICAL HEALTH DETERIORATION (4,644); DEATH (454); ILL-DEFINED DISORDER (355); PROSTATIC SPECIFIC ANTIGEN INCREASED (183); MALIGNANT NEOPLASM PROGRESSION (173)","mdl":null,"effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:irbesartan","dataset":"drug-events","jurisdiction":"US","ingredient":"IRBESARTAN","level":"ingredient","rank":301,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"IRBESARTAN: 5,526 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 4,543 were serious (82.2%) and 330 reported a death outcome (6.0%). Most reported reactions: ACUTE KIDNEY INJURY (444); FATIGUE (396); NAUSEA (350); OFF LABEL USE (349); FALL (307). Named in open multidistrict litigation MDL-2875. A report does not show that the drug caused the event.","value":5526,"unit":"FAERS reports received in the window","reports":5526,"serious":4543,"deaths":330,"serious_pct":82.2,"death_pct":6,"reports_q1":666,"reports_q2":705,"reports_q3":772,"reports_q4":674,"reports_q5":720,"reports_q6":657,"reports_q7":657,"reports_q8":675,"serious_q1":551,"serious_q2":585,"serious_q3":668,"serious_q4":554,"serious_q5":561,"serious_q6":553,"serious_q7":539,"serious_q8":532,"topReactions":"ACUTE KIDNEY INJURY (444); FATIGUE (396); NAUSEA (350); OFF LABEL USE (349); FALL (307)","mdl":"MDL-2875","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:liraglutide","dataset":"drug-events","jurisdiction":"US","ingredient":"LIRAGLUTIDE","level":"ingredient","rank":302,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"LIRAGLUTIDE: 4,306 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,020 were serious (70.1%) and 123 reported a death outcome (2.9%). Most reported reactions: NAUSEA (554); IMPAIRED GASTRIC EMPTYING (449); VOMITING (449); DIARRHOEA (348); OFF LABEL USE (314). Named in open multidistrict litigation MDL-3094. A report does not show that the drug caused the event.","value":4306,"unit":"FAERS reports received in the window","reports":4306,"serious":3020,"deaths":123,"serious_pct":70.1,"death_pct":2.9,"reports_q1":401,"reports_q2":409,"reports_q3":783,"reports_q4":350,"reports_q5":545,"reports_q6":525,"reports_q7":822,"reports_q8":471,"serious_q1":354,"serious_q2":353,"serious_q3":446,"serious_q4":302,"serious_q5":460,"serious_q6":440,"serious_q7":457,"serious_q8":208,"topReactions":"NAUSEA (554); IMPAIRED GASTRIC EMPTYING (449); VOMITING (449); DIARRHOEA (348); OFF LABEL USE (314)","mdl":"MDL-3094","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:naloxone-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"NALOXONE HYDROCHLORIDE","level":"ingredient","rank":303,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"NALOXONE HYDROCHLORIDE: 4,232 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 2,788 were serious (65.9%) and 580 reported a death outcome (13.7%). Most reported reactions: TOXICITY TO VARIOUS AGENTS (382); NAUSEA (360); OFF LABEL USE (332); DENTAL CARIES (316); INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (285). Named in open multidistrict litigation MDL-3092. A report does not show that the drug caused the event.","value":4232,"unit":"FAERS reports received in the window","reports":4232,"serious":2788,"deaths":580,"serious_pct":65.9,"death_pct":13.7,"reports_q1":508,"reports_q2":667,"reports_q3":474,"reports_q4":491,"reports_q5":562,"reports_q6":648,"reports_q7":471,"reports_q8":411,"serious_q1":344,"serious_q2":433,"serious_q3":332,"serious_q4":356,"serious_q5":419,"serious_q6":337,"serious_q7":299,"serious_q8":268,"topReactions":"TOXICITY TO VARIOUS AGENTS (382); NAUSEA (360); OFF LABEL USE (332); DENTAL CARIES (316); INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (285)","mdl":"MDL-3092","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ranitidine-hydrochloride","dataset":"drug-events","jurisdiction":"US","ingredient":"RANITIDINE HYDROCHLORIDE","level":"ingredient","rank":304,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RANITIDINE HYDROCHLORIDE: 3,468 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 3,234 were serious (93.3%) and 1,428 reported a death outcome (41.2%). Most reported reactions: OFF LABEL USE (1,070); PAIN (932); DRUG INEFFECTIVE (791); RASH (757); INFUSION RELATED REACTION (734). Named in open multidistrict litigation MDL-2924. A report does not show that the drug caused the event.","value":3468,"unit":"FAERS reports received in the window","reports":3468,"serious":3234,"deaths":1428,"serious_pct":93.3,"death_pct":41.2,"reports_q1":534,"reports_q2":545,"reports_q3":594,"reports_q4":376,"reports_q5":538,"reports_q6":371,"reports_q7":237,"reports_q8":273,"serious_q1":445,"serious_q2":509,"serious_q3":569,"serious_q4":359,"serious_q5":516,"serious_q6":358,"serious_q7":223,"serious_q8":255,"topReactions":"OFF LABEL USE (1,070); PAIN (932); DRUG INEFFECTIVE (791); RASH (757); INFUSION RELATED REACTION (734)","mdl":"MDL-2924","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:rabeprazole-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"RABEPRAZOLE SODIUM","level":"ingredient","rank":305,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RABEPRAZOLE SODIUM: 3,100 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 2,717 were serious (87.6%) and 291 reported a death outcome (9.4%). Most reported reactions: OFF LABEL USE (444); HEADACHE (333); DRUG INEFFECTIVE (301); DIARRHOEA (232); HYPERSENSITIVITY (215). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":3100,"unit":"FAERS reports received in the window","reports":3100,"serious":2717,"deaths":291,"serious_pct":87.6,"death_pct":9.4,"reports_q1":413,"reports_q2":460,"reports_q3":440,"reports_q4":374,"reports_q5":418,"reports_q6":357,"reports_q7":340,"reports_q8":298,"serious_q1":381,"serious_q2":394,"serious_q3":403,"serious_q4":324,"serious_q5":356,"serious_q6":322,"serious_q7":292,"serious_q8":245,"topReactions":"OFF LABEL USE (444); HEADACHE (333); DRUG INEFFECTIVE (301); DIARRHOEA (232); HYPERSENSITIVITY (215)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:dexlansoprazole","dataset":"drug-events","jurisdiction":"US","ingredient":"DEXLANSOPRAZOLE","level":"ingredient","rank":306,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"DEXLANSOPRAZOLE: 2,597 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 1,956 were serious (75.3%) and 273 reported a death outcome (10.5%). Most reported reactions: OFF LABEL USE (350); FATIGUE (323); DRUG INEFFECTIVE (290); NAUSEA (232); DYSPNOEA (228). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":2597,"unit":"FAERS reports received in the window","reports":2597,"serious":1956,"deaths":273,"serious_pct":75.3,"death_pct":10.5,"reports_q1":331,"reports_q2":351,"reports_q3":331,"reports_q4":288,"reports_q5":361,"reports_q6":320,"reports_q7":321,"reports_q8":294,"serious_q1":248,"serious_q2":253,"serious_q3":252,"serious_q4":214,"serious_q5":266,"serious_q6":259,"serious_q7":246,"serious_q8":218,"topReactions":"OFF LABEL USE (350); FATIGUE (323); DRUG INEFFECTIVE (290); NAUSEA (232); DYSPNOEA (228)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:esomeprazole-magnesium-dihydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"ESOMEPRAZOLE MAGNESIUM DIHYDRATE","level":"ingredient","rank":307,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"ESOMEPRAZOLE MAGNESIUM DIHYDRATE: 2,400 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 1,589 were serious (66.2%) and 163 reported a death outcome (6.8%). Most reported reactions: DRUG INEFFECTIVE (308); OFF LABEL USE (297); NAUSEA (294); HEADACHE (257); FATIGUE (207). Named in open multidistrict litigation MDL-2789. A report does not show that the drug caused the event.","value":2400,"unit":"FAERS reports received in the window","reports":2400,"serious":1589,"deaths":163,"serious_pct":66.2,"death_pct":6.8,"reports_q1":299,"reports_q2":313,"reports_q3":350,"reports_q4":295,"reports_q5":322,"reports_q6":276,"reports_q7":266,"reports_q8":279,"serious_q1":203,"serious_q2":234,"serious_q3":232,"serious_q4":202,"serious_q5":184,"serious_q6":177,"serious_q7":183,"serious_q8":174,"topReactions":"DRUG INEFFECTIVE (308); OFF LABEL USE (297); NAUSEA (294); HEADACHE (257); FATIGUE (207)","mdl":"MDL-2789","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:ranitidine","dataset":"drug-events","jurisdiction":"US","ingredient":"RANITIDINE","level":"ingredient","rank":308,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"RANITIDINE: 1,972 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 1,832 were serious (92.9%) and 712 reported a death outcome (36.1%). Most reported reactions: OFF LABEL USE (575); DRUG INEFFECTIVE (463); PAIN (444); NAUSEA (363); HYPERTENSION (358). Named in open multidistrict litigation MDL-2924. A report does not show that the drug caused the event.","value":1972,"unit":"FAERS reports received in the window","reports":1972,"serious":1832,"deaths":712,"serious_pct":92.9,"death_pct":36.1,"reports_q1":378,"reports_q2":295,"reports_q3":407,"reports_q4":191,"reports_q5":246,"reports_q6":184,"reports_q7":136,"reports_q8":135,"serious_q1":317,"serious_q2":269,"serious_q3":395,"serious_q4":183,"serious_q5":236,"serious_q6":177,"serious_q7":128,"serious_q8":127,"topReactions":"OFF LABEL USE (575); DRUG INEFFECTIVE (463); PAIN (444); NAUSEA (363); HYPERTENSION (358)","mdl":"MDL-2924","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:nilotinib-hydrochloride-monohydrate","dataset":"drug-events","jurisdiction":"US","ingredient":"NILOTINIB HYDROCHLORIDE MONOHYDRATE","level":"ingredient","rank":309,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"NILOTINIB HYDROCHLORIDE MONOHYDRATE: 1,567 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 1,406 were serious (89.7%) and 247 reported a death outcome (15.8%). Most reported reactions: DRUG INEFFECTIVE (128); OFF LABEL USE (127); DIARRHOEA (113); NAUSEA (109); ARTHRALGIA (104). Named in open multidistrict litigation MDL-3006. A report does not show that the drug caused the event.","value":1567,"unit":"FAERS reports received in the window","reports":1567,"serious":1406,"deaths":247,"serious_pct":89.7,"death_pct":15.8,"reports_q1":242,"reports_q2":234,"reports_q3":180,"reports_q4":215,"reports_q5":175,"reports_q6":177,"reports_q7":176,"reports_q8":168,"serious_q1":211,"serious_q2":209,"serious_q3":151,"serious_q4":199,"serious_q5":163,"serious_q6":162,"serious_q7":157,"serious_q8":154,"topReactions":"DRUG INEFFECTIVE (128); OFF LABEL USE (127); DIARRHOEA (113); NAUSEA (109); ARTHRALGIA (104)","mdl":"MDL-3006","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:varenicline-tartrate","dataset":"drug-events","jurisdiction":"US","ingredient":"VARENICLINE TARTRATE","level":"ingredient","rank":310,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"VARENICLINE TARTRATE: 1,142 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 600 were serious (52.5%) and 18 reported a death outcome (1.6%). Most reported reactions: NAUSEA (181); HEADACHE (61); FATIGUE (59); DYSPNOEA (56); ABNORMAL DREAMS (55). Named in open multidistrict litigation MDL-3050. A report does not show that the drug caused the event.","value":1142,"unit":"FAERS reports received in the window","reports":1142,"serious":600,"deaths":18,"serious_pct":52.5,"death_pct":1.6,"reports_q1":97,"reports_q2":89,"reports_q3":141,"reports_q4":154,"reports_q5":120,"reports_q6":201,"reports_q7":158,"reports_q8":182,"serious_q1":38,"serious_q2":28,"serious_q3":63,"serious_q4":57,"serious_q5":74,"serious_q6":116,"serious_q7":109,"serious_q8":115,"topReactions":"NAUSEA (181); HEADACHE (61); FATIGUE (59); DYSPNOEA (56); ABNORMAL DREAMS (55)","mdl":"MDL-3050","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:pentosan-polysulfate-sodium","dataset":"drug-events","jurisdiction":"US","ingredient":"PENTOSAN POLYSULFATE SODIUM","level":"ingredient","rank":311,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"PENTOSAN POLYSULFATE SODIUM: 430 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 300 were serious (69.8%) and 20 reported a death outcome (4.7%). Most reported reactions: OFF LABEL USE (144); MACULOPATHY (65); PIGMENTARY MACULOPATHY (58); DRY AGE-RELATED MACULAR DEGENERATION (30); DRUG INEFFECTIVE (24). Named in open multidistrict litigation MDL-2973. A report does not show that the drug caused the event.","value":430,"unit":"FAERS reports received in the window","reports":430,"serious":300,"deaths":20,"serious_pct":69.8,"death_pct":4.7,"reports_q1":36,"reports_q2":97,"reports_q3":71,"reports_q4":24,"reports_q5":76,"reports_q6":53,"reports_q7":21,"reports_q8":52,"serious_q1":28,"serious_q2":88,"serious_q3":11,"serious_q4":17,"serious_q5":53,"serious_q6":43,"serious_q7":17,"serious_q8":43,"topReactions":"OFF LABEL USE (144); MACULOPATHY (65); PIGMENTARY MACULOPATHY (58); DRY AGE-RELATED MACULAR DEGENERATION (30); DRUG INEFFECTIVE (24)","mdl":"MDL-2973","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"},{"id":"drug-events:exenatide","dataset":"drug-events","jurisdiction":"US","ingredient":"EXENATIDE","level":"ingredient","rank":312,"quarters":"2024Q3,2024Q4,2025Q1,2025Q2,2025Q3,2025Q4,2026Q1,2026Q2","status":"P","text":"EXENATIDE: 173 FAERS reports listing this ingredient were received 2024Q3 to 2026Q2; 100 were serious (57.8%) and 10 reported a death outcome (5.8%). Most reported reactions: NAUSEA (24); VOMITING (20); IMPAIRED GASTRIC EMPTYING (17); PRODUCT DOSE OMISSION ISSUE (16); CONSTIPATION (14). Named in open multidistrict litigation MDL-3094. A report does not show that the drug caused the event.","value":173,"unit":"FAERS reports received in the window","reports":173,"serious":100,"deaths":10,"serious_pct":57.8,"death_pct":5.8,"reports_q1":36,"reports_q2":54,"reports_q3":37,"reports_q4":16,"reports_q5":14,"reports_q6":8,"reports_q7":4,"reports_q8":4,"serious_q1":25,"serious_q2":34,"serious_q3":15,"serious_q4":6,"serious_q5":12,"serious_q6":6,"serious_q7":2,"serious_q8":0,"topReactions":"NAUSEA (24); VOMITING (20); IMPAIRED GASTRIC EMPTYING (17); PRODUCT DOSE OMISSION ISSUE (16); CONSTIPATION (14)","mdl":"MDL-3094","effectiveFrom":"2024-07-01","effectiveTo":"2026-06-30","sources":[{"label":"FDA openFDA drug adverse event API (FAERS)","url":"https://open.fda.gov/apis/drug/event/","kind":"primary","accessed":"2026-10-29"},{"label":"openFDA licence (CC0 1.0) and terms","url":"https://open.fda.gov/license/","kind":"primary","accessed":"2026-10-29"}],"source":{"agency":"U.S. Food and Drug Administration (openFDA, FAERS)","url":"https://open.fda.gov/apis/drug/event/","table":"drug/event: count on patient.drug.openfda.substance_name.exact by receivedate","release":"openFDA last updated 2026-07-30; reports received 2024-07-01 to 2026-06-30","accessed":"2026-10-29"},"flags":{"suppressed":false,"noise":false,"preliminary":true,"moe":null},"lastChecked":"2026-10-29","confidence":"medium","confidenceBasis":"preliminary figure"}]}